SURMODICS INC Form 8-K March 18, 2019

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

March 15, 2019

Date of report (Date of earliest event reported)

Surmodics, Inc.

(Exact Name of Registrant as Specified in its Charter)

Minnesota 0-23837 (State of (Commission

41-1356149 (I.R.S. Employer

Incorporation) File Number) Identification No.)

9924 West 74th Street

Eden Prairie, Minnesota (Address of Principal Executive Offices) (952) 500-7000

55344 (**Zip Code**)

(Registrant s Telephone Number, Including Area Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 8.01 Other Events.

On March 15, 2019, the United States Food and Drug Administration (<u>FDA</u>) issued a communication to healthcare providers about the potential for increased long-term mortality after use of paclitaxel-coated balloons and paclitaxel-eluting stents (collectively <u>paclitaxel-coated products</u>) to treat peripheral arterial disease (<u>PAD</u>) in the femoropopliteal artery. The communication updates a previous notification from the FDA on the same topic, which was in response to meta-analysis of randomized trials published in the Journal of the American Heart Association in December 2018. The FDA communication can be accessed on the FDA s website at: https://www.fda.gov/MedicalDevices/Safety/LetterstoHealthCareProviders/ucm633614.htm.

In the communication, the FDA provides certain recommendations regarding the treatment of patients with PAD and the use of paclitaxel-coated products. The communication does not provide any recommendations regarding the conduct of ongoing clinical trials involving paclitaxel-coated products. The Company is working with the FDA to obtain clarification regarding the recommendations contained in the communication and their impact on the Company s TRANSCEND clinical trial, which is a randomized trial intended to evaluate the safety and effectiveness of the Company s SurVen drug-coated balloon (the <u>SurVeil DCB</u>) for the treatment of subjects with symptomatic PAD. The TRANSCEND clinical trial will enroll up to 446 subjects at up to 60 sites in the U.S. and 18 outside the U.S. In the communication, the FDA indicated that it plans to convene an advisory committee meeting of the Circulatory System Devices Panel to, among other things, continue its discussion and analysis of the presence and magnitude of a long-term mortality signal, consider modifications to ongoing and future US clinical trials evaluating paclitaxel-coated products, including the TRANSCEND clinical trial. These potential modifications include added surveillance, updated informed consent, and enhanced adjudication for drug-related adverse events and deaths.

The Company is currently assessing the impact of the FDA communication on the TRANSCEND clinical trial, its expectations regarding the timing of completion of patient enrollment in the TRANSCEND clinical trial and related regulatory approvals for the *SurVeil DCB*, and any corresponding effect on its fiscal 2019 financial guidance.

The information in this Item 8.01 shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the <u>Exchange Act</u>), or otherwise subject to liabilities under Section 18, nor shall such information be deemed incorporated by reference into any filings of the Company under the Securities Act of 1933, as amended, or the Exchange Act.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SURMODICS, INC.

Date: March 18, 2019 /s/ Bryan K. Phillips Bryan K. Phillips

Sr. Vice President, Legal and Human Resources,

General Counsel and Secretary

background: #ffffff;">

the purchase, construction or expansion of healthcare facilities, agencies or locations;

capital expenditures exceeding a prescribed amount; or

changes in services or bed capacity.

To the extent that we are required to obtain a CON or other similar approvals to expand our operations (either by acquiring facilities, agencies or locations or expanding or providing new services or other changes), our expansion could be adversely affected by our failure or inability to obtain the necessary approvals, changes in the standards applicable to those approvals, and possible delays and expenses associated with obtaining those approvals. We cannot assure you that we will be able to obtain CON approval for all future projects requiring this approval.

Our civil settlement agreement with the United States Government with respect to alleged violations of cost allocations under Medicare negatively impacts our cash flows and subjects us to a Corporate Integrity Agreement.

On February 3, 2000, we entered into a series of separate agreements with the OIG of HHS. Under the civil settlement agreement, we paid the federal government \$25.0 million during the first quarter of 2000 and agreed to reimburse the federal government an additional \$145.0 million through withholdings from our biweekly Medicare periodic interim payments. As of December 31, 2004, the present value of the remaining obligation was \$48.8 million. As a result of such withholdings, our cash flows from operations were negatively impacted by \$18.1 million in 2004, and are expected to be negatively impacted at an annual rate of \$18.1 million, ending in the first quarter of 2008.

As part of this series of agreements, we entered into a Corporate Integrity Agreement with the OIG, which was subsequently revised in 2002 and 2004. This agreement requires that we monitor our activities, on an ongoing basis, to ensure our compliance with the requirements of participation in federal healthcare programs. It also includes functional and training obligations, audit and review requirements and record keeping and reporting requirements. The revisions were made to provide an independent quality monitor to all of our nursing facilities and to modify the requirements under the agreement with respect to training and education.

We believe that we are generally in compliance with the requirements of our Corporate Integrity Agreement and file annual reports with the OIG documenting our compliance. If we fail to comply with our Corporate Integrity Agreement, we may be subject to penalties or exclusion from the Medicare and Medicaid programs, which could have an adverse effect on our financial condition and results of operations.

Table of Contents

We are subject to material litigation.

We are, and may in the future be, subject to litigation which, if determined adversely against us, could have a material adverse effect on our business, financial condition, results of operations and cash flows (see Item 3).

If we fail to cultivate new, or maintain existing, relationships with the physicians or other referral sources in the communities in which we operate, our patient base may decrease.

Our Nursing Facilities and AseraCare patient bases depend in part upon the admissions and referral practices of the physicians in the communities in which we operate and our ability to cultivate and maintain relationships with these physicians or other referral sources. Physicians or other sources referring patients to us are not our employees and are free to refer their patients to other providers. If we are unable to successfully cultivate and maintain strong relationships with these physicians, our patient population may decline, which, if significant, could have an adverse effect on our financial condition and results of operations.

Changes in the acuity of the patients and the mix of our patient population among the Medicare, Medicaid and private categories may significantly affect our nursing facility revenues and profitability.

The sources and amounts of our nursing facility revenues are determined by a number of factors, including licensed bed capacity and census of our nursing facilities, average length of stay of our residents, the mix of our patients by payor type (for example, Medicare versus Medicaid or private) and the acuity level of our patients. Changes in the acuity of patients, the mix of patients by payor type and payment methodologies may significantly affect our profitability. In particular, changes which increase the percentage of Medicaid residents within our nursing facilities could have an adverse effect on our financial condition and results of operations due to Medicaid rates being generally lower than Medicare and private pay rates.

Certain trends in the healthcare industry are putting pressure on our ability to maintain nursing facility census. Over the past decade, a number of trends have developed that impact our nursing facility census. These trends include:

overbuilding of nursing facilities in states that have eliminated the CON process for new construction;

creation of nursing facilities by acute-care hospitals to keep discharged patients within their complex;

rapid growth of assisted living centers, which sometimes are more attractive to less medically complex patients; and

the availability of eldercare services delivered to the home.

The negative impact of these trends on nursing facility census varies from facility to facility, from community to community and from state to state, and if we are not successful in responding to them, these trends could have an adverse effect on our Nursing Facilities segment.

Our executive officers and other key personnel are critical to our business, and if they choose to leave, it could harm our business.

The loss of the services of one or more of our executive officers or key employees, or the decision of one or more such officers or employees to join a competitor or otherwise compete directly or indirectly with us, could disrupt our business and could have an adverse effect on our financial condition and results of operations.

18

Table of Contents

A group including Arnold Whitman, the Chief Executive Officer of Formation Capital, LLC and Appaloosa Management, LP, a New Jersey based hedge fund, among others, has expressed an interest in purchasing all or a part of our Company. This interest could be disruptive to our business and could threaten to adversely affect our operations and results.

Our results of operations, financial condition and cash flows may be adversely impacted by the unsolicited indications of interest in an acquisition of us in January 2005, by a group including Arnold Whitman, the Chief Executive Officer of Formation Capital, LLC and Appaloosa Management, LP, a New Jersey based hedge fund, among others, and related actions taken by this group, including the nomination of candidates for election to our Board of Directors. These actions may materially impact our ability to attract and retain customers, management and employees and may result in the incurrence of significant advisory fees, litigation costs and other expenses. In addition, some of our key employees may seek other employment opportunities as a consequence of the uncertainty surrounding our future. Any such impact from the actions of the Whitman/Appaloosa group could have a material adverse effect on our business and results of operations. In addition, the actions of the Whitman/Appaloosa group may lead to a diversion on management s attention from other ongoing business concerns.

Provisions in our charter documents, under Delaware law, and in our stockholder rights plan could discourage a takeover that stockholders may consider favorable.

Our restated certificate of incorporation, as amended, and bylaws may discourage, delay or prevent a merger or acquisition that a stockholder may consider favorable because they:

authorize the issuance by the Board of Directors of preferred stock without the requirement of stockholder approval, which could make it more difficult for a third party to acquire a majority of our outstanding voting stock;

prohibit cumulative voting in the election of directors;

prohibit our stockholders from acting by written consent;

limit the persons who may call special meetings of stockholders;

establish advance notice requirements for nominations for election to the Board of Directors or for proposing matters to be approved by stockholders at stockholder meetings; and

require an 80% vote to approve certain business combinations with persons holding 10% or more of our common stock, unless certain conditions are met.

Delaware law may also discourage, delay or prevent someone from acquiring or merging with us. Under Delaware law, a corporation may not engage in a business combination with any holder of 15% or more of its capital stock until the holder has held the stock for three years unless, among other possibilities, the Board of Directors approves the transaction. Our Board of Directors will not approve takeovers that are not reasonably believed to be in the best interest of the stockholders, and therefore, certain acquisitions may be prevented or delayed.

As permitted by our charter, our Board of Directors approved a Rights Plan on January 25, 2005, which awards one one-thousandth of a preferred share purchase right for each share of our common stock. These rights are triggered in the event that any individual or entity acquires 10% or more of our outstanding common stock without the approval of our Board of directors. These purchase rights will cause substantial dilution to any person or group that attempts to acquire us without obtaining the approval of the Board of Directors.

These provisions could discourage potential acquisition proposals and could delay or prevent a change of control transaction. As a result, they may limit the price investors may be willing to pay for our stock in the future.

19

Table of Contents

Available Information

Our website, www.beverlycorp.com, provides access, free of charge, to our SEC reports, including our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to these reports, as soon as reasonably practicable. In addition, our corporate governance guidelines, code of conduct, code of ethics for senior financial officers, and charters for each key committee of the Board of Directors will be available on this website and in print to any stockholder who requests them.

You may read and copy any materials we file with the SEC at the SEC s Public Reference Room at 450 Fifth Street, NW, Washington, DC 20549. You may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC maintains a website that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC, including us, at http://www.sec.gov.

20

ITEM 2. PROPERTIES.

On December 31, 2004, we operated 351 nursing facilities, 18 assisted living centers, 52 hospice and home health locations and 10 outpatient clinics in 25 states and the District of Columbia. As of December 31, 2004, we had 27 nursing facilities (2,572 beds) and 10 outpatient clinics classified as held for sale (see Item 8. Note 15 regarding the sale of the 10 outpatient clinics in February 2005). Most of our 87 leased nursing facilities are subject to net leases which require us to pay all taxes, insurance and maintenance costs. Most of these leases have original terms from ten to fifteen years and contain at least one renewal option. Renewal options typically extend the original terms of the leases by five to fifteen years. Many of these leases also contain purchase options. We consider our physical properties to be in good operating condition and suitable for the purposes for which they are being used. Certain of our nursing facilities and assisted living centers are included in the collateral securing our obligations under various debt agreements (see Item 8. Note 9).

The following is a summary of our nursing facilities, assisted living centers, hospice and home health locations and outpatient clinics at December 31, 2004:

	Nursing	g Facilities				
			Assis Livi Cent	ng	Hospice	
Location	Number	Total Licensed Beds	Number	Total Units	and Home Health Locations	Outpatient Clinics
Alabama	14	1,692			11	
Arkansas	19	2,270	1	16		
California	24	2,306			2	
District of Columbia	1	355				
Georgia	13	1,595	2	72	1	
Illinois	3	275				
Indiana	26	3,064			1	
Iowa					1	
Kansas	19	1,175				
Kentucky	8	1,039				
Maryland	4	585	1	19		
Massachusetts	18	2,048			1	
Minnesota	28	2,324	1	16		
Mississippi	10	1,148			7	
Missouri	18	1,723	3	109	2	
Nebraska	24	2,037	1	16	4	
New Jersey	1	140				
North Carolina	10	1,278			1	10
Ohio	9	1,252				
Pennsylvania	41	4,659	3	72	9	
South Dakota	17	1,165	1	36		
Tennessee	5	555	2	55	5	
Texas					4	
Virginia	13	1,720	3	84		
West Virginia	3	310				

Edgar Filing: SURMODICS INC - Form 8-K

Wisconsin	23	2,280			3	
	351	36,995	18	495	52	10
Classification						
Owned	264	27,448	17	426		
Leased	87	9,547	1	69	52	10
	351	36,995	18	495	52	10
		21				

ITEM 3. LEGAL PROCEEDINGS.

- (a) On January 26, 2005, a putative class action complaint brought on behalf of all shareholders of the Company was filed against the Company and each of its directors in the Delaware Chancery Court in New Castle County. The complaint, captioned *Chaya Perlstein v. William R. Floyd, et. al.*, Civil Action No. CA1050-N, asserts a claim for breach of fiduciary duty in connection with our response to an unsolicited expression of interest by a group of investors that collectively had purchased 8.1% of our common stock on the open market prior to January 24, 2005. A second, substantially identical, putative class action complaint was filed in the same court on February 1, 2005, bearing the caption *Robert Strougo v. Beverly Enterprises, Inc., et. al.*, Civil Action No. CA1067-N. On February 23, 2005, the Delaware Chancery Court consolidated these cases under the caption *In re Beverly Shareholders Litigation*, Civil Action No. CA1050-N, and designated the *Floyd* complaint as operative. In addition, the Chancery Court extended the defendants time to respond to the operative complaint to May 9, 2005. The plaintiffs seek preliminary and permanent injunctive relief, an unspecified amount of compensatory damages, an accounting, as well as an award of attorneys fees, expert fees, and costs. Due to the preliminary state of these actions, we are unable to assess the probable outcome and can give no assurance of the ultimate impact on our financial position, results of operations and cash flows.
- (b) As previously reported, on October 31, 2002, a shareholder derivative action entitled *Paul Dunne and Helene* Dunne, derivatively on behalf of nominal defendant Beverly Enterprises, Inc. v. Beryl F. Anthony, Jr., et. al. was filed in the Circuit Court of Sebastian County, Arkansas, Fort Smith Division (No. CIV-2002-1241). This case was purportedly brought derivatively on our behalf against various current and former officers and directors. The complaint alleges causes of action for breach of fiduciary duty against the defendants based on: (1) allegations that defendants failed to establish and maintain adequate accounting controls such that we failed to record adequate reserves for general and professional liability costs; and (2) allegations that certain defendants sold Company stock while purportedly in possession of material non-public information. On May 16, 2003, two additional derivative complaints (Holcombe v. Floyd, et. al. and Flowers v. Floyd, et. al.) were filed and subsequently transferred to the Circuit Court of Sebastian County, Arkansas, Fort Smith Division and consolidated with the Dunne action as Holcomb v. Beverly Enterprises, Inc. The Dunnes were subsequently dismissed as plaintiffs. On November 19, 2004, Beverly moved to dismiss these actions on the grounds that the plaintiffs failed to make a pre-suit demand upon Beverly s Board of Directors and did not show that the failure to make such demand was excused as futile. The other defendants also moved to dismiss the actions for failure to state a claim upon which relief can be granted. Plaintiffs have opposed both motions. The court has scheduled oral argument on the motions to dismiss for June 17, 2005. Due to the preliminary state of this action, we are unable to assess the probable outcome of the case and can give no assurance of the ultimate impact on our financial position, results of operations and cash flows.
- (c) In 2002, we notified federal and California healthcare regulatory authorities (CMS, OIG, the California Attorney General s office and the California Department of Health) of our intent to conduct an internal investigation of past billing practices relating to MK Medical, our former medical equipment business unit based in Fresno, California. An independent accounting firm has reviewed MK Medical s government payor billings since October 1, 1998, the date Beverly acquired the business unit. Deficiencies identified by the accounting firm primarily relate to inadequate documentation supporting Medicare and Medi-Cal claims for reimbursement for drugs, wheelchairs, and other durable medical equipment distributed by MK Medical. Specifically, the review identified instances of missing or incomplete certificates of medical necessity, treatment authorization requests, prescriptions and other documentation MK Medical is required to maintain in order to be entitled to reimbursement from government payors. Based on the results of the accounting firm s review, we established a reserve in 2002, included in Other accrued liabilities on the consolidated balance sheets in the amount of \$18.0 million to cover potential overpayments from government payors for the period from October 1, 1998 to 2002. We have advised regulatory authorities of the results of the accounting firm s review. On September 15, 2003, we received a subpoena from the United States Attorney s Office in Oakland, California, requesting the production of additional documents relating to MK Medical s operations and our review of MK Medical s claims. We have produced documents in response to this subpoena and continue to cooperate with the government s request for information. Our liability with respect to this matter could exceed the reserved amount,

which continues to be the best estimate of our exposure in this matter. We are actively

22

Table of Contents

cooperating with the government in this matter and expect to fund or resolve this liability within 12 months. We can give no assurance of the final outcome of this matter or its impact on our financial position, results of operations and cash flows.

- (d) We are a party to various legal matters relating to patient care, including claims that our services have resulted in injury or death to residents of our facilities. Over the past few years, we have experienced an increasing trend in the number and severity of the claims asserted against us. We believe that there has been, and will continue to be, an increase in governmental investigations of long-term care providers. Adverse determinations in legal proceedings or governmental investigations, whether currently asserted or arising in the future, could have a material adverse effect on us.
- (e) There are various other lawsuits and regulatory actions pending against us arising in the normal course of business, some of which seek punitive damages that are generally not covered by insurance. We do not believe that the ultimate resolution of such other matters will have a material adverse effect on our consolidated financial position, results of operations or cash flows.

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.

There were no matters submitted to a vote of our security holders during the last quarter of our fiscal year ended December 31, 2004.

23

PART II

ITEM 5. MARKET FOR THE COMPANY S COMMON EQUITY AND RELATED STOCKHOLDER MATTERS.

Our common stock is listed on the New York Stock Exchange and the Pacific Exchange under the symbol BEV. The table below sets forth, for the periods indicated, the range of high and low sales prices of our common stock as reported on the New York Stock Exchange composite tape.

Drigos

		Pric	es	
]	High	Ι	Low
2003				
First Quarter	\$	3.00	\$	1.63
Second Quarter		4.30		1.80
Third Quarter		6.99		3.71
Fourth Quarter		8.60		5.06
2004				
First Quarter	\$	8.96	\$	5.84
Second Quarter		8.92		5.83
Third Quarter		8.70		6.78
Fourth Quarter		9.41		7.49
2005				
First Quarter (through March 7)	\$	12.32	\$	8.33

On March 7, 2005, there were 4,838 record holders of our common stock.

We are subject to certain restrictions under our long-term debt agreements related to the payment of cash dividends on our common stock. We have not paid any cash dividends on our common stock since 1987, and no future cash dividends are currently planned. In deciding whether to propose a cash dividend and determining the dividend amount, our Board of Directors would take into account such matters as the availability of funds for dividends, general business conditions, our financial results, other capital requirements, contractual, legal and regulatory restrictions on the payment of cash dividends to our stockholders and such other factors as our Board of Directors may deem relevant (see Item 7. Liquidity and Capital Resources).

During 2004 and 2003, we did not purchase any of our common stock. We did not make any unregistered sales of equity securities during 2004.

24

ITEM 6. SELECTED FINANCIAL DATA.

The following table of selected financial data should be read along with our consolidated financial statements and related notes for 2004, 2003 and 2002 included in Item 8. Consolidated Financial Statements and Supplementary Data.

At or For the Years Ended December 31,

	2004(1)	2003(1)	2002(1)	2001(1)	2000(1)
		(Dollars in tho	usands, except p	er share data)	
Consolidated Statement of		`	, 1	ŕ	
Operations Data:					
Revenues	\$ 1,988,852	\$ 1,802,026	\$ 1,766,726	\$ 1,953,084	\$ 1,908,173
Costs and expenses:					
Wages and related	1,147,743	1,078,548	1,068,629	1,203,932	1,188,908
Provision for insurance and					
related items	127,653	109,377	84,161	75,385	102,237
Other operating and					
administrative	522,603	462,144	458,311	503,951	542,539
Depreciation and amortization	62,166	58,807	62,906	63,549	70,667
Florida insurance reserve					
adjustment			22,179		
Special charge and adjustment					
related to California					
investigation settlement		(925)	6,300		
Special charge and adjustments					
related to settlements of federal					
government investigations			(9,441)	77,495	
Asset impairments, workforce					
reductions and other unusual	4.40	2 02 7	46.00	100.000	4.6.00.
items	448	3,825	46,287	180,000	16,895
Total costs and expenses	1,860,613	1,711,776	1,739,332	2,104,312	1,921,246
Income (loss) before other					
income (expenses)	128,239	90,250	27,394	(151,228)	(13,073)
Other income (expenses):					
Interest expense	(45,637)	(63,314)	(62,652)	(74,447)	(75,119)
Costs related to early					
extinguishments of debt	(40,935)	(6,634)			(354)
Interest income	5,485	5,363	4,688	2,911	2,485
Net gains on dispositions	396	422	2,142	988	2,433
Gains on sales of equity					
investments		6,686		256	1,477
Total other expenses, net	(80,691)	(57,477)	(55,822)	(70,292)	(69,078)
Income (loss) before provision for income taxes, discontinued	47,548	32,773	(28,428)	(221,520)	(82,151)

		-								
operations and cumulative effect of change in accounting for goodwill										
Provision for (benefit from)										
income taxes		4,890		5,069		6,085		60,432		(25,791)
Income (loss) before discontinued operations and cumulative effect of change in										
accounting for goodwill		42,658		27,704		(34,513)		(281,952)		(56,360)
Discontinued operations, net of taxes of 2004 \$55; 2003 \$3,37 2002 \$0; 2001 \$956; and 2000		42,036		21,704		(34,313)		(201,932)		(30,300)
\$3,529	,	(14,637)		52,764		(34,406)		(19,320)		1,858
Cumulative effect of change in accounting for goodwill, net of		(1,,007)		<i>5</i> 2 ,7 <i>5</i> .				(13,020)		1,000
income taxes of \$0(2)						(77,171)				
Net income (loss)	\$	28,021	\$	80,468	\$	(146,090)	\$	(301,272)	\$	(54,502)
Net income (loss) per share of										
common stock:										
Basic:										
Before discontinued operations and cumulative effect of change in										
accounting for goodwill	\$	0.40	\$	0.26	\$	(0.33)	\$	(2.71)	\$	(0.55)
Discontinued operations, net										
of taxes		(0.14)		0.49		(0.32)		(0.19)		0.02
Cumulative effect of change in accounting for goodwill, net of taxes						(0.74)				
						()				
Net income (loss) per share of common stock	\$	0.26	\$	0.75	\$	(1.39)	\$	(2.90)	\$	(0.53)
Shares used to compute per										
share amounts		107,749		106,582		104,726		104,037		102,452
Diluted:(3)										
Before discontinued operations and cumulative										
effect of change in	\$	0.37	\$	0.26	\$	(0.33)	\$	(2.71)	\$	(0.55)
accounting for goodwill Discontinued operations, net	Ф		Ф		Ф		Ф	(2.71)	Ф	(0.55)
of taxes		(0.12)		0.48		(0.32)		(0.19)		0.02
Cumulative effect of change in accounting for goodwill, net of taxes						(0.74)				
						, ,				
	\$	0.25	\$	0.74	\$	(1.39)	\$	(2.90)	\$	(0.53)

Net income (loss) per share of common stock

Shares used to compute per share amounts	124,334	109,922	104,726	104,037	102,452
		25			

At or For the Years Ended December 31,

	2004	2004(1)		2003(1)		2002(1)		2001(1)		2000(1)
			(De	ollars in tho	usa	nds, except p	er s	share data)		
Other Financial Data:										
Cash flows from operations	\$ 7	5,660	\$	69,861	\$	116,633	\$	220,897	\$	37,010
EBITDA(4)	19	0,801		156,165		92,442		(86,435)		61,504
EBITDA Margin %(4)		9.59%		8.67%		5.23%		(4.43)%		3.22%
Capital expenditures	6	2,718		43,984		100,103		89,401		76,027
Consolidated Balance Sheet										
Data:										
Total assets	\$ 1,36	1,385	\$ 1	1,346,421	\$	1,349,895	\$	1,681,070	\$	1,875,993
Current portion of long-term										
debt	1	2,240		13,354		41,463		64,231		227,111
Long-term debt, excluding										
current portion	54	5,943		552,873		588,714		677,442		564,247
Total stockholders equity	27	2,413		238,186		153,472		296,497		583,993
Other Data:										
Average occupancy(5)		88.9%		88.2%		88.2%		86.6%		86.5%

- (1) The operations of Matrix, MK Medical, Care Focus, 125 nursing facilities and eight assisted living centers have been reclassified as discontinued operations for all periods presented, including 27 nursing facilities and 10 outpatient clinics classified as held for sale during the year ended December 31, 2004, since they met the applicable criteria under Statement of Financial Accounting Standards No. 144, Accounting for the Impairment or Disposal of Long-Lived Assets (see Item 8 Note 6).
- (2) Includes a \$77.2 million goodwill impairment charge relating to the 2002 adoption of Statement of Financial Accounting Standards No. 142, *Goodwill and Other Intangible Assets*.
- (3) Assumes the conversion of our 2.75% convertible subordinated notes since their issuance in October 2003, on an if-converted basis, in accordance with Emerging Issues Task Force Issue No. 04-8, *The Effect of Contingently Convertible Debt on Diluted Earnings per Share* (see Item 8. Note 1 *Earnings Per Share*).
- (4) We define EBITDA as earnings from continuing operations before interest expense (including costs related to early extinguishments of debt), interest income, income taxes, depreciation and amortization. EBITDA margin is EBITDA as a percentage of revenues. EBITDA is commonly used by our lenders and investors to assess our leverage capacity, debt service ability and liquidity, and we use EBITDA to evaluate financial performance and to design incentive compensation for management. EBITDA is not considered a measure of financial performance under U.S. generally accepted accounting principles (GAAP), and the items excluded from EBITDA are significant components in understanding and assessing our financial performance. EBITDA should not be considered as an alternative to net income, cash flows provided by or used in operating, investing or financing activities or other financial statement data presented in our consolidated financial statements as an indicator of financial performance or liquidity. Since EBITDA is not a measure determined in accordance with GAAP and is thus susceptible to varying calculations, EBITDA, as presented, may not be comparable to other similarly titled measures of other companies.

EBITDA has limitations as an analytical tool, and you should not consider it in isolation or as a substitute for analysis of our results as reported under GAAP. Some of these limitations are:

EBITDA does not reflect our cash expenditures, or future requirements, for capital expenditures or contractual commitments;

EBITDA does not reflect changes in, or cash requirements for, our working capital needs;

EBITDA does not reflect interest expense, or the cash requirements necessary to service interest or principal payments, on our debt; and

although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and EBITDA does not reflect any cash requirements for such replacements. Because of these limitations, EBITDA should not be considered as a measure of discretionary cash available to us to invest in the growth of our business. We compensate for these limitations by relying primarily on our GAAP results and using EBITDA only supplementally. See our Consolidated Statements of Cash Flows included in Item 8. The following table provides a reconciliation from our pre-tax income (loss) from continuing operations, which is the most directly comparable financial measure presented in accordance with GAAP for the periods indicated (in thousands):

	2004	2003	2002	2001	2000
Income (loss) before provision for income taxes, discontinued operations and cumulative effect of change in accounting for goodwill Plus:	\$ 47,548	\$ 32,773	\$ (28,428)	\$ (221,520)	\$ (82,151)
Depreciation and amortization	62,166	58,807	62,906	63,549	70,667
Interest expense(a) Minus:	86,572	69,948	62,652	74,447	75,473
Interest income	5,485	5,363	4,688	2,911	2,485
EBITDA	\$ 190,801	\$ 156,165	\$ 92,442	\$ (86,435)	\$ 61,504

26

⁽a) Includes \$40.9 million, \$6.6 million and \$354,000, respectively, for the years ended December 31, 2004, 2003 and 2000 of costs related to the early extinguishments of debt.

⁽⁵⁾ Calculated by dividing the nursing facilities—actual patient days by available patient days from continuing operations. Available patient days are calculated by multiplying total calendar days by the number of beds that are operationally ready for use.

ITEM 7. MANAGEMENT S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as expects, anticipates, intends, plans, believes, seeks, estimates or words of similar meaning and include, but are not limited to, statements about of expected future business and financial performance. Forward-looking statements are based on management is current expectations and assumptions, which are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict. Actual outcomes and results may differ materially from these expectations and assumptions due to changes in, among other things, political, economic, business, competitive, market, regulatory, demographic and other factors. We undertake no obligation to publicly update or revise any forward-looking information, whether as a result of new information, future developments or otherwise.

Overview

We are a much stronger company than we were just a few years ago with better operating units, a solid financial position, and a more disciplined culture. On any given day, we have 34,000 dedicated associates providing high quality care and generating annual revenues totaling approximately \$2 billion. In just a few years we have made dramatic progress in transforming us into a leading provider of eldercare services. Just for example, since the end of 2000 we have:

decreased our balance sheet debt from \$791 million to less than \$560 million:

eliminated off-balance sheet debt of \$184 million:

increased our cash balance from \$26 million to \$216 million; and

cut our Nursing Facilities patient receivables by 64% to \$179 million and less than 35 days sales outstanding; and

substantially completed the divestiture program begun in 2001.

In 2004, we successfully delivered the profitable growth we had expected, through strong performance by all three of our principal business segments. Our EBITDA for the year ended December 31, 2004 was \$190.8 million exceeding the high end of our guidance for 2004 by \$5.8 million. For purposes of generally accepted accounting principles (GAAP), EBITDA is most directly comparable to pre-tax income from continuing operations of \$47.5 million (see Item 6 for a reconciliation of EBITDA to pre-tax income from continuing operations and a definition of, and discussion of why we use EBITDA). We reported diluted earnings per share from continuing operations of 37 cents, a 42% increase from 2003, despite a \$40.9 million refinancing charge and an increase in the shares used to compute diluted earnings per share of approximately 14.4 million, primarily due to the effect of our 2.75% convertible subordinated notes.

A key to our success was the focused execution of our strategic plan by our seasoned leadership team. Critical measures of our 2004 success in terms of our four core strategies are as follows:

Strengthen and grow our Nursing Facilities segment

6.8% revenue growth;

45.9% pre-tax income growth; and

divested 18 non-strategic facilities, substantially completing our divestiture strategy.

27

Accelerate the growth of our service businesses

61.4% revenue growth, including: 58.2% from Aegis and

67.5% from AseraCare; 75 new Aegis customers, net;

70% growth in hospice average daily census; and

30 new hospice locations (including the acquisition of Hospice USA).

Lead innovation in eldercare

completed construction on 29 Alzeheimer s units; and

Aegis Freedom Through Functionality program added in 33 locations.

Continually re-engineer our Company

\$17.7 million or 27.9% drop in interest expense; and

new technologies implemented to improve the documentation of resident care and to effectively manage labor costs at the local level (resulting in a weighted average wage rate increase of 3.7%).

Revenues consistently grew quarter over quarter during 2004. We generated a 45% increase in pre-tax income from continuing operations on a 10% increase in revenues (dollars in millions):

	Qtr 1		Qtr 2		Qtr 3		Qtr 4		Total	
Revenues:										
2004	\$	481	\$	488	\$	503	\$	517	\$	1,989
2003	\$	433	\$	442	\$	457	\$	470	\$	1,802
% change		11%		10%		10%		10%		10%
Pre-tax income (loss) from continuing operations:										
2004	\$	23	\$	(14)	\$	22	\$	17	\$	48
2003	\$	4	\$	7	\$	10	\$	12	\$	33
% change		475%				120%		42%		45%

As further discussed in *Results of Operations* Continuing Operations, we strategically incurred \$40.9 million of costs related to the refinancing of high-cost debt, primarily during the second quarter of 2004. We believe it was the right thing to do because it improved our capital structure by:

increasing the maturities on 36% of our long-term debt by more than five years;

providing greater covenant flexibility;

lowering our interest rate 175 basis points on that layer of debt; and

providing additional financing capacity and flexibility by refinancing with subordinated debt.

Our solid operating and financial performance was further demonstrated by our increase in cash flows from operations to \$75.7 million in 2004, from \$69.9 million in 2003. Our 2004 cash flows from operations were negatively impacted by approximately \$82 million due to the reconsolidation of Beverly Funding Corporation (BFC). BFC was reconsolidated in the second quarter of 2004, as a result of the repayment of its outstanding obligations (see Item 8 Note 1 *Transfers of Financial Assets*). Excluding this one-time impact, our cash flows from operations would have been approximately \$157.7 million for 2004, a 126% increase over 2003. Our significant cash generation during 2004

enabled us to strategically invest \$62.7 million in capital expenditures and \$71.4 million for acquisitions. 28

Table of Contents

We expect that our momentum in 2004, together with diligent and focused attention to our strategic plan, will drive further profitable growth in 2005 and beyond.

Critical Accounting Policies

The accompanying consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (GAAP). The accounting policies detailed below are considered by management to be critical to an understanding of our financial statements, and are discussed annually with the Audit and Compliance Committee of our Board of Directors, because their application requires significant judgment and reliance on estimations of matters that are inherently uncertain. Certain risks related to these critical accounting policies are described in the following paragraphs.

Revenue Recognition, Accounts Receivable and Allowance for Doubtful Accounts

Our revenues are derived primarily from providing long-term healthcare services. Approximately 80% of our current revenues is derived from federal and state healthcare programs (primarily Medicare and Medicaid). All providers participating in the Medicare and Medicaid programs are required to meet certain financial cost reporting requirements. Federal and state regulations generally require the submission of annual cost reports covering revenues, costs and expenses associated with the services provided to Medicare beneficiaries and Medicaid recipients. Annual cost reports are subject to routine audits and retroactive adjustments. These audits often require several years to reach the final determination of amounts due to, or by, us under these programs.

Compliance with laws and regulations governing the Medicare and Medicaid programs is subject to government review and interpretation, as well as significant regulatory action including fines, penalties, and possible exclusion from the Medicare and Medicaid programs. In addition, under the Medicare program, if the federal government makes a formal demand for reimbursement, even related to contested items, payment must be made for those items before the provider is given an opportunity to appeal and resolve the issue.

Revenue Assumptions and Approach Used. As discussed more fully in Item 8 Note 1, we record revenues when services are provided at standard charges, adjusted to amounts estimated to be received under governmental programs or other third-party contractual arrangements based on contractual terms and historical experience. On an annual basis, state Medicaid programs may adjust their plan reimbursement rates in accordance with state specific guidelines and calculations. In addition, our reimbursement rates are adjusted based on information we file in annual cost reports to each state. Using these state plans, and filed cost report data, we estimate rate adjustments and record revised per diem rates beginning in the period the rate adjustment would apply according to state plans.

As adjustments to recorded revenues become known or as cost reporting years are no longer subject to audits, reviews or investigations, the amounts of our revenues and receivables are revised. Our revenues are reported at their estimated net realizable amounts, and we believe adequate provision has been made to reflect any adjustments that could result from audits of cost reports. However, due to the complexity of the laws and regulations governing the Medicare and Medicaid programs, there is at least a possibility that recorded estimates will change by a material amount in the near term. Changes in estimates related to third-party receivables due to retroactive rate adjustments and cost report settlements resulted in an increase in revenues from continuing operations of approximately \$8.0 million, \$8.7 million and \$948,000 for the years ended December 31, 2004, 2003 and 2002, respectively.

Allowance Assumptions and Approach Used. We record bad debt expense monthly as a percentage of revenue reflecting our historical experience. Each quarter we adjust the allowance for doubtful accounts according to the aging and payor mix of the receivables. These adjustments are based on our weighted average collection experience by payor type, and recognize the relative risk depending on the source of the expected payment. Private pay accounts usually represent our highest collectibility risk. In addition, specific accounts that are determined to be uncollectible (due to bankruptcy, insufficient documentation, lack of third-party coverage or financial resources and the like) are fully reserved when such determinations are made. We write off uncollectible accounts receivable after all collection efforts have been exhausted and we determine they

29

Table of Contents

will not be collected. If circumstances change (including, but not limited to: economic downturn; higher than expected defaults or denials; reduced collections; and changes in our payor mix), our estimates of the recoverability of our receivables could be reduced by a material amount. For our Nursing Facilities segment, the aging of our receivables has improved over the past three years and our cash collections continue to be in line with, or ahead of, our generated revenues. These factors have led to a decrease in our total provision for bad debts and a reduction in our total allowance for doubtful accounts.

The following table provides an analysis of our allowance and provision for doubtful accounts (from continuing and discontinued operations) at or for the years ended December 31 (dollars in thousands):

	2004	2003		2002
Allowance for doubtful accounts	\$ 26,320	\$	31,615	\$ 44,536
As a % of accounts receivable	10.1%		16.1%	20.2%
As a % of accounts over 180 days old	190.5%		119.6%	115.5%
Provision for doubtful accounts	\$ 8,898	\$	22,743	\$ 54,558
As a % of revenues	0.4%		1.3%	3.1%

Sensitivity Analysis. We believe adequate provision has been made for receivables that may prove to be uncollectible. During 2004, our Nursing Facilities segment weighted average collection experience improved 21 basis points when compared to 2003. As a result of the improved collection rates, we reduced our recorded allowance for doubtful accounts by approximately \$4.0 million. However, changes in collection rates or payment patterns could affect the assumptions used to estimate the current level of allowance for doubtful accounts. If our collection rates increase or decrease by ten basis points, the impact on pre-tax income from continuing operations on the consolidated statement of operations would be approximately \$2.0 million.

General and Professional Liabilities and Other Insurance Risks

General and professional liability costs for the long-term healthcare industry have become expensive and difficult to estimate. In addition, insurance coverage for general and professional liability and certain other risks, for nursing facilities specifically and companies in general, has become increasingly difficult to obtain. When obtained, insurance carriers are often requiring companies to significantly increase their liability retention levels and pay substantially higher premiums for reduced terms of coverage. The majority of our workers—compensation and auto liability risks are insured through loss-sensitive insurance policies with affiliated and unaffiliated insurance companies.

For our general and professional liabilities, we are responsible for the first dollar of each claim, up to a self-insurance limit determined by the individual policies, subject to aggregate limits in certain prior policy years, and accrue liabilities for claims when they are probable and can be reasonably estimated. We evaluate our purchased insurance coverage for risk transfer and we exercise care in selecting companies from which we purchase insurance, including review of published ratings by recognized rating agencies, advice from national brokers and consultants and review of trade information sources. There exists a risk that any of these insurance companies may become insolvent and unable to fulfill their obligation to defend, pay or reimburse us when that obligation becomes due. In several prior policy years, losses exceed our self-insurance aggregate limits. For claims relating to these years, our insurers have assumed their obligations for defense and payment of covered claims, and we expect them to continue to meet these obligations. Although we believe the companies we have purchased insurance from are solvent, in light of the dramatic changes occurring in the insurance industry in recent years, we cannot assure you that they will remain solvent and able to fulfill their obligations.

Assumptions and Approach Used. Our outstanding liabilities for general and professional liability risks and workers compensation risks are estimated by our independent actuaries twice a year using the most recent historical trends of data, including frequency and severity of claims, settlements and other relevant data. On an undiscounted basis, these liabilities totaled \$209.8 million at December 31, 2004. On our financial statements, these liabilities are discounted at 8.5% to their present value using actuarially determined loss payment timing patterns. The discount rate

is based upon our best estimate of the incremental borrowing rate that would be required to fund these liabilities with incremental uncollateralized debt. We continually evaluate the discount

30

Table of Contents

rate utilized to measure our outstanding insurance liabilities. Due to changes in our capital structure and the overall interest rate environment, we decreased our discount rate from 10% to 8.5% and recorded a pre-tax charge of \$6.0 million on these liabilities during the fourth quarter of 2004.

Sensitivity Analysis. A reduction in the discount rate by one-half of a percentage point would have resulted in an additional pre-tax charge of \$1.9 million for the year ended December 31, 2004. Based on information provided by our independent actuaries, we estimate our range of discounted exposure for these liabilities to be \$163.8 million to \$189.7 million. At December 31, 2004, our recorded reserves for these liabilities totaled \$172.7 million. We believe adequate provision has been made in the financial statements for liabilities that may arise out of patient care and other services.

Tax Valuation Allowance

In 2001, based upon our operating results in previous years, our reported cumulative losses, and the inherent uncertainty associated with the realization of future income, we provided a full valuation allowance on our net deferred tax assets. During 2004 and 2003, our valuation allowance decreased by \$10.8 million and \$30.1 million, respectively, primarily due to the reversal of temporary differences and the utilization of net operating loss carryforwards, partially offset by increases in general business tax credits and state tax credits. During 2004, the decrease in the valuation allowance was further offset by the generation of alternative minimum tax credits. During 2002, our valuation allowance increased by \$45.5 million primarily due to the generation of net operating loss carryforwards and increases in general business tax credits and state tax credits, partially offset by the reversal of temporary differences.

Assumptions and Approach Used. We assess the need for, and amount of, a valuation allowance for deferred tax assets in accordance with Statement of Financial Accounting Standards No. 109, Accounting for Income Taxes (SFAS No. 109). A valuation allowance is required when it is more likely than not that all, or a portion, of a deferred tax asset will not be realized. Realization of deferred tax assets ultimately depends on the existence of sufficient taxable income, which may be derived from future reversals of existing temporary differences, taxable income in prior carryback years, tax planning strategies or future taxable income, exclusive of reversing temporary differences and carryforwards. We believe a significant cumulative pre-tax loss for the current and two preceding years is significant evidence to warrant a full valuation allowance on our net deferred tax assets.

Sensitivity Analysis. Currently we have a \$158.3 million valuation allowance on our net deferred tax assets and any change in net deferred tax assets resulting from the reversal of existing temporary differences, the origination of future temporary differences, and the utilization/ generation of net operating losses is being applied against the valuation allowance, and, therefore, does not affect the provision for income taxes. All available evidence has been, and will continue to be, considered at least quarterly in assessing the need to maintain a full valuation allowance.

We expect to maintain a valuation allowance on our net deferred tax assets until an appropriate level of profitability is sustained for the current and two preceding years, or we are able to develop and implement tax strategies enabling us to conclude it is more likely than not that our net deferred tax assets will be realized.

Asset Impairments

Long-Lived Assets. We recorded pre-tax asset impairment charges from continuing operations of \$3.5 million, \$2.1 million and \$41.4 million for the years ended December 31, 2004, 2003 and 2002, respectively. We evaluate our long-lived assets for impairment whenever indicators of impairment exist, in accordance with Statement of Financial Accounting Standards No. 144, Accounting for the Impairment or Disposal of Long-Lived Assets (SFAS No. 144). These indicators of impairment can include, but are not limited to, the following:

a history of operating losses, with expected future losses;

changes in the regulatory environment affecting reimbursement;

31

Table of Contents

decreases in cash flows or cash flow deficiencies:

changes in the way an asset is used in the business; and

commitment to a plan to sell or otherwise dispose of an asset.

SFAS No. 144 Assumptions and Approach Used. A history of operating losses, with expected future losses, and cash flow deficiencies led to impairments in our Nursing Facilities segment on seven facilities in 2004 and three facilities in 2003. During 2002, changes in the regulatory environment affecting Medicare reimbursement led to a long-lived asset impairment analysis on each facility within our Nursing Facilities segment.

These impairment analyses included:

estimating the undiscounted cash flows to be generated by each facility or property, primarily over the remaining life of the primary asset; and

reducing the carrying value of the asset to the estimated fair value when the total estimated undiscounted cash flows was less than the carrying value of the facility or property.

In order to estimate the fair values of the nursing facilities, we used a discounted cash flow approach, supplemented by public resource information on valuations of nursing facility sales transactions by region of the country. Where the estimated undiscounted cash flows were negative, we estimated the fair values based on discounted public resource information, sales values or estimated salvage values.

SFAS No. 144 Sensitivity Analysis. In estimating the undiscounted cash flows for our nursing facilities, we primarily used our internally prepared budgets and forecast information, with certain probability adjustments, including, but not limited to, the following items: Medicare and Medicaid funding; overhead costs; capital expenditures; and general and professional liability costs. A change in the estimated future cash flows could change our estimated fair values resulting in additional impairments.

Indefinite-Lived Intangible Assets. We also recorded impairments of goodwill of \$77.2 million in 2002 as the cumulative effect of an accounting change in accordance with Statement of Financial Accounting Standards No. 142, *Goodwill and Other Intangible Assets* (SFAS No. 142). In July 2001, SFAS No. 142 was issued, which established new rules on the accounting for goodwill and other intangible assets.

SFAS No. 142 Assumptions and Approach Used. In accordance with this standard, we performed the initial screening for potential impairments of our indefinite-lived intangible assets by reporting unit as of January 1, 2002. We determined the estimated fair values of each reporting unit using discounted cash flow analyses, along with independent source data related to recent transactions. Based on this determination, we identified potential goodwill impairments at our former Matrix segment and at Care Focus, a former reporting unit within our AseraCare segment. The fair values of the reporting units were derived from a five-year projection of revenues and expenses plus residual value, with the resulting projected cash flows discounted at an appropriate weighted average cost of capital. The analysis was completed in the fourth quarter of 2002, and led to the recording of goodwill impairment charges as the cumulative effect of an accounting change of \$77.2 million as of January 1, 2002, including \$70.6 million for Matrix and \$6.6 million for Care Focus. The outpatient therapy clinic operations and the managed care network of Matrix were sold during January 2003. The Care Focus unit was sold in June 2003. We perform assessments of goodwill for all reporting units on an annual basis during the fourth quarter. Based on these analyses, there have been no additional impairments of goodwill since 2002.

SFAS No. 142 Sensitivity Analysis. Our estimated future cash flows by reporting unit would have to decline by nearly 50% to result in additional impairments of goodwill and other intangible assets.

Off-Balance Sheet Arrangements

On June 15, 2004, \$70.0 million of off-balance sheet medium-term notes (Medium-Term Notes) were repaid. These notes were obligations of Beverly Funding Corporation (BFC), a bankruptcy remote, qualifying special purpose entity, which was not consolidated with us prior to the repayment of the notes. Upon

Table of Contents

repayment of the Medium-Term Notes, BFC no longer had third-party beneficial owners and no longer met the conditions of a qualifying special purpose entity. Therefore, during the second quarter of 2004, BFC was reconsolidated with us (see Item 8. Note 1 *Transfer of Financial Assets*).

As of December 31, 2004, we were contingently liable for approximately \$11.8 million of long-term debt maturing on various dates through 2019, as well as annual interest on that debt. These contingent liabilities principally arose from previous sales of nursing facilities. We also guarantee certain third-party operating leases. Those guarantees arose from our dispositions of leased facilities and, as of December 31, 2004, the underlying leases have \$54.8 million of minimum rental commitments remaining through the initial lease terms. In accordance with the FASB s Interpretation No. 45, *Guarantor s Accounting and Disclosure Requirements for Guarantees, Including Indirect Guarantees of Indebtedness of Others*, we have recorded approximately \$627,000, included in Other accrued liabilities on the consolidated balance sheet at December 31, 2004, as the estimated fair value of our guarantees initiated in 2003 and 2004.

Operating Results

General

Our business consists principally of providing healthcare services, including the operation of nursing facilities, assisted living centers, hospice and home health locations and rehabilitation therapy services. We are one of the largest operators of nursing facilities in the United States. As of December 31, 2004, we operated 351 nursing facilities (36,995 licensed beds) that range in capacity from 34 to 355 licensed beds. As of December 31, 2004, we also operated 18 assisted living centers containing 495 units, 52 hospice and home health locations and 10 outpatient clinics. Our operations include rehabilitation therapy services in 37 states and the District of Columbia. As of December 31, 2004, we had 27 nursing facilities (2,572 beds) and 10 outpatient clinics classified as held for sale (see Item 8. Note 15 regarding the sale of the 10 outpatient clinics in February 2005). See Item 1. Business Operations and Services for a more detailed description of our operations by segment.

Reclassification

Results of operations for the years ended December 31, 2004, 2003 and 2002, reflect asset dispositions during 2004 and 2003, and assets classified as held for sale, as discontinued operations. The following discussions reflect this reclassification.

Results of Operations Continuing Operations

We reported a 45% increase in pre-tax income from continuing operations to \$47.5 million for the year ended December 31, 2004, compared to \$32.8 million for the same period in 2003. In 2002, we reported a pre-tax loss of \$28.4 million from continuing operations. The year-over-year comparisons of our financial results are affected by material special pre-tax charges (adjustments) discussed below. Excluding these special pre-tax charges (adjustments), we would have more than doubled our pre-tax income from continuing operations for the year ended December 31, 2004, compared to the same period in 2003. Before we discuss and analyze our operating performance year-over-year, we have included on the following table, and in the discussion below, the items that affect comparability of our operating results:

	2004	2003	2002
Costs related to early extinguishments of debt	40,935	6,634	
Florida insurance reserve adjustment			22,179
Charge and adjustment related to California investigations		(925)	6,300
Adjustments related to settlements of federal government			
investigations			(9,441)
Asset impairments, workforce reductions and other unusual items	448	3,825	46,287
Gain on sale of equity investment		(6,686)	

Table of Contents

Pre-tax income from continuing operations for 2004 included the following special pre-tax charges (adjustments):

\$40.9 million for costs related to the early extinguishments of debt. During the second quarter 2004, we issued \$215.0 million of 77/8% senior subordinated notes. The proceeds from the senior subordinated notes, together with cash on hand, were used to purchase \$190.6 million of our 95/8% senior notes and to pay related fees and expenses. In conjunction with these transactions, we paid a prepayment premium of \$36.1 million, wrote off \$3.7 million of related deferred financing costs and paid \$681,000 in fees and expenses related to the early extinguishment of the 95/8% senior notes. We also wrote off \$505,000 of deferred financing costs related to early extinguishments of certain other debt;

\$3.5 million for asset impairments, primarily related to seven nursing facilities (see *Asset Impairments* in our Critical Accounting Policies above);

\$422,000 for net workforce reduction charges, including \$1.3 million resulting from operational reorganizations, net of a \$536,000 reversal of workforce reduction charges which were no longer needed. The charge is partially offset by \$362,000 primarily due to the cancellation of restricted stock. During 2004, we notified 53 associates that their positions would be eliminated. The \$1.3 million for workforce reductions was an all cash expense, \$500,000 of which was paid during the year ended December 31, 2004; partially offset by

\$3.4 million gain due to the sale or settlement of previously impaired assets above carrying value. Pre-tax income from continuing operations for 2003 included the following special pre-tax charges (adjustments): \$6.6 million for costs related to the early extinguishment of debt. During the fourth quarter of 2003, we entered into a \$210.0 million senior credit facility and issued \$115.0 million of 2.75% convertible subordinated notes. The net proceeds from these transactions were used to pay off our 9% senior notes and certain mortgages, bonds and other debt obligations. In conjunction with these transactions, we wrote off \$3.9 million of deferred financing costs and paid a prepayment premium of \$2.7 million;

\$2.1 million for asset impairments, primarily related to three nursing facilities (see *Asset Impairments* in our Critical Accounting Policies above);

\$2.5 million for net workforce reduction charges, including \$2.9 million resulting from operational reorganizations, net of a \$395,000 reversal of workforce reduction charges which were no longer needed. During 2003, we notified 67 associates that their positions would be eliminated. The charge included the following: \$2.8 million of cash expenses, \$1.8 million and \$900,000 of which was paid during the years ended December 31, 2003 and 2004, respectively; and

non-cash expenses of approximately \$84,000 related to the issuance of 108,230 shares under our Stock Grant Plan (the Stock Grant Plan), less approximately \$400,000 due to the cancellation of restricted stock; partially offset by a \$6.7 million gain on the sale of a publicly traded equity security that was acquired in 1995;

a \$1.0 million reversal of previously recorded exit costs and \$447,000 primarily resulting from the settlement of a previously impaired asset above carrying value; and

the reversal of \$925,000 of costs originally accrued for the settlement, recorded in 2002, related to the investigation of patient care issues at certain California nursing homes (the California investigation settlement).

Table of Contents 29

34

Table of Contents

Pre-tax loss from continuing operations for 2002 included the following special pre-tax charges (adjustments):

\$41.4 million for the write-down of property and equipment on certain assets of the Nursing Facilities segment (see *Asset Impairments* in our Critical Accounting Policies above);

\$22.2 million for an insurance reserve adjustment related to Florida facilities sold in 2002;

\$7.9 million of net workforce reduction charges, including \$8.5 million resulting from an operational reorganization required to support the implementation of our three-year strategic plan, net of a \$585,000 reversal of workforce reduction charges recorded in 2001, which were no longer needed. During 2002, we notified 133 associates that their positions would be eliminated. The charge included the following:

\$8.0 million of cash expenses, \$4.1 million, \$2.8 million and \$1.1 million of which was paid during the years ended December 31, 2002, 2003 and 2004, respectively; and

non-cash expenses of approximately \$500,000 related to the issuance of 124,212 shares under our Stock Grant Plan:

\$6.3 million for the California investigation settlement and related costs (see Item 8. Note 3); partially offset by

\$9.4 million adjustment to reserves established in conjunction with previous settlements of federal government investigations (see Item 8. Note 4); and

\$3.0 million gain primarily related to the sale of previously impaired assets above carrying value.

We estimate the annual cost savings of these workforce reductions for 2004, 2003 and 2002 to be approximately \$3.4 million, \$5.0 million and \$11.2 million, respectively. The following table summarizes activity in our estimated workforce reductions and exit costs for the years ended December 31 (in thousands):

	20	004		2003				2002									
	orkforce ductions	1	Exit Costs		Workforce Reductions Exit C				Exit Costs		Exit Costs					Ex	xit Costs
Balance beginning of																	
year	\$ 3,029	\$	7,270	\$	5,418	\$	4,991	\$	7,631	\$	15,030						
Charged to continuing																	
operations	1,320		185		2,902		(884)		8,454								
Charged to discontinued																	
			4 251				26,599				2 622						
operations	(0.647)		4,251		(4.006)				(0.07.4)		2,633						
Cash payments	(2,647)		(7,134)		(4,896)		(22,579)		(9,074)		(10,313)						
Stock transactions									(1,008)								
Reversals	(536)				(395)		(857)		(585)		(2,359)						
Balance end of year	\$ 1,166	\$	4,572	\$	3,029	\$	7,270	\$	5,418	\$	4,991						

Workforce reductions and exit costs accruals are included in Accrued wages and related liabilities and Other accrued liabilities on our consolidated balance sheets.

Revenues

Revenues by operating segment for the years ended December 31 (in thousands) are as follows:

		2003		Change					
	2004			2004 vs. 2003		2003 vs. 2002			
			2002	\$	%	\$	%		
Nursing Facilities Aegis	\$ 1,794,471 121,846	\$ 1,680,420 77,007	\$ 1,677,892 52,871	\$ 114,051 44,839	6.8% 58.2%	\$ 2,528 24,136	0.2% 45.7%		
AseraCare Other	65,604 6,931	39,164 5,435	34,315 1,648	26,440 1,496	67.5% 27.5%	4,849 3,787	14.1%		
Total revenues	\$ 1,988,852	\$ 1,802,026	\$ 1,766,726	\$ 186,826	10.4%	\$ 35,300	2.0%		

2004 Compared to 2003. Approximately 90% and 93% of our revenues for the years ended December 31, 2004 and 2003, respectively, were derived from services provided by our Nursing Facilities segment. The increase in total revenues of \$186.8 million for the year ended December 31, 2004, as compared to the same period in 2003, is primarily due to the following, by operating segment:

Nursing Facilities:

an increase of \$57.8 million, \$33.9 million and \$11.4 million in Medicaid, Medicare and private payment rates, respectively;

an increase of \$18.1 million due to Medicare Part B revenues, primarily due to increased therapy-related services;

an increase of \$4.4 million due to one additional calendar day during 2004 as compared to the same period in 2003; partially offset by

a decrease of \$11.8 million due to a decline in census;

Aegis:

an increase of \$44.8 million from growth in Aegis external therapy business, including a 14.7% increase in the number of contracts and a 28% growth in average revenue per contract;

AseraCare:

an increase of \$19.5 million due to the Hospice USA acquisition (see Item 8. Note 7) and the opening of 14 hospice locations; and

an increase of \$6.9 million primarily due to a 29% increase in average daily census in our core AseraCare business.

2003 Compared to 2002. Approximately 93% and 95% of our revenues for the years ended December 31, 2003 and 2002, respectively, were derived from services provided by our Nursing Facilities segment. The increase in total revenues of \$35.3 million for the year ended December 31, 2003, as compared to the same period in 2002, is primarily due to the following, by operating segment:

Nursing Facilities:

an increase of \$41.3 million and \$12.0 million in Medicaid and private payment rates, respectively;

an increase of \$7.7 million due to adjustments related to favorable prior year cost report settlements;

an increase of \$6.8 million due to a shift in our patient mix, primarily from private to Medicare; partially offset by

a decrease of \$47.3 million due to 2002 dispositions;

36

Table of Contents

a decrease of \$11.4 million due to a decline in census; and

a decrease of \$6.6 million due to various other items;

Aegis:

an increase of \$24.1 million from growth in Aegis external therapy business, including a 32.5% increase in the number of contracts;

AseraCare:

an increase of \$3.6 million primarily due to a 21% increase in average daily census in our core AseraCare business; and

an increase of \$1.2 million due to the opening of three hospice locations.

Costs and Expenses

The following table details costs and expenses excluding special pre-tax charges (adjustments) for the years ended December 31 (in thousands):

				Change					
				2004 vs. 2	003	2003 vs. 2002			
	2004	2003	2002	\$	%	\$	%		
Wages and related Provision for insurance and related	\$ 1,147,743	\$ 1,078,548	\$ 1,068,629	\$ 69,195		\$ 9,919	0.9%		
Other operating and administrative	127,653 522,603	109,377 462,144	84,161 458,311	18,276 60,459	16.7%	25,216 3,833	0.8%		
Depreciation and amortization	62,166	58,807	62,906	3,359	5.7%	(4,099)	(6.5)%		
Total costs and expenses excluding special pre-tax charges (adjustments)	\$ 1,860,165	\$ 1,708,876	\$ 1,674,007	\$ 151,289	8.9%	\$ 34,869	2.1%		

2004 Compared to 2003. Excluding special pre-tax charges (adjustments) discussed above, our total costs and expenses increased \$151.3 million, primarily due to the following:

an increase of \$34.1 million related to Aegis wages and related expenses due to increased staffing related to the increased volume of new contracts. This increase also includes a \$5.6 million, or 49%, increase in Aegis contract therapy cost;

an increase of \$32.6 million related to our Nursing Facilities wages and related expenses, primarily due to a 3.7% increase in our weighted average wage rate and an increase in nursing hours per patient day, partially offset by an adjustment in reserves related to revised employee benefit programs;

an increase of \$12.6 million in contracted services, primarily due to outsourcing certain dietary and laundry services in our Nursing Facilities segment;

an increase in our provision for insurance and related items. We adjust our reserves for current and prior year general, professional, and workers compensation liabilities based primarily on actuarial studies conducted twice per year. Adjustments to premiums and other costs are recorded as incurred. The provision increase included the following:

\$12.3 million due to an increase in the estimate of outstanding general, professional and workers compensation liabilities, net of a decrease in insurance premiums and related program costs; and

37

Table of Contents

\$6.0 million due to a change in the discount rate used to estimate the present value of our insurance liabilities (from 10% to 8.5%) due to a decrease in our incremental borrowing rate resulting from changes in our capital structure and the overall interest rate environment;

an increase of \$17.1 million due to the Hospice USA acquisition, the opening of 14 hospice locations and two start-up businesses;

an increase of \$10.0 million in state-imposed provider taxes in our Nursing Facilities segment; and

an increase in depreciation and amortization expense, primarily due to an increase in capital expenditures in our Nursing Facilities segment.

2003 Compared to 2002. Excluding special pre-tax charges (adjustments) discussed above, our total costs and expenses increased \$34.9 million, primarily consisting of the following:

an increase in our provision for insurance and related items due to an increase in the estimate of outstanding general, professional and workers compensation liabilities and increased insurance premiums and related program costs;

an increase of \$18.3 million related to Aegis wages and related expenses, which includes a \$2.6 million, or 29%, increase in Aegis contract therapy cost;

an increase of \$21.6 million related to Nursing Facilities wages and related expenses, primarily due to a 4.6% increase in our weighted average wage rate and an increase in nursing hours per patient day;

an increase of \$14.5 million in contracted services, primarily due to outsourcing certain housekeeping, laundry and dietary services in our Nursing Facilities segment;

an increase of \$3.5 million due to the opening of three hospice locations and two start-up businesses; partially offset by

a decrease of \$21.4 million in our provision for reserves on accounts and notes receivable due to improvements in the timing and amount of account collections, as well as the collection of certain accounts that had previously been fully reserved;

a decrease of \$22.7 million primarily due to 2002 dispositions; and

a decrease in depreciation and amortization expense, primarily due to the impact of asset impairments recorded in the fourth quarter of 2002.

Other Income and Expenses, Net

Other income and expenses for the years ended December 31 (in thousands) are as follows:

				Change					
				2004 vs. 2003			2003 vs. 2002		2002
	2004	2003	2002		\$	%		\$	%
Other income (expenses):									
Interest expense	\$ (45,637)	\$ (63,314)	\$ (62,652)	\$	17,677	(27.9)%	\$	(662)	1.1%
Costs related to early extinguishments of debt(1)	(40,935)	(6,634)			(34,301)			(6,634)	
extinguisinnents of debt(1)	$(\pm 0, 233)$	(0,037)			(37,301)			(0,057)	

Edgar Filing: SURMODICS INC - Form 8-K

Interest income	5,485	5,363	4,688	122	2.3%	675	14.4%
Net gains on dispositions	396	422	2,142	(26)	(6.2)%	(1,720)	(80.3)%
Gain on sale of equity							
investment(1)		6,686		(6,686)		6,686	

(1) See *Results of Operations Continuing Operations* for a discussion of special pre-tax charges for 2004 and 2003.

Interest Expense

Interest expense decreased 28% to \$45.6 million for the year ended December 31, 2004, as compared to \$63.3 million for the year ended December 31, 2003. This was primarily due to the October 2003 refinancing of both our credit facility and our 9% senior notes as well as the reduction of debt using the proceeds from sales of facilities, clinics and other assets in 2003.

Results of Operations Discontinued Operations

The results of operations of disposed facilities, clinics and other assets during the years ended December 31, 2004 and 2003, as well as the results of operations of held-for-sale assets as of December 31, 2004, have been reported as discontinued operations for all periods presented in the consolidated statements of operations.

A summary of discontinued operations by operating segment for the years ended December 31 is as follows (in thousands):

2003

2002

2004

				2001										
	N	Aatri x	lome Care	Nursing Facilities Total		Ma	atrix		Home Care		Nursing acilities	Total		
Revenues	\$	14,021	\$ 148	\$ 163,745	\$	177,914	\$ 1	8,550	\$	20,395	\$	515,008	\$	553,953
Operating income (loss)(1) Gain (loss) on sales and exit costs Impairments and other unusual items(2)	\$	1,106 (49)	\$ 110 369	\$ (10,335) (1,441) (4,342)	\$	(9,119) (1,121) (4,342)		749 1,120	\$	(2,446) 1,557 (540)	\$	(2,817) 67,113 (18,594)	\$	(4,514) 79,790 (19,134)
Pre-tax income (loss)	\$	1,057	\$ 479	\$ (16,118)		(14,582)	\$ 1	1,869	\$	(1,429)	\$	45,702		56,142
Provision for state income taxes						55								3,378
Discontinued operations, net of taxes					\$	(14,637)							\$	52,764

			_			
	ľ	Matrix	Home Care	Nursing acilities	Total	
Revenues(3)	\$	86,109	\$ 20,894	\$ 644,811	\$ 751,814	
Operating income (loss)(1)(3)	\$	810	\$ (31,057)	\$ 35,435	\$ 5,188	

Edgar Filing: SURMODICS INC - Form 8-K

Gain (loss) on sale and exit costs Impairments and other unusual items(4)	((1,001) 230	(1,257) (4,239)	(107) (33,220)	(2,365) (37,229)
Pre-tax income (loss)	\$	39	\$ (36,553)	\$ 2,108	(34,406)

Provision for income taxes

Discontinued operations, net of taxes \$ (34,406)

- (1) Includes net interest expense of \$143,000, \$2.8 million and \$4.1 million for 2004, 2003 and 2002, respectively, and depreciation and amortization expense of \$2.1 million, \$10.9 million and \$26.0 million for 2004, 2003 and 2002, respectively. Also includes an \$8.6 million charge in 2004 primarily due to an increase in the estimate of outstanding general and professional liability reserves and related program costs.
- (2) Includes an accrual in 2003 for the purchase of incremental general and professional liability insurance on disposed nursing facilities.
- (3) Includes an adjustment of \$18.0 million in 2002 for estimated overpayments to MK Medical by government payors. MK Medical was part of our former Home Care segment.
- (4) Includes an accrual of \$1.0 million in 2002 for legal and related fees associated with the MK Medical estimated overpayment issue, and asset impairment charges related to certain nursing facilities and MK Medical.

39

Table of Contents

We recognized net gains on sales of \$67.1 million in discontinued operations related to divestitures of certain nursing facilities and assisted living centers during the year ended December 31, 2003. During 2002, we recognized asset impairment charges on certain of these divested facilities, amounting to \$33.2 million. These impairments were precipitated by an estimated decline in future cash flows, primarily associated with Medicare funding reductions. Of the divested nursing facilities that incurred impairment charges in 2002, we recognized net losses on sales of \$5.3 million.

Income Taxes

Our provision for income taxes of \$4.9 million for the year ended December 31, 2004, primarily related to state income taxes. We decreased the valuation allowance on our deferred tax assets by \$10.8 million during 2004 to \$158.3 million as of December 31, 2004, primarily due to the reversal of temporary differences and the utilization of net operating loss carryforwards, partially offset by increases in general business tax credits, state tax credits and alternative minimum tax credits (see *Tax Valuation Allowance* in our Critical Accounting Policies above).

At December 31, 2004, for income tax purposes, we had federal net operating loss carryforwards of \$60.8 million which expire in years 2018 through 2020; general business tax credit carryforwards of \$39.0 million which expire in years 2006 through 2024; and alternative minimum tax credit carryforwards of \$23.0 million which do not expire. Future tax benefits associated with these carryforwards are not recorded in our 2004 and 2003 consolidated financial statements as a result of the valuation allowance recorded in 2001.

Cumulative Effect of Accounting Change (see Asset Impairments in our Critical Accounting Policies above.)

New Accounting Standard

In December 2004, the Financial Accounting Standards Board (FASB) issued Statement of Financial Accounting Standards No. 123 (revised), *Share-Based Payment* (SFAS No. 123R). SFAS No. 123R eliminates the intrinsic value method as an alternative method of accounting for stock-based awards. SFAS No. 123R also revises the fair value-based method of accounting for share-based payment liabilities, forfeitures and modifications of stock-based awards and clarifies SFAS No. 123 s guidance in several areas, including measuring fair value, classifying an award as equity or as a liability and attributing compensation cost to reporting periods. In addition, SFAS No. 123R amends Statement of Financial Accounting Standards No. 95, *Statement of Cash Flows*, to require that excess tax benefits be reported as a financing cash inflow rather than as a reduction of taxes paid. We are required to adopt SFAS No. 123R for the interim period beginning July 1, 2005 and expect to use the modified version of prospective application. Based on the estimated value of current unvested stock options, we expect wages and related expenses to increase \$1.5 million in the last six months of 2005.

Liquidity and Capital Resources

At December 31, 2004, we had \$215.7 million in cash and cash equivalents and \$5.0 million of investments with maturities between three and six months. We anticipate that \$67.8 million of our cash balance, while not legally restricted, will be utilized primarily to fund certain general and professional liabilities and workers compensation claims and expenses. In addition, at December 31, 2004, we had approximately \$16.0 million in funds that are restricted for the payment of insured claims and are included in Prepaid expenses and other on our consolidated balance sheet. At December 31, 2004, we had positive working capital of \$175.3 million reflected on our consolidated balance sheet, an increase of 73% over the prior year. Also at December 31, 2004, we had \$75.0 million of borrowing capacity under our \$90.0 million revolving credit facility and \$21.5 million availability under our \$40.0 million letter of credit facility.

40

Table of Contents

Cash Flows. Our cash flows consisted of the following for the years ended December 31 (in thousands):

	2004	2003	2002
Net cash provided by operating activities	\$ 75,660	\$ 69,861	\$ 116,633
Net cash provided by (used for) investing activities	(69,979)	219,188	62,335
Net cash used for financing activities	(48,831)	(145,679)	(152,866)
Net increase (decrease) in cash and cash equivalents	\$ (43,150)	\$ 143,370	\$ 26,102

Net cash provided by operating activities, under the direct method, consists of the following for the years ended December 31 (in thousands):

	2004	2003	2002
Cash received from patients and third-party			
payors	\$ 2,094,684	\$ 2,342,011	\$ 2,526,436
Interest received	5,521	5,524	4,748
Cash paid to suppliers and employees	(1,972,340)	(2,217,620)	(2,352,598)
Interest paid	(46,356)	(67,710)	(65,658)
Income tax (paid) refunds received	(5,849)	7,656	3,705
-			
Net cash provided by operating activities	\$ 75,660	\$ 69,861	\$ 116,633

With the termination of daily purchases of receivables by BFC from Beverly Health and Rehabilitation Services, Inc. on March 1, 2004, accounts receivable on our consolidated balance sheet have increased and resulted in an \$82.0 million detriment to cash from operating activities on our consolidated statement of cash flows for the year ended December 31, 2004.

For the year ended December 31, 2004, proceeds from dispositions and collections on notes receivable totaling \$53.6 million, as well as cash generated from operations and cash on hand, were used to acquire Hospice USA, LLC and its affiliates for \$69.1 million and to fund capital expenditures of \$62.7 million, including \$54.7 million related to our Nursing Facilities segment.

Debt Transactions. At December 31, 2004, we had \$75.0 million of availability under our \$90.0 million revolving credit facility, with \$15.0 million being utilized for standby letters of credit primarily in support of certain insurance programs, security deposits, and debt or guaranteed debt obligations. During October 2004, we entered into a \$40.0 million letter of credit facility, of which \$18.5 million was utilized for standby letters of credit as of December 31, 2004. As of January 31, 2005, we had transferred all outstanding letter of credit commitments under our revolving credit facility to the new letter of credit facility, thereby increasing our availability under the revolving credit facility to the full \$90.0 million.

During June 2004, we commenced a cash tender offer to purchase any and all of our \$200.0 million principal amount outstanding of $9^5/8\%$ senior notes due 2009 at an offer price of \$1,190 per \$1,000 principal amount tendered, plus accrued and unpaid interest, and a solicitation of consents to amend the indenture under which the $9^5/8\%$ senior notes were issued. Holders of \$190.6 million of the $9^5/8\%$ senior notes tendered their notes and delivered consents. During June 2004, we issued \$215.0 million of $7^7/8\%$ senior subordinated notes due June 15, 2014 (the Senior Subordinated Notes). The Senior Subordinated Notes were issued at a discount (98.318% of par) to yield 8.125%. The Senior Subordinated Notes are general unsecured obligations subordinated in right of payment to our existing and future senior unsubordinated indebtedness and are guaranteed by certain of our subsidiaries. The Senior Subordinated

Notes were issued through a private placement; however during February 2005, we completed an exchange of these notes for publicly tradable notes.

The proceeds from the Senior Subordinated Notes, together with cash on hand, were used to purchase \$190.6 million of our 95/8% senior notes tendered, as well as to pay related fees and expenses. We recorded a pre-tax charge of \$40.4 million related to this transaction, including \$36.1 million for the prepayment premium, \$3.7 million for the write-off of deferred financing costs, as well as \$681,000 for fees and expenses related to the cash tender offer. Approximately \$36.1 million of the pre-tax charge and \$4.1 million of deferred

41

Table of Contents

financing costs related to the Senior Subordinated Notes were paid out in cash, using \$20.6 million of net proceeds from the issuance of the Senior Subordinated Notes and \$19.6 million of cash on hand.

During the second quarter of 2004, we entered into two amendments to our senior credit facility which, among other things, permitted the issuance of the Senior Subordinated Notes and the purchase of our 95/8% senior notes, reduced the interest rate on the term loan portion of the senior credit facility, increased the size of our revolving credit facility from \$75.0 million to \$90.0 million and modified certain financial covenant levels.

Our revolving credit and term loan agreements contain a number of financial covenants, such as a limit on the ratio of total debt and senior secured debt to earnings before interest, taxes, depreciation, and amortization (see Item 6). Other covenants limit our ability to incur additional debt, to pledge/sell assets and to make substantial payments in connection with our common stock. The revolving credit and term loan agreements allow for \$80.0 million of annual capital expenditures, plus a provision to carry forward any unused availability from the previous year. Our outstanding indentures contain customary covenants, including limits on liens, subsidiary debt and payments in connection with our common stock. None of these covenants are presently considered restrictive to our operations. We are currently in compliance with all of our debt covenants.

A credit rating reflects an assessment by the rating agency of the credit risk associated with particular securities we issue, based on information provided by us and other sources. Credit ratings are not recommendations to buy, sell or hold securities and are subject to revision or withdrawal at any time by the assigning rating agency. Each rating agency may have different criteria for evaluating company risk, and therefore ratings should be evaluated independently for each rating agency. Lower credit ratings generally result in higher borrowing costs and reduced access to capital markets. Our credit ratings are below investment grade. Any credit downgrade could affect our ability to enter into and maintain certain contracts on favorable terms and increase our cost of borrowing.

Our credit ratings as of December 31, 2004, are as follows:

		2.75% Convertible			
	Senior Implied/	Subordinated Notes and			
	Corporate	7 ⁷ /8% Senior Subordinated			
Rating Agency	Rating	Notes			
Standard & Poor s(a)	BB-	В			
Moody s(a)	Ba3	B2			
Fitch(a)	BB-	B+			

(a) Ratings outlook is stable.

Acquisitions, Divestitures and Other. On July 30, 2004, we purchased substantially all of the assets of Hospice USA, LLC and its affiliates, which were privately held companies providing hospice services in Mississippi, Alabama and Tennessee, for cash of approximately \$69.1 million. At the time of acquisition, Hospice USA, LLC and its affiliates operated 18 hospice locations and had an additional 16 locations under development. The acquisition was part of our ongoing strategy to expand our service businesses.

In 2003, we completed a full evaluation of our Nursing Facilities segment portfolio, which included the identification of non-strategic facilities and facilities that account for a disproportionately high share of projected general and professional liability costs. As a result of this analysis, we have divested a significant portion of our nursing facility capacity. During the years ended December 31, 2004 and 2003, we sold, closed or terminated the leases on 103 nursing facilities, nine assisted living centers, of which 89 nursing facilities and seven assisted living centers were part of this divestiture strategy. We received net cash proceeds of \$290.6 million from the sales of these nursing facilities, our former Matrix outpatient therapy clinics and managed care network, certain assets of our

AseraCare segment and other assets.

As of December 31, 2004, we had 27 nursing facilities classified as held for sale that met the criteria set forth in SFAS No. 144 to be classified as held for sale and we expect to dispose of them within the first half of 2005. The 10 outpatient clinics classified as held for sale at December 31, 2004, were sold in February 2005 (see Item 8. Note 15).

42

Table of Contents

Our financial condition, results of operations and cash flows may be adversely impacted by the unsolicited indication of interest in acquiring us by a group including Arnold Whitman, the Chief Executive Officer of Formation Capital, LLC and Appaloosa Management, LP, a New Jersey based hedge fund, among others, and related actions taken by this group, including the nomination of candidates for election to our Board of Directors. These actions may impact our ability to attract and retain customers, management and employees and may result in the incurrence of significant advisory fees, litigation costs and other expenses.

Summary. We currently anticipate that cash on hand, cash flows from operations and availability under our banking arrangements will be adequate to repay our debts due within one year of \$12.2 million, to make capital additions and improvements of approximately \$100.0 million, to make operating lease and other contractual obligation payments, to make selective acquisitions, including previously leased facilities and to meet working capital requirements for the twelve months ending December 31, 2005.

Our ability to make payments on, and to refinance, our indebtedness, as well as to fund planned capital expenditures, including strategic acquisitions, and research and development efforts, will depend on our ability to generate cash in the future. This, to a certain extent, is subject to general economic, financial, competitive, legislative, regulatory and other factors that are beyond our control. However, based on our current level of operations and anticipated cost savings and operating improvements, we believe our cash flows from operations, current cash and cash equivalents and available borrowings will be adequate to meet our future liquidity needs for at least the next five years.

We cannot assure you, however, that our business will generate sufficient cash flows from operations, that currently anticipated cost savings and operating improvements will be realized on schedule or that future borrowings will be available to us in an amount sufficient to enable us to pay our indebtedness or to fund our other liquidity needs. We may need to refinance all or a portion of our indebtedness on or before maturity. We cannot assure you that we will be able to refinance any of our indebtedness on commercially reasonable terms or at all. If cash flows from operations or availability under our existing banking arrangements fall below expectations, we may be required to utilize cash on hand, delay capital expenditures, dispose of certain assets, issue additional debt securities, or consider other alternatives to improve liquidity. (See Item 1. Business Risks Relating to our Company *To service our indebtedness, we will require a significant amount of cash. Our ability to generate cash depends on many factors, some of which are beyond our control.*)

Obligations and Commitments

As of December 31, 2004, we have off-balance sheet debt guarantees of \$11.8 million that primarily arose from our sales of nursing facilities. We also guarantee certain third-party operating leases. Those guarantees arose from our dispositions of leased nursing facilities, and the underlying leases have \$54.8 million of minimum rental commitments remaining through the initial lease terms, with the latest termination date being February 2019. We have recorded approximately \$627,000, included in Other accrued liabilities on the consolidated balance sheet at December 31, 2004, as the estimated fair value of guarantees in accordance with FASB Interpretation No. 45, *Guarantor s Accounting and Disclosure Requirements for Guarantees, Including Indirect Guarantees of Indebtedness of Others*.

43

We are party to many contractual obligations involving commitments to make payments to third parties. A summary of our long-term contractual obligations and commitments in future years as of December 31, 2004, including principal and interest, is shown below (in thousands):

Payments Due by Period

	Total	2005		2006-2007		008-2009	Ai	ter 2009
Contractual obligations:								
Long-term debt(a)	\$ 874,595	\$ 48,287	\$	129,517	\$	175,824	\$	520,967
Capital lease obligations	7,799	530		906		820		5,543
Operating leases	95,488	37,362		30,315		14,913		12,898
Federal government								
settlement obligations	55,769	18,125		36,250		1,394		
Unconditional purchase								
obligations(b)	8,277	4,273		4,004				
Total contractual cash								
obligations	\$ 1,041,928	\$ 108,577	\$	200,992	\$	192,951	\$	539,408

	Total		Amount	of Cor	nmitme	nt Ex	piration l	Per Period				
	 Amounts Committed		2005	2000	6-2007	200	08-2009		After 2009			
Other commercial commitments:												
Letters of credit	\$ 33,455	9	33,455	\$		\$		\$				
Guarantees	11,822				950		2,002		8,870			
Total commercial commitments	\$ 45,277	\$	\$ 33,455	\$	950	\$	2,002	\$	8,870			

- (a) For variable-rate debt, we estimated future interest payments based on published forward yield curve analyses. The long-term debt amounts exclude \$3.5 million of unamortized discounts related to our 77/8% senior subordinated notes.
- (b) We have unconditional purchase obligations totaling \$8.3 million primarily due to our outsourcing of certain information technology functions, as well as contracts relative to our frame relay network and certain office equipment. These contracts involve future minimum commitments that are noncancelable or impose a penalty if these agreements are cancelled prior to expiration.

Excluded from the contractual obligations and commitments table are payments we may make for general and professional liabilities and workers compensation risks. Our recorded reserves for these liabilities primarily includes estimated reserves for losses retained by us and not covered by insurance (see Item 8 Note 2).

The expected timing and amount of payments for obligations and commitments discussed above are estimated based on currently available information. The actual timing and amount of payments may be different.

44

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

We are exposed to market risk because we utilize financial instruments. The market risks inherent in these instruments are attributable to the potential loss from adverse changes in the general level of United States interest rates. We manage our interest rate risk exposure by maintaining a mix of fixed and variable rates for debt. The following table provides information regarding our market sensitive financial instruments and constitutes a forward-looking statement. The actual results of our mix of financial instruments could differ materially from the outlook set forth below.

	Expected Maturity Dates										г		Fair Value ember 3	l oc	Fair Value	21			
		2005	2	2006	2	2007		2008		2009	T	hereafter		Total	Jec.	2004	rçı	2003	,1,
								(Dol	lar	rs in thou	IS	ands)							
Total long-term debt:(1)																			
Fixed rate	\$	10,740	\$	8,755	\$ 1	14,652	\$	8,057	\$	16,180	\$	368,757	\$ 4	127,141	\$	503,776	\$	503,923	,
Average interest		c = 2 cr		c = 100		c = 2 cr				6.60%		6 4 0 00							
rate		6.73%		6.74%		6.73%		6.69%		6.68%		6.58%							
Variable rate	\$	1,500	\$	1,510	\$ 3	33,583	\$	97,381	\$	193	9	369	\$	134.536	\$	134,536	\$	136.800)
Average interest	Ψ	1,000	Ψ	1,510	ψ.	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	Ψ	77,501	Ψ	195	4		Ψ.	.51,550	Ψ	15 1,550	Ψ	120,000	
rate		5.98%		6.28%		6.62%		6.90%		8.36%		8.86%							
Total notes receivable:																			
Fixed rate	\$	2,269	\$	427	\$	329	\$	208	\$	216	\$	1,709	\$	5,158	\$	5,158	\$	27,459	,
Average interest		0.460		0.420		0.670		0.720		0.25%		0.750							
rate Variable		9.46%		9.42%		9.67%		9.73%		9.25%		9.75%							
rate	\$	38	\$	40	\$	43	\$	45	\$	48	9	5 163	\$	377	\$	377	\$	414	
Average interest								-		-							·		
rate		6.25%		6.25%		6.25%		6.25%		6.25%		6.25%							

⁽¹⁾ See Item 8-Note 9 for a discussion of our 2004 and 2003 refinancings. For variable-rate debt, we estimate future interest rates based on published forward yield curve analyses. The long-term debt amounts exclude \$3.5 million of unamortized discounts related to our 77/8% senior subordinated notes.

45

Table of Contents

ITEM 8. CONSOLIDATED FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.

	Page
Report of Ernst & Young LLP, Independent Registered Public Accounting Firm	47
Report of Ernst & Young LLP, Independent Registered Public Accounting Firm	48
Consolidated Balance Sheets	49
Consolidated Statements of Operations	50
Consolidated Statements of Stockholders Equity	51
Consolidated Statements of Cash Flows	52
Notes to Consolidated Financial Statements	53
Supplementary Data (Unaudited) Quarterly Financial Data	93
46	

Table of Contents

REPORT OF ERNST & YOUNG LLP, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

The Board of Directors and Stockholders

Beverly Enterprises, Inc.

We have audited the accompanying consolidated balance sheets of Beverly Enterprises, Inc. as of December 31, 2004 and 2003, and the related consolidated statements of operations, stockholders—equity, and cash flows for each of the three years in the period ended December 31, 2004. Our audits also included the financial statement schedule listed in the Index at Item 15(a). These financial statements and schedule are the responsibility of the Company s management. Our responsibility is to express an opinion on these financial statements and schedule based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of Beverly Enterprises, Inc. at December 31, 2004 and 2003, and the consolidated results of its operations and its cash flows for each of the three years in the period ended December 31, 2004, in conformity with U.S. generally accepted accounting principles. Also, in our opinion, the related financial statement schedule, when considered in relation to the basic consolidated financial statements taken as a whole, presents fairly in all material respects the information set forth therein.

As discussed in Note 1 to the consolidated financial statements, in 2002 the Company changed its method of accounting for goodwill.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the effectiveness of Beverly Enterprises, Inc. s internal control over financial reporting as of December 31, 2004, based on criteria established in Internal Control Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated March 8, 2005, expressed an unqualified opinion thereon.

Fort Smith, Arkansas March 8, 2005

47

Table of Contents

REPORT OF ERNST & YOUNG LLP, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

The Board of Directors and Stockholders Beverly Enterprises, Inc.

We have audited management s assessment, included in the accompanying Management s Report on Internal Control Over Financial Reporting, that Beverly Enterprises, Inc. (the Company) maintained effective internal control over financial reporting as of December 31, 2004, based on criteria established in Internal Control Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (the COSO criteria). The Company s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting. Our responsibility is to express an opinion on management s assessment and an opinion on the effectiveness of the Company s internal control over financial reporting based on our audit.

We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, evaluating management s assessment, testing and evaluating the design and operating effectiveness of internal control, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

A company s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

In our opinion, management s assessment that Beverly Enterprises, Inc. maintained effective internal control over financial reporting as of December 31, 2004, is fairly stated, in all material respects, based on the COSO criteria. Also, in our opinion, Beverly Enterprises, Inc. maintained, in all material respects, effective internal control over financial reporting as of December 31, 2004, based on the COSO criteria.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated balance sheets of Beverly Enterprises, Inc. as of December 31, 2004 and 2003, and the related consolidated statements of operations, stockholders equity, and cash flows for each of the three years in the period ended December 31, 2004 of Beverly Enterprises, Inc. and our report dated March 8, 2005 expressed an unqualified opinion thereon.

Fort Smith, Arkansas March 8, 2005

48

BEVERLY ENTERPRISES, INC. CONSOLIDATED BALANCE SHEETS

December 31,

2004	2003
------	------

(Dollars	in	thousands))
----------	----	------------	---

215,665	\$ 258,815
235,477	164,635
2,786	13,724
9,181	10,425
14,898	3,498
	31,342
37,266	33,377
515,273	515,816
653,656	694,220
124,066	57,102
68,390	79,283
192,456	136,385
1,361,385	\$ 1,346,421
	235,477 2,786 9,181 14,898 37,266 515,273 653,656 124,066 68,390 192,456

LIABILITIES AND STOCKHOLDERS	EQUITY	
Current liabilities:		
Accounts payable \$	67,778	\$ 67,572
Accrued wages and related liabilities	104,037	116,717
Accrued interest	3,602	6,896
General and professional liabilities	54,216	93,736
Federal government settlement obligations	14,359	13,125
Liabilities held for sale	676	672
Other accrued liabilities	83,097	102,289
Current portion of long-term debt	12,240	13,354
Total current liabilities	340,005	414,361
Long-term debt	545,943	552,873
Other liabilities and deferred items	203,024	141,001
Commitments and contingencies		
Stockholders equity:		

Preferred stock, shares authorized: 25,000,000

Edgar Filing: SURMODICS INC - Form 8-K

Common stock, shares issued: 2004 116,62	21,715; 2003		
115,594,806		11,662	11,559
Additional paid-in capital		902,053	895,950
Accumulated deficit		(532,804)	(560,825)
Treasury stock, at cost: 8,283,316		(108,498)	(108,498)
Total stockholders equity		272,413	238,186
	\$	1,361,385	\$ 1,346,421

See accompanying notes.

49

BEVERLY ENTERPRISES, INC. CONSOLIDATED STATEMENTS OF OPERATIONS

Years Ended December 31,

		2004		2002					
	(In thousands, except per share amounts)								
Revenues	\$	1,988,852	\$	1,802,026	\$	1,766,726			
Costs and expenses:									
Wages and related		1,147,743		1,078,548		1,068,629			
Provision for insurance and related items		127,653		109,377		84,161			
Other operating and administrative		522,603		462,144		458,311			
Depreciation and amortization		62,166		58,807		62,906			
Florida insurance reserve adjustment						22,179			
Special charge and adjustment related to						,			
California investigation settlement				(925)		6,300			
Adjustment related to settlements of federal				, ,		,			
government investigations						(9,441)			
Asset impairments, workforce reductions									
and other unusual items		448		3,825		46,287			
				- ,		-, -·			
Total costs and expenses		1,860,613		1,711,776		1,739,332			
1		, ,		, , , , , , ,		,,.			
Income before other income (expenses)		128,239		90,250		27,394			
Other income (expenses):				, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		,			
Interest expense		(45,637)		(63,314)		(62,652)			
Costs related to early extinguishments of		(10,007)		(00,01.)		(02,002)			
debt		(40,935)		(6,634)					
Interest income		5,485		5,363		4,688			
Net gains on dispositions		396		422		2,142			
Gain on sale of equity investment		270		6,686		2,1 12			
Sum on suite of equity investment				0,000					
Total other expenses, net		(80,691)		(57,477)		(55,822)			
•									
Income (loss) before provision for income taxes,									
discontinued operations and cumulative effect of									
change in accounting for goodwill		47,548		32,773		(28,428)			
Provision for income taxes		4,890		5,069		6,085			
		,		,		,			
Income (loss) before discontinued operations and									
cumulative effect of change in accounting for									
goodwill		42,658		27,704		(34,513)			
Discontinued operations, net of taxes: 2004 \$55;		,		.,		(= ,= =)			
2003 \$3,378; 2002 \$0		(14,637)		52,764		(34,406)			
Cumulative effect of change in accounting for		(= 1,007)				(2 1,100)			
goodwill, net of income taxes of \$0						(77,171)			
6, 1 , 1						(,,,1,1)			
Net income (loss)	\$	28,021	\$	80,468	\$	(146,090)			
1.00 110 (1000)	Ψ	20,021	Ψ	00,100	Ψ	(110,070)			

Net income (loss) per share of common stock:

Basic:										
Before discontinued operations and cumulative effect of change in accounting										
for goodwill	\$	0.40	\$	0.26	\$	(0.33)				
Discontinued operations, net of taxes		(0.14)		0.49		(0.32)				
Cumulative effect of change in accounting for goodwill, net of taxes						(0.74)				
Net income (loss) per share of common										
stock	\$	0.26	\$	0.75	\$	(1.39)				
Shares used to compute basic net income (loss) per share		107,749		106,582		104,726				
Diluted:										
Before discontinued operations and cumulative effect of change in accounting										
for goodwill	\$	0.37	\$	0.26	\$	(0.33)				
Discontinued operations, net of taxes		(0.12)		0.48		(0.32)				
Cumulative effect of change in accounting for goodwill, net of taxes						(0.74)				
Net income (loss) per share of common										
stock	\$	0.25	\$	0.74	\$	(1.39)				
Shares used to compute diluted net income (loss) per share		124,334		109,922		104,726				
See accompanying notes.										

50

BEVERLY ENTERPRISES, INC. CONSOLIDATED STATEMENTS OF STOCKHOLDERS EQUITY

	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Accumulated Other Comprehensive Income (Loss)	Treasury Stock	Total
			(Dollars i	in thousands)		
Balances at January 1, 2002	\$ 11,281	\$ 887,668	\$ (495,203)	\$ 2,029	\$ (109,278)	\$ 296,497
Employee stock transactions related to 436,038 shares of	44	2 (00				2.724
common stock, net Reissuance of	44	3,680				3,724
124,212 shares of common stock from						
treasury		434			419	853
Comprehensive income (loss):						
Unrealized losses on securities, net of						
income taxes of \$0 Foreign currency translation adjustments, net of				(1,464)		(1,464)
income taxes of \$0				(48)		(48)
Net loss			(146,090)	,		(146,090)
Total comprehensive loss						(147,602)
Balances at December 31, 2002	11,325	891,782	(641,293)	517	(108,859)	153,472
Employee stock transactions related to 2,345,465 shares of						
common stock, net	234	4,274				4,508
Reissuance of 108,230 shares of common stock from						
treasury		(106)			361	255
Comprehensive income (loss):						
Unrealized losses on securities, net of						
income taxes of \$0				(512)		(512)

Edgar Filing: SURMODICS INC - Form 8-K

Foreign currency translation adjustments, net of									
income taxes of \$0				(5)		(5)			
Net income			80,468			80,468			
Total comprehensive income						79,951			
Balances at December 31,									
2003	11,559	895,950	(560,825)		(108,498)	238,186			
Employee stock transactions related to 1,026,909 shares of									
common stock, net	103	6,103				6,206			
Net income and total comprehensive income			28,021			28,021			
Balances at December 31, 2004	\$ 11,662	\$ 902,053	\$ (532,804)	\$	\$ (108,498)	\$ 272,413			
See accompanying notes.									
	51								

BEVERLY ENTERPRISES, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS

Years Ended December 31,

	2	2004 2003		2002		
			(In t	thousands)		
Cash flows from operating activities:						
Net income (loss)	\$	28,021	\$	80,468	\$	(146,090)
Adjustments to reconcile net income (loss) to net cash						
provided by operating activities, including discontinued						
operations:						
Depreciation and amortization		64,301		69,663		88,943
Provision for reserves on patient, notes and other						
receivables, net		8,815		21,605		55,570
Amortization of deferred financing costs		2,754		4,474		3,096
Florida insurance reserve adjustment						22,179
Special charge and adjustment related to California						
investigation settlement				(925)		6,300
Adjustment related to settlements of federal						
government investigations						(9,441)
Asset impairments, workforce reductions and other						
unusual items		4,790		7,459		85,773
Costs related to early extinguishments of debt		40,935		6,634		
Cumulative effect of change in accounting for						55 151
goodwill						77,171
Losses (gains) on dispositions of facilities and other		705		(01.500)		(1.055)
assets, net		725		(81,508)		(1,855)
Insurance related accounts		6,523		(32,727)		8,411
Changes in operating assets and liabilities, net of						
acquisitions and dispositions: Accounts receivable		(72.092)		(12.069)		7.906
		(72,082)		(13,968)		7,896
Operating supplies Prepaid expenses and other receivables		352 5,155		1,467		3,081 988
• •				(2,502) 117		(85,335)
Accounts payable and other accrued expenses Income taxes payable		(8,584) (904)		16,103		9,790
Other, net		(5,141)		(6,499)		(9,844)
Other, liet		(3,141)		(0,499)		(9,044)
Total adjustments		47,639		(10,607)		262,723
Total adjustments		1 1,037		(10,007)		202,723
Net cash provided by operating activities		75,660		69,861		116,633
Cash flows from investing activities:		73,000		02,001		110,033
Capital expenditures		(62,718)		(43,984)		(100,103)
Proceeds from dispositions of facilities and other		(02,710)		(15,501)		(100,100)
assets, net		15,557		275,039		169,471
Payments for acquisitions, net of cash acquired		(71,352)		(459)		,
Collections on notes receivable		38,089		8,689		1,616
Payments for designated funds, net		(1,009)		(5,183)		(260)
,		(-,)		(-,-00)		(=00)

Edgar Filing: SURMODICS INC - Form 8-K

Proceeds from Beverly Funding Corporation									
investment		28,956							
Other, net		(17,502)		(14,914)		(8,389)			
Net cash provided by (used for) investing									
activities		(69,979)		219,188		62,335			
Cash flows from financing activities:									
Proceeds from issuance of long-term debt		211,384		250,000		5,000			
Repayments of long-term debt		(219,428)		(313,352)		(116,496)			
Repayments of off-balance sheet financing				(69,456)		(42,901)			
Proceeds from exercise of stock options		3,592		1,108		1,699			
Deferred financing and other costs (including those									
related to early extinguishments of debt)		(44,379)		(13,979)		(168)			
Net cash used for financing activities		(48,831)		(145,679)		(152,866)			
Net increase (decrease) in cash and cash equivalents		(43,150)		143,370		26,102			
Cash and cash equivalents at beginning of year		258,815		115,445		89,343			
Cash and cash equivalents at end of year	\$	215,665	\$	258,815	\$	115,445			
Supplemental schedule of cash flow information:									
Cash paid (received) during the year for:									
Interest, net of amounts capitalized	\$	46,356	\$	67,710	\$	65,658			
Income tax payments (refunds), net		5,849		(7,656)		(3,705)			
See accompa	nying	g notes.							
5	2								
52									

BEVERLY ENTERPRISES, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Years ended December 31, 2004, 2003, and 2002

1. Summary of Significant Accounting Policies

Basis of Presentation

References herein to the Company include Beverly Enterprises, Inc. and its wholly owned subsidiaries.

On December 31, 2004, we operated 351 nursing facilities (of which 27 were held for sale), 18 assisted living centers, 52 hospice and home health locations and 10 outpatient clinics (all of which were held for sale see Note 15) in 25 states and the District of Columbia. Our operations also included rehabilitation therapy services in 37 states and the District of Columbia. Our consolidated financial statements include the accounts of the Company and all of its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.

Restatement

The accompanying consolidated financial statements have been restated to report facilities, clinics and other assets which have been sold, closed or classified as held for sale during the year ended December 31, 2004, as discontinued operations. See *Earnings Per Share* below for a change in the calculated 2003 diluted earnings per share to include our convertible subordinated notes, on an if-converted basis, since their issuance in October 2003, in accordance with Emerging Issues Task Force Issue No. 04-8, *The Effect of Contingently Convertible Debt on Diluted Earnings Per Share* (EITF 04-8).

Use of Estimates

Generally accepted accounting principles require management to make estimates and assumptions when preparing financial statements that affect:

the reported amounts of assets and liabilities at the date of the financial statements; and

the reported amounts of revenues and expenses during the reporting period.

They also require management to make estimates and assumptions regarding contingent assets and liabilities at the date of the financial statements. Actual results could differ from those estimates.

Cash and Cash Equivalents

Cash and cash equivalents include time deposits and certificates of deposit with original maturities of three months or less.

Receivables and Concentration of Credit Risk

We have significant accounts receivable whose collectibility or realizability is dependent upon the performance of certain governmental programs, primarily Medicare and Medicaid. Approximately 70% and 56% of our net patient accounts receivable at December 31, 2004 and 2003, respectively, are due from such programs. These receivables represent our primary concentration of credit risk. We do not believe there are significant credit risks associated with these governmental programs. We believe that an adequate provision, based on historical experience, has been made for the possibility of a portion of these and other receivables becoming uncollectible and we continually monitor and adjust these allowances as necessary. In establishing our estimate of uncollectible accounts, we consider our historical collection experience, the aging of the account, and the payor classification. Private pay accounts usually represent our highest collectibility risk. We write off uncollectible accounts receivable after all collection efforts have been exhausted and we determine they will not be collected.

53

BEVERLY ENTERPRISES, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) Years ended December 31, 2004, 2003, and 2002

1. Summary of Significant Accounting Policies (Continued)

Our allowance for doubtful accounts represented approximately 10% and 16% of accounts receivable at December 31, 2004 and 2003, respectively. We believe adequate provision has been made for receivables that may prove to be uncollectible. During 2004, our Nursing Facilities segment s weighted average collection experience improved 21 basis points when compared to 2003. As a result of the improved collection rates, we reduced our recorded allowance for doubtful accounts by approximately \$4.0 million. Changes in collection rates or payment patterns could affect the assumptions used to estimate the current level of allowance for doubtful accounts.

Certain interest-bearing notes receivable are placed on a nonaccrual basis when uncertainty arises as to the collectibility of principal or interest. Notes receivable of \$4.6 million and \$6.7 million at December 31, 2004 and 2003, respectively, were on a nonaccrual basis. After considering the estimated collateral values, specific collectibility allowances of \$2.5 million and \$3.7 million, respectively, have been recorded on these nonaccrual notes.

Property and Equipment, net

Property and equipment is stated at the lower of carrying value or fair value, or where appropriate, the present value of the related capital lease obligations less accumulated amortization. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the assets.

Intangible Assets

Following is a summary of our goodwill and other indefinite-lived intangible assets and related accumulated amortization, included in Other assets, at December 31 (in thousands):

	Co	st Basis	Carrying Value			
	2004	2003	2004	2003	2004	2003
Goodwill Other indefinite-lived	\$ 145,43	\$ 78,609	\$ 21,364	\$ 21,507	\$ 124,066	\$ 57,102
intangible assets	10,02	9,546	4,569	4,547	5,451	4,999
	\$ 155,45	\$ 88,155	\$ 25,933	\$ 26,054	\$ 129,517	\$ 62,101

In July 2004, we purchased substantially all of the assets of Hospice USA, LLC and its affiliates (Hospice USA) which led to the recording of \$67.6 million of goodwill, of which all is expected to be deductible for income tax purposes, \$725,000 of other indefinite-lived intangible assets and \$1.3 million of operating rights and licenses.

In July 2001, Statement of Financial Accounting Standards No. 142, *Goodwill and Other Intangible Assets* (SFAS No. 142) was issued, which established new rules on the accounting for goodwill and other intangible assets. Under SFAS No. 142, goodwill and intangible assets with indefinite lives are no longer amortized; however, they are subject to annual impairment tests as prescribed by the Statement. Intangible assets with definite lives continue to be amortized over their estimated useful lives. With respect to our goodwill and intangible assets, SFAS No. 142 was effective for us beginning January 1, 2002.

In accordance with this standard, we performed the initial screening for potential impairments of our indefinite-lived intangible assets by reporting unit as of January 1, 2002. We determined the estimated fair values of each reporting unit using discounted cash flow analyses, along with independent source data related

BEVERLY ENTERPRISES, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) Years ended December 31, 2004, 2003, and 2002

1. Summary of Significant Accounting Policies (Continued)

to recent transactions. Based on this determination, we identified potential goodwill impairments at our former Matrix and Home Care Services

Care Focus reporting units.

The fair values of the reporting units were derived from a five-year projection of revenues and expenses plus residual value, with the resulting projected cash flows discounted at an appropriate weighted average cost of capital. The analysis was completed in the fourth quarter of 2002, and led to the recording of goodwill impairment charges as the cumulative effect of an accounting change of \$77.2 million as of January 1, 2002, including \$70.6 million for Matrix and \$6.6 million for Care Focus.

Following is a summary of our finite-lived intangible assets and related accumulated amortization, by major classification, which are included in Other assets, at December 31 (in thousands):

	Cost	Cost Basis			Carrying Value		
	2004	2003	2004	2003	2004	2003	
Operating rights and licenses Leasehold interests	\$ 3,091 349	\$ 1,801 439	\$ 451 349	\$ 203 389	\$ 2,640	\$ 1,598 50	
	\$ 3,440	\$ 2,240	\$ 800	\$ 592	\$ 2,640	\$ 1,648	

The acquisition of Hospice USA caused our weighted-average amortization period for operating rights and licenses to decrease to approximately 6 years due to the estimated useful lives of the acquired intangibles. Amortization expense related to these intangibles for the years ended December 31, 2004, 2003 and 2002 was approximately \$300,000, \$100,000 and \$300,000, respectively. Our estimated aggregate annual amortization expense for these intangibles for each of the next five years is approximately \$300,000.

On an ongoing basis, we review the carrying value of our finite-lived intangibles in light of any events or circumstances that indicate they may be impaired or that the amortization period may need to be adjusted and make any necessary adjustments. As of December 31, 2004, we do not believe there are any indications that the carrying values, or the useful lives, of these assets need to be adjusted. We have no residual values assigned to our finite-lived intangible assets.

Insurance

We record our provisions for insurance based on estimates of projected claims cost, premiums, and program related expenses. We discount our insurance reserves using our incremental borrowing rate. See Note 2 for a discussion of our insurance liabilities and related items.

We are primarily self-insured for employee medical and dental insurance programs. During the second quarter of 2004, we recorded a change in estimate relative to reserves established for these insurance programs of \$6.1 million. This change in estimate was primarily due to a reduction in claims experience resulting from a change in our medical insurance programs in 2003.

Income Taxes

We follow the liability method in accounting for income taxes in accordance with Statement of Financial Accounting Standards No. 109, *Accounting for Income Taxes* (SFAS No. 109). Under the liability method, deferred tax assets and liabilities are recorded at currently enacted tax rates based on the difference between the tax basis of assets and liabilities and their carrying amounts for financial reporting purposes, referred to as temporary differences.

Due to uncertainties surrounding the generation of sufficient future

55

BEVERLY ENTERPRISES, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) Years ended December 31, 2004, 2003, and 2002

1. Summary of Significant Accounting Policies (Continued)

income in the near term necessary to realize certain deferred tax benefits, primarily relating to net operating loss carryforwards, we have established a full valuation allowance on our net deferred tax assets (see Note 12).

Transfers of Financial Assets

Through February 29, 2004 and during 2003 and 2002, the Company, through its wholly owned subsidiary Beverly Health and Rehabilitation Services, Inc. (BHRS), sold on a revolving basis certain Medicaid and Veterans Administration patient accounts receivable to a non-consolidated bankruptcy remote, qualifying special purpose entity (QSPE), Beverly Funding Corporation (BFC), at a discount of 1%. These daily transactions constituted true sales of receivables for which BFC bore the risk of collection. The Company accounted for the transfers of receivables as sales in accordance with Statement of Financial Accounting Standards No. 140, Accounting for Transfers and Servicing of Financial Assets and Extinguishments of Liabilities (SFAS No. 140).

In accordance with its medium-term notes agreement, BFC ceased purchasing receivables from BHRS on March 1, 2004. Cash collections on and after March 1, 2004, on receivables purchased by BFC prior to March 1, 2004, were accumulated by BFC to repay its \$70.0 million of medium-term notes on June 15, 2004. Upon repayment of the medium-term notes on June 15, 2004, BFC no longer had third-party beneficial owners and, therefore, no longer met the conditions of a qualifying special purpose entity, in accordance with SFAS No. 140. Therefore, during the second quarter of 2004, we reconsolidated the remaining balances of BFC with us. Activities related to the revolving sales structure with BFC were as follows for the years ended December 31 (in thousands):

	2004	2003	2002
New receivables sold	\$ 119,360	\$ 824,475	\$ 867,772
Cash collections remitted	197,123	830,457	857,731
Fees received for servicing	658	2,142	2,119
Loss on sale of receivables	(1,194)	(8,245)	(8,678)

BHRS provided invoicing and collection services related to the receivables owned by BFC for a market-based servicing fee. BHRS recognized a loss for the 1% discount at the time of sale which is included in Other operating and administrative costs and expenses and in Net cash provided by operating activities in our consolidated financial statements.

At December 31, 2003, we had an investment in BFC of approximately \$31.3 million. The investment was recorded at its estimated fair value and was subjected to periodic review for other than temporary impairment. Prior to consolidation, we received \$29.0 million of cash from BFC as a return on our investment. The remaining investment balance was recovered through cash collections on the reconsolidated receivables owned by BFC.

Under the revolving sales structure, BFC purchased receivables for cash on a daily basis from BHRS. When BFC ceased its purchases on March 1, 2004, accounts receivable began to increase on our condensed consolidated balance sheet. Our cash flows from operating activities in 2004 have temporarily been negatively impacted since the timing of collections of these receivables is longer than when the receivables were being sold to BFC daily.

56

BEVERLY ENTERPRISES, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) Years ended December 31, 2004, 2003, and 2002

1. Summary of Significant Accounting Policies (Continued) Revenues

Our revenues are derived primarily from providing long-term healthcare services. Approximately 80% of our revenues in 2004 was derived from federal (Medicare) and state (Medicaid) medical assistance programs. We record revenues when services are provided at standard charges adjusted to amounts estimated to be received under governmental programs and other third-party contractual arrangements based on contractual terms and historical experience. These revenues and receivables are reported at their estimated net realizable amounts and are subject to audit and retroactive adjustment.

Retroactive adjustments are estimated in the recording of revenues in the period the related services are rendered. These amounts are adjusted in future periods as adjustments become known or as cost reporting years are no longer subject to audits, reviews or investigations. Due to the complexity of the laws and regulations governing the Medicare and Medicaid programs, there is at least a possibility that recorded estimates will change by a material amount in the near term. See Note 4 for a discussion of a settlement with the federal government related to Medicare cost reimbursement issues and Note 10 for the estimated potential overpayment from government programs resulting from an internal investigation of our former MK Medical business unit. Excluding these items, changes in estimates related to third-party receivables resulted in an increase in revenues of approximately \$8.0 million, \$8.7 million and \$948,000 for the years ended December 31, 2004, 2003 and 2002, respectively.

Stock-Based Awards

On December 31, 2002, the Financial Accounting Standards Board (FASB) issued Statement of Financial Accounting Standards No. 148, *Accounting for Stock-Based Compensation Transition and Disclosure* (SFAS No. 148). SFAS No. 148 amends Statement of Financial Accounting Standards No. 123, *Accounting for Stock-Based Compensation* (SFAS No. 123) to provide methods of transition for an entity that changes to the fair value method of accounting for stock-based employee compensation. In addition, SFAS No. 148 amends the disclosure provisions of SFAS No. 123 and Accounting Principles Board Opinion No. 28, *Interim Financial Reporting* (APB 28) to require expanded disclosure of the effects of an entity s accounting policy with respect to stock-based employee compensation on reported net income and earnings per share in annual and interim financial statements and allows companies to continue to use the intrinsic value method.

We continue to use the intrinsic value method to account for our stock options. Accordingly, we do not recognize compensation expense for our stock option grants, which are issued at fair market value on the date of grant. However, we recognize compensation expense for our restricted stock grants at the fair market value of our common stock on the date of grant over the respective vesting periods on a straight-line basis. See Note 11 for other disclosures required by SFAS No. 148 and for the pro forma effects on our reported net income (loss) and diluted net income (loss) per share if we recognized compensation expense on all stock-based awards using estimated fair values over the vesting periods and other disclosures required by SFAS No. 148.

In December 2004, the FASB issued Statement of Financial Accounting Standards No. 123 (revised), *Share-Based Payment* (SFAS No. 123R). SFAS No. 123R prospectively eliminates the intrinsic value method as an alternative method of accounting for stock-based awards. SFAS No. 123R also revises the fair value-based method of accounting for share-based payment liabilities, forfeitures and modifications of stock-based awards and clarifies SFAS No. 123 s guidance in several areas, including measuring fair value, classifying an award as equity or as a liability and attributing compensation expense to reporting periods. In addition, SFAS No. 123R amends Statement of Financial Accounting Standard No. 95, *Statement of Cash*

57

BEVERLY ENTERPRISES, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) Years ended December 31, 2004, 2003, and 2002

1. Summary of Significant Accounting Policies (Continued)

Flows, (SFAS No. 95) to require the reporting of excess tax benefits as a financing cash inflow rather than as a reduction of taxes paid. We are required to adopt SFAS No. 123R for the interim period beginning July 1, 2005 and expect to use the modified version of prospective application. Based on the number of current unvested stock options, we expect wages and related expenses to increase \$1.5 million in the last six months of 2005.

Impairment of Long-Lived Assets

In August 2001, the FASB issued Statement of Financial Accounting Standards No. 144, *Accounting for the Impairment or Disposal of Long-Lived Assets* (SFAS No. 144), which addresses financial accounting and reporting for the impairment of long-lived assets (other than goodwill and indefinite-lived intangibles). We adopted the provisions of SFAS No. 144 in the fourth quarter of 2002. SFAS No. 144 requires impairment losses to be recognized for long-lived assets used in operations when other than temporary indicators of impairment are present and the estimated undiscounted cash flows are not sufficient to recover the assets—carrying amounts. The impairment loss is measured by comparing the estimated fair value of the asset, usually based on discounted cash flows, to its carrying amount. In accordance with SFAS No. 144, we assess the need for an impairment write-down when indicators of impairment are present (see Note 5).

Discontinued Operations

SFAS No. 144 also addresses the accounting for and disclosure of long-lived assets to be disposed of by sale. Under SFAS No. 144, when a long-lived asset or group of assets (disposal group) meets the criteria set forth in the Statement:

the long-lived asset (disposal group) will be measured and reported at the lower of its carrying value or fair value less costs to sell and classified as held for sale on the consolidated balance sheet; and

the related operations of the long-lived asset (disposal group) will be reported as discontinued operations in the consolidated statement of operations, with all comparable periods restated.

SFAS No. 144 also addresses the accounting for and disclosure surrounding the disposal of long-lived assets. Our consolidated statements of operations have been restated for all periods presented to report as discontinued operations 125 nursing facilities, eight assisted living centers, our Matrix outpatient therapy clinics, our MK Medical business unit and our Care Focus business unit. At December 31, 2004, 27 nursing facilities and 10 outpatient clinics had met the criteria set forth in SFAS No. 144 to be classified as held for sale and, therefore, are reported in discontinued operations (see Note 6).

58

BEVERLY ENTERPRISES, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) Years ended December 31, 2004, 2003, and 2002

1. Summary of Significant Accounting Policies (Continued) Earnings Per Share

The following table sets forth the calculation of basic and diluted earnings per share from continuing operations for the years ended December 31 (in thousands, except per share data):

	2004	2003	2002
Numerator:			
Numerator for basic net income (loss) per share from continuing operations	\$ 42,658	\$ 27,704	\$ (34,513)
Effect of dilutive securities:			
Interest on 2.75% convertible subordinated notes, net of income taxes of \$0	3,301	633	
Numerator for diluted net income (loss) per share from			
continuing operations	\$ 45,959	\$ 28,337	\$ (34,513)
Denominator:			
Denominator for basic net income (loss) per share from			
continuing operations weighted average shares	107,749	106,582	104,726
Effect of dilutive securities:			
Employee stock options	1,153	338	
2.75% convertible subordinated notes	15,432	3,002	
Denominator for diluted net income (loss) per share from continuing operations adjusted weighted average shares			
and assumed conversions	124,334	109,922	104,726
Basic net income (loss) per share from continuing operations	\$ 0.40	\$ 0.26	\$ (0.33)
Diluted net income (loss) per share from continuing operations	\$ 0.37	\$ 0.26	\$ (0.33)

Diluted net income (loss) per share from continuing operations does not include the impact of 289,000, 4.0 million and 8.9 million of employee stock options outstanding for the years ended December 31, 2004, 2003 and 2002, respectively, because their effect would have been antidilutive. In accordance with EITF 04-8, we have included the dilutive effect of our 2.75% convertible subordinated notes since their issuance in October 2003, on an if-converted basis, in our calculation of diluted net income (loss) per share from continuing operations.

Comprehensive Income (Loss)

During the fourth quarter of 2003, we sold all of our holdings in a publicly traded equity security, acquired in 1995, for gross proceeds of \$8.5 million. This investment had been accounted for as available for sale, with all changes in fair value being recorded as comprehensive income. In conjunction with the sale of the investment, we reversed accumulated comprehensive income, net of income taxes, of \$512,000 and recognized a pre-tax gain of

\$6.7 million. Comprehensive income equaled net income for the year ended December 31, 2004.

59

Table of Contents

BEVERLY ENTERPRISES, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) Years ended December 31, 2004, 2003, and 2002

2. Insurance

General and professional liability costs for the long-term care industry have become expensive and difficult to estimate. In addition, insurance coverage for general and professional liabilities and certain other risks, for nursing facilities specifically and companies in general, has become increasingly difficult to obtain. When obtained, insurance carriers are often requiring companies to significantly increase their liability retention levels and/or pay substantially higher premiums for reduced coverage. Our insurance covering general and professional liabilities and workers compensation was renewed in the second quarter of 2004 with retention levels remaining consistent and premiums being generally the same as the prior year. We cannot assure you that we will be able to renew our insurance coverages in future years on terms as favorable as those we currently have.

We exercise care in selecting companies from which we purchase insurance, including review of published ratings by recognized rating agencies, advice from national brokers and consultants and review of trade information sources. There exists a risk that any of these insurance companies may become insolvent and unable to fulfill their obligation to defend, pay or reimburse us when that obligation becomes due. Although we believe the companies we have purchased insurance from are solvent, in light of the dramatic changes occurring in the insurance industry in recent years, we cannot be assured that they will remain solvent and able to fulfill their obligations.

We believe that adequate provision has been made in the financial statements for liabilities that may arise out of patient care and related services provided to date. These provisions are based primarily upon the results of independent actuarial valuations, prepared by experienced actuaries. These independent valuations are formally prepared twice a year using the most recent trends of claims, settlements and other relevant data. In addition to the estimate of retained losses, our provision for insurance includes accruals for insurance premiums and related costs for the coverage period and our estimate of any experience adjustments to premiums.

60

BEVERLY ENTERPRISES, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) Years ended December 31, 2004, 2003, and 2002

2. Insurance (Continued)

The following table summarizes our provisions for insurance and related items, including the Florida insurance reserve adjustment in 2002, for the years ended December 31 (in thousands):

	2004	2003	2002
General and professional liability:			
Continuing operations(1)	\$ 80,514	\$ 55,910	\$ 41,002
Florida insurance reserve adjustment(2)			22,179
Discontinued operations(3)	23,696	50,749	29,375
	\$ 104,210	\$ 106,659	\$ 92,556
Workers compensation:			
Continuing operations	\$ 36,052	\$ 39,988	\$ 35,545
Discontinued operations	3,727	11,873	12,349
	\$ 39,779	\$ 51,861	\$ 47,894
Other insurance:			
Continuing operations	\$ 11,087	\$ 13,479	\$ 7,614
Discontinued operations	347	876	1,107
	\$ 11,434	\$ 14,355	\$ 8,721
Total provision for insurance and related items:			
Continuing operations(1)	\$ 127,653	\$ 109,377	\$ 84,161
Florida insurance reserve adjustment(2)			22,179
Discontinued operations(3)	27,770	63,498	42,831
	\$ 155,423	\$ 172,875	\$ 149,171

- (1) Includes a \$5.7 million adjustment in 2004 to change the discount rate from 10% to 8.5% and \$18.9 million in 2004 primarily due to increases in the estimate of prior years—outstanding general and professional liability reserves and related program costs.
- (2) Based on the results of the 2002 mid-year actuarial study, we recorded a pre-tax charge of \$22.2 million attributable to our previously operated Florida facilities. We completed the sale of our Florida facilities in January 2002; however, we are liable for general and professional liability claims and other costs for those facilities through the date of sale, subject to insurance.
- (3) Includes an accrual in 2003 for the purchase of incremental general and professional liability insurance on divested nursing facilities.

We insure certain of our auto liability, general liability, professional liability and workers compensation risks through various types of loss sensitive insurance policies with affiliated and unaffiliated insurance companies. For our general and professional liabilities, we are typically responsible for the first dollar of each claim, up to a self-insurance limit determined by the individual policies, subject to aggregate limits for certain policy years, and accrue liabilities for claims when they are probable and can be reasonably estimated. In several prior policy years, losses exceed our self-insurance aggregate limits. For claims relating to these years, our insurers have assumed their obligations for defense and payment of covered claims, and we expect them to continue to meet these obligations.

The liabilities for incurred losses retained by Beverly and not covered by insurance are estimated by independent actuaries and are discounted on our financial statements to their present value using actuarially

61

BEVERLY ENTERPRISES, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) Years ended December 31, 2004, 2003, and 2002

2. Insurance (Continued)

determined loss payment timing patterns. The discount rate is based upon our best estimate of the incremental borrowing rate that would be required to fund these liabilities with incremental uncollateralized debt. Due to changes in our capital structure and the overall interest rate environment, our incremental borrowing rate decreased from 10% to 8.5% in 2004, resulting in a pre-tax charge of \$6.0 million during the fourth quarter. A reduction in the discount rate by one-half of a percentage point would have resulted in an additional pre-tax charge of approximately \$1.9 million for the year ended December 31, 2004.

Discounted insurance liabilities are included in the consolidated balance sheet captions as follows at December 31 (in thousands):

	2004	2003		
Accrued wages and related liabilities	\$ 488	\$	2,528	
General and professional liabilities	54,216		93,736	
Other accrued liabilities			10,678	
Other liabilities and deferred items	117,962		52,954	
	\$ 172,666	\$	159,896	

On an undiscounted basis, total retained liabilities as of December 31, 2004 and 2003 were approximately \$209.8 million and \$203.7 million, respectively. As of December 31, 2004, we had approximately \$16.0 million in funds (the Beverly Indemnity funds) that are restricted for the payment of insured claims, which are included in Prepaid expenses and other on our consolidated balance sheet. In addition, we anticipate that \$67.8 million of our cash balance at December 31, 2004, while not legally restricted, will be utilized primarily to fund certain general and professional liabilities and workers compensation claims and expenses.

3. California Investigation Settlement, Related Costs and Adjustments

On August 1, 2002, the Company and the State of California reached an agreement on the settlement of an investigation by the Attorney General s office and the District Attorney of Santa Barbara County of patient care issues in several California nursing facilities. In accordance with the terms of the settlement agreement, Beverly Enterprises California, Inc. entered a plea of *nolo contendere* to two felony charges under California s Elder Abuse statute and paid a fine of \$54,000 related to the plea. In addition, Beverly Enterprises California, Inc. reimbursed the Attorney General and the Santa Barbara County District Attorney \$533,000 for the costs of their investigations and paid a \$2.0 million civil penalty in four equal, quarterly installments of \$500,000.

A permanent injunction was entered requiring nursing facilities in California, operated by subsidiaries of the Company, to comply with all applicable laws and regulations and conduct certain training and education programs. The Company recorded a pre-tax charge against earnings of \$6.3 million during the second quarter of 2002 to reflect the terms of the settlement and related costs. During the second quarter of 2003, approximately \$925,000 of the reserves related to this settlement were reversed when it was determined they were no longer required.

4. Special Charge and Adjustments Related to Settlements with the Federal Government

Effective October 15, 2002, we entered into a settlement agreement with the Centers for Medicare and Medicaid Services (CMS), which resolved certain reimbursement issues relating to: (1) costs of services provided to Medicare patients during 1996 through 1998 under the federal government s former cost-reimbursement system; (2) co-payments due from Medicare beneficiaries, who were also eligible for

BEVERLY ENTERPRISES, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) Years ended December 31, 2004, 2003, and 2002

4. Special Charge and Adjustments Related to Settlements with the Federal Government (Continued)

Medicaid, for the years 1996 through 2000; and (3) all outstanding issues from our Allocation Investigations (see Note 10). Under the terms of the settlement agreement, we paid CMS \$35.0 million in November 2002.

In connection with the final settlement with CMS in 2002, we were able to revise the amount of legal fees and other costs we originally expected to incur in conjunction with these settlements. Accordingly, legal and related fees accrued for these matters in prior years were reduced by \$9.4 million during 2002.

The present value of our remaining obligation under the Civil Settlement Agreement (see Note 10) is included in the consolidated balance sheet captions as follows at December 31 (in thousands):

	2004	2003
Federal government settlement obligations Other liabilities and deferred items	\$ 14,359 34,402	\$ 13,125 48,763
	\$ 48,761	\$ 61,888

5. Asset Impairments, Workforce Reductions and Other Unusual Items

We recorded pre-tax charges for asset impairments, workforce reductions and other unusual items as follows for the years ended December 31 (in thousands):

	2004	2003	2002
Asset impairments	\$ 3,5	\$ 2,076	\$ 41,385
Workforce reductions	4	122 2,507	7,869
Other unusual items, including exit costs	(3,4	481) (758)	(2,967)
	\$ 4	148 \$ 3.825	\$ 46.287

Asset Impairments

During 2004 and 2003, we recorded asset impairments in the Nursing Facilities segment of \$3.5 million on seven facilities and \$2.1 million on three facilities, respectively, primarily related to the write-down of property and equipment. These facilities had a history of operating losses with expected future losses and cash flow deficiencies.

During 2002, we recorded asset impairments of \$41.4 million relating to the write-down of property and equipment on certain assets of the Nursing Facilities segment. The October 1, 2002 elimination of certain funding under the Medicare program affected the cash flows, and therefore the fair values, of each of our nursing facilities. This event led to an impairment assessment on each of our nursing facilities.

We assess and record asset impairments by:

estimating the undiscounted cash flows to be generated by each of the facilities over the remaining life of the primary asset; and

reducing the carrying value of the asset to the estimated fair value when the total estimated undiscounted future cash flows is less than the current book value of the long-lived tangible assets.

In estimating undiscounted cash flows, we primarily use our internally prepared budgets and forecast information, with certain probability adjustments, including, but not limited to, the following items: Medicare and Medicaid funding; overhead costs; capital expenditures; and general and professional liability costs. In

63

BEVERLY ENTERPRISES, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) Years ended December 31, 2004, 2003, and 2002

5. Asset Impairments, Workforce Reductions and Other Unusual Items (Continued)

order to estimate the fair values of the nursing facilities, we use a discounted cash flow approach, supplemented by public resource information on valuations of nursing facility sales transactions by region of the country. Where the estimated undiscounted cash flows are negative, we estimate the fair values based on discounted public resource information, sales values or estimated salvage values. A substantial change in the estimated future cash flows for our facilities could materially change the estimated fair values of these assets, possibly resulting in additional impairments.

Workforce Reductions

During 2004, we recorded \$422,000 for net workforce reduction charges, including \$1.3 million resulting from operational reorganizations, net of a \$536,000 reversal of workforce reduction charges which were no longer needed and \$362,000 due to the cancellation of restricted stock. During 2004, we notified 53 associates that their positions would be eliminated. The \$1.3 million charge for workforce reductions was all cash expenses, \$500,000 of which was paid during the year ended December 31, 2004.

During 2003, we recorded \$2.5 million for net workforce reduction charges, including \$2.9 million resulting from operational reorganizations, net of a \$395,000 reversal of workforce reduction charges which were no longer needed. During 2003, we notified 67 associates that their positions would be eliminated. The charge included the following:

\$2.8 million of cash expenses, \$1.8 million and \$900,000 of which was paid during the years ended December 31, 2003 and 2004, respectively; and

non-cash expenses of approximately \$84,000 related to the issuance of 108,230 shares under our Stock Grant Plan (the Stock Grant Plan), less approximately \$400,000 due to the cancellation of restricted stock.

During 2002, we recorded \$7.9 million for net workforce reduction charges, which included a charge of approximately \$8.5 million for 133 associates who were notified in 2002 that their positions would be eliminated, net of a \$585,000 reversal of workforce reduction charges recorded in 2001 which were no longer needed. The \$8.5 million of pre-tax charges included the following:

\$8.0 million of cash expenses, \$4.1 million, \$2.8 million and \$1.1 million of which was paid during the years ended December 31, 2002, 2003 and 2004, respectively; and

non-cash expenses of \$500,000 related to the issuance of 124,212 shares under our Stock Grant Plan.

64

BEVERLY ENTERPRISES, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) Years ended December 31, 2004, 2003, and 2002

5. Asset Impairments, Workforce Reductions and Other Unusual Items (Continued)

The following table summarizes activity in our accruals for estimated workforce reductions and exit costs for the years ended December 31 (in thousands):

	2004				20	003		2002					
		orkforce ductions		Exit Costs	Workforce Reductions Exit Costs		cit Costs		orkforce ductions	Exit Costs			
Balance beginning of													
year	\$	3,029	\$	7,270	\$ 5,418	\$	4,991	\$	7,631	\$	15,030		
Charged to continuing													
operations		1,320		185	2,902		(884)		8,454				
Charged to discontinued													
operations				4,251			26,599				2,633		
Cash payments		(2,647)		(7,134)	(4,896)		(22,579)		(9,074)		(10,313)		
Stock transactions									(1,008)				
Reversals		(536)			(395)		(857)		(585)		(2,359)		
Balance end of year	\$	1,166	\$	4,572	\$ 3,029	\$	7,270	\$	5,418	\$	4,991		

6. Discontinued Operations

During the fourth quarter of 2002, a formal plan was approved by our Board of Directors to pursue the sale of our Matrix segment and MK Medical business unit. The decision to sell these non-strategic assets was made primarily to allow us to further reduce our debt level and to reinvest in the services businesses, nursing facilities, technology and other business opportunities consistent with our strategic objectives.

During 2002, in accordance with SFAS No. 144, the assets and liabilities of our former Matrix segment, the assets of our MK Medical business unit, and certain non-strategic assets of our Nursing Facilities segment were reclassified to the corresponding held-for-sale asset and liability line items. The outpatient therapy clinics and managed care network of Matrix, the MK Medical business unit, and certain non-strategic assets of our Nursing Facilities segment were sold during 2003. The remaining Matrix assets (10 outpatient clinics) were sold in February 2005 (see Note 15).

During 2004, 27 facilities were classified as held for sale in accordance with SFAS No. 144. We continue to actively market these assets and expect to dispose of them within the next six months.

A summary of the asset and liability line items from which the reclassifications have been made at December 31 is as follows (in thousands):

		20	004		2	2003	
	ursing cilities	N	Iatrix	ŗ	Γotal	N	Iatrix
Current assets	\$ 479	\$	1,970	\$	2,449	\$	2,042
Property and equipment, net	10,655		1,212		11,867		1,100

Edgar Filing: SURMODICS INC - Form 8-K

Goodwill			332	332	332
Other assets	2:	22	28	250	24
Total assets held for sale	\$ 11,3	56 \$	3,542	\$ 14,898	\$ 3,498
Current liabilities held for sale	\$	\$	676	\$ 676	\$ 672
	65				

BEVERLY ENTERPRISES, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) Years ended December 31, 2004, 2003, and 2002

6. Discontinued Operations (Continued)

The following facilities and business disposed of during the year ended December 31, 2004, as well as the operations of 27 nursing facilities (2,572 beds) classified as held for sale, are reflected as discontinued operations for all periods presented in the accompanying consolidated statements of operations:

18 nursing facilities (2,065 beds) and one assisted living center (32 units) for net cash proceeds totaling \$1.7 million, and a \$11.5 million note receivable. The net cash proceeds are net of a \$7.5 million lease buy-out of an Indiana facility; and

a home medical equipment business of our former Home Care segment for cash proceeds totaling \$370,000. The following facilities, clinics and other assets disposed of during the year ended December 31, 2003, are reflected as discontinued operations for all periods presented in the accompanying consolidated statements of operations:

80 nursing facilities (9,468 beds), seven assisted living centers (278 units) and certain other assets for cash proceeds totaling approximately \$223.8 million and a \$4.0 million note receivable;

the outpatient rehabilitation clinic operations and the managed care network of our former Matrix segment for cash proceeds of \$36.0 million; and

the Care Focus and MK Medical business units and certain other assets of our former Home Care segment for cash proceeds totaling \$11.0 million and a \$1.0 million note receivable.

Also included in discontinued operations are gains and losses on sales, impairments, exit costs and other unusual items relative to these facilities, clinics and other assets. A summary of discontinued operations by operating segment for the years ended December 31 is as follows (in thousands):

					2004					2003							
	N	Iatrix	Home Care		Nursing Facilities		Total		Matrix		Home Care	Nursing Facilities			Total		
Revenues	\$	14,021	\$	148	\$ 163,745	\$	177,914	\$ 1	18,550	\$	20,395	\$	515,008	\$:	553,953		
Operating income (loss)(1) Gain (loss) on sales and exit costs Impairments and other unusual items(2)	\$	1,106 (49)	\$	110 369	\$ (10,335) (1,441) (4,342))	(9,119) (1,121) (4,342)		749 11,120	\$	(2,446) 1,557 (540)	\$	(2,817) 67,113 (18,594)	\$	(4,514) 79,790 (19,134)		
Pre-tax income (loss)	\$	1,057	\$	479	\$ (16,118)	(14,582)	\$ 1	11,869	\$	(1,429)	\$	45,702		56,142		
Provision for state income taxes							55								3,378		

Discontinued		
operations, net of		
taxes	\$ (14,637)	\$ 52,764
	66	

BEVERLY ENTERPRISES, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) Years ended December 31, 2004, 2003, and 2002

6. Discontinued Operations (Continued)

2	n	n	1
ZΙ	IJ	u	Z

	Matrix Home Care		Nursing acilities		Total	
Revenues(3)	\$	86,109	\$ 20,894	\$ 644,811	\$	751,814
Operating income (loss)(1)(3) Gain (loss) on sale and exit costs Impairments and other unusual items(4)	\$	810 (1,001) 230	\$ (31,057) (1,257) (4,239)	\$ 35,435 (107) (33,220)	\$	5,188 (2,365) (37,229)
Pre-tax income (loss)	\$	39	\$ (36,553)	\$ 2,108		(34,406)
Provision for income taxes					¢	(24.406)
Discontinued operations, net of taxes					\$	(34,406)

- (1) Includes net interest expense of \$143,000, \$2.8 million and \$4.1 million for 2004, 2003 and 2002, respectively, and depreciation and amortization expense of \$2.1 million, \$10.9 million and \$26.0 million for 2004, 2003 and 2002, respectively. Also includes an \$8.6 million charge due to an increase in the estimate of outstanding general and professional liability reserves and related program costs.
- (2) Includes an accrual in 2003 for the purchase of incremental general and professional liability insurance on disposed nursing facilities.
- (3) Includes an adjustment of \$18.0 million in 2002 for estimated overpayments to MK Medical by government payors. MK Medical was part of our former Home Care segment.
- (4) Includes an accrual of \$1.0 million in 2002 for legal and related fees associated with the MK Medical estimated overpayment issue, and asset impairment charges related to certain nursing facilities and MK Medical.

 We recognized net gains on sales of \$67.1 million related to divestitures of certain nursing facilities and assisted

We recognized net gains on sales of \$67.1 million related to divestitures of certain nursing facilities and assisted living centers during the year ended December 31, 2003. During 2002, we recognized asset impairment charges on certain of these divested facilities, amounting to \$33.2 million. These impairments were precipitated by an estimated decline in future cash flows, primarily associated with Medicare funding reductions. Of the divested nursing facilities that incurred impairment charges in 2002, we recognized net losses on sales of \$5.3 million.

7. Acquisitions and Dispositions

On July 30, 2004, we purchased substantially all of the assets of Hospice USA, which were privately held companies providing hospice services in Mississippi, Alabama and Tennessee, for cash of approximately \$69.1 million. At the time of acquisition, Hospice USA operated 18 hospice locations and had an additional 16 locations under development. The acquisition was part of our ongoing strategy to expand our service businesses. We

allocated the purchase price based on estimated fair values. Goodwill related to the Hospice USA acquisition was \$67.6 million as of December 31, 2004. In February 2005, the Company reached a settlement of the working capital related to the Hospice USA acquisition, resulting in a reduction of the purchase price by approximately \$1.4 million.

67

BEVERLY ENTERPRISES, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) Years ended December 31, 2004, 2003, and 2002

7. Acquisitions and Dispositions (Continued)

The unaudited pro forma condensed statements of operations for the years ended December 31 have been prepared as if the acquisition had taken place on January 1, 2002. The following table summarizes our unaudited pro forma information (in thousands, except per share amounts):

	2004	2003	2002
Revenues	\$ 2,007,627	\$ 1,830,450	\$ 1,786,052
Income (loss) before discontinued operations and			
cumulative effect of change in accounting for			
goodwill	45,431	35,028	(30,948)
Income (loss) per share before discontinued			
operations and cumulative effect of change in			
accounting for goodwill:			
Basic	0.42	0.33	(0.30)
Diluted	0.39	0.32	(0.30)
Net income (loss)	30,794	87,792	(142,525)
Net income (loss) per share	0.27	0.80	(1.36)

Excluding discontinued operations in 2004 (see Note 6), we sold six nursing facilities (821 beds) and certain other assets for cash proceeds of \$12.2 million, closed one nursing facility (24 beds) and one assisted living center (9 units). We did not operate three of the nursing facilities sold, which were previously leased to another nursing home operator. We recognized net pre-tax gains of \$396,000, included in Net gains on dispositions on the consolidated statement of operations, as a result of these disposal activities. These dispositions did not meet the criteria in SFAS No. 144 to be included in discontinued operations.

During the year ended December 31, 2003, we acquired the remaining six leased properties (649 beds) and our corporate office building, which had been subject to our off-balance sheet lease arrangement, for cash of \$69.5 million. The acquisition was primarily funded with the proceeds from the sales of nursing facilities, our outpatient rehabilitation clinics and Care Focus. We also entered into an operating lease on a nursing facility (140 beds) and purchased certain other assets for cash of approximately \$459,000 plus closing and related costs. Excluding discontinued operations during 2003 (see Note 6), we closed one nursing facility (94 beds), sold one non-operational nursing facility (120 beds) and certain other assets for \$7.6 million, including cash and a \$4.1 million note receivable. We recognized net pre-tax gains of \$422,000 during the year ended December 31, 2003, included in Net gains on dispositions on the consolidated statement of operations, as a result of these disposal activities. These dispositions did not meet the criteria in SFAS No. 144 to be included in discontinued operations.

During the year ended December 31, 2002, we sold, closed or terminated the leases on 69 nursing facilities (8,132 beds), four assisted living centers (315 units), four home care centers, 10 outpatient clinics and certain other assets for cash proceeds of approximately \$170.9 million and notes receivable of approximately \$21.7 million. In December 2001, we leased to another operator 49 nursing facilities (6,129 beds) and four assisted living centers, all of which were located in Florida. Excluding the Florida properties, which had been written down to net realizable value in 2001, we recognized net pre-tax gains of \$2.1 million during the year ended December 31, 2002, included in Net gains on dispositions on the consolidated statement of operations, as a result of these disposal activities. These disposed assets did not meet the criteria for classification as discontinued operations.

68

BEVERLY ENTERPRISES, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) Years ended December 31, 2004, 2003, and 2002

8. Property and Equipment

A summary of property and equipment and related accumulated depreciation and amortization, by major classification, at December 31 is as follows (in thousands):

		To	tal			Ow	ned		Leased			
	2004 2003		2004			2003	2004		2003			
Land, buildings and												
improvements	\$	997,560	\$	1,038,702	\$	992,670	\$	1,029,657	\$ 4,890	\$	9,045	
Furniture and equipment		239,122		241,412		237,009		239,071	2,113		2,341	
Construction in progress		21,157		8,091		21,157		8,091				
		1,257,839		1,288,205		1,250,836		1,276,819	7,003		11,386	
Less accumulated												
depreciation and												
amortization		604,183		593,985		599,752		585,995	4,431		7,990	
	\$	653,656	\$	694,220	\$	651,084	\$	690,824	\$ 2,572	\$	3,396	

We record depreciation and amortization using the straight-line method over the following estimated useful lives: land improvements 5 to 25 years; buildings 35 to 40 years; building improvements 5 to 25 years; leasehold improvements 5 to 25 years; furniture and equipment 3 to 20 years. Capital leased assets are amortized over the estimated useful life of the assets or the remaining initial terms of the leases.

Depreciation and amortization expense related to property and equipment, including the amortization of assets under capital lease obligations, for the years ended December 31, 2004, 2003 and 2002 was \$55.3 million, \$61.9 million and \$77.7 million, respectively, including depreciation and amortization expense related to property and equipment on discontinued operations of \$2.0 million, \$10.4 million and \$22.4 million, respectively.

Capitalized software costs of \$55.1 million and \$53.4 million at December 31, 2004 and 2003, respectively, net of accumulated amortization of \$33.5 million and \$28.4 million, respectively, are included in the accompanying consolidated balance sheet caption. Other assets. Amortization expense related to capitalized software costs for the years ended December 31, 2004, 2003 and 2002 was \$8.7 million, \$8.0 million and \$10.3 million, respectively, including amortization expense related to capitalized software on discontinued operations of \$97,000, \$361,000 and \$2.6 million, respectively.

69

BEVERLY ENTERPRISES, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) Years ended December 31, 2004, 2003, and 2002

9. Long-term Debt

Long-term debt consists of the following at December 31 (in thousands):

	20	04		2003
Revolving credit facility, maturing October 22, 2007	\$		\$	
Term Loan, due October 22, 2008, secured by first priority liens on 78				
nursing facilities (8,868 beds) with an aggregate carrying value of \$181,913	4	22 212		124.662
at December 31, 2004	1	33,313		134,662
Notes and mortgages, less imputed interest; due in installments through the year 2016, at effective interest rates of 4.75% to 12.50%, a portion of which				
is secured by property, equipment and other assets with a carrying value of				
\$67,686 at December 31, 2004		48,685		63,584
Industrial development revenue bonds, due in installments through the year		,		00,00
2013, at effective interest rates of 5.21% to 10.00%, a portion of which is				
secured by property and other assets with a carrying value of \$49,439 at				
December 31, 2004		36,515		48,565
95/8% Senior Notes due April 15, 2009, unsecured		9,390		200,000
7 ⁷ /8% Senior Subordinated Notes due June 15, 2014	2	11,506		
2.75% Convertible Subordinated Notes due November 1, 2033, unsecured	1	15,000		115,000
	5	54,409		561,811
Present value of capital lease obligations, less imputed interest:				
2004 \$87; 2003 \$95 at effective interest rates of 6.62% to 13.89%		3,774		4,416
	_			
		58,183		566,227
Less amounts due within one year		12,240		13,354
	\$ 5	45,943	\$	552,873
	Þ 3	45,945	Ф	332,813

We have a \$225.0 million senior credit facility (the Credit Facility), which consists of a \$135.0 million term loan facility and a \$90.0 million revolving credit facility. The revolving credit facility is available for general corporate purposes and up to \$55.0 million for the issuance of letters of credit. The term loan facility is fully drawn and requires minimal quarterly principal payments until the year of maturity. At December 31, 2004, \$15.0 million of the revolving credit facility was being utilized for letters of credit. The Credit Facility bears interest at the prime lending rate plus 2.00%, or the Eurodollar rate plus 3.00%, at our option. These rates may be adjusted quarterly based on our senior secured leverage ratio calculation. The revolving credit facility is secured by first priority liens on 83 nursing facilities (6,440 beds) with an aggregate carrying value of \$118.9 million at December 31, 2004. The Credit Facility has a security interest in certain patient accounts receivable, is guaranteed by substantially all of our present and future subsidiaries and imposes on us certain financial tests and restrictive covenants.

During the second quarter of 2004, we entered into two amendments to our Credit Facility which, among other things, permitted the issuance of \$215.0 million of $7^7/8\%$ Senior Subordinated Notes due June 15, 2014 (the Senior Subordinated Notes) and the purchase of our 98% senior notes, reduced the interest rate on the term loan portion of the Credit Facility, increased the size of our revolving credit facility from \$75.0 million to \$90.0 million and modified

certain financial covenant levels.

During October 2004, we entered into a \$40.0 million letter of credit facility (the LOC facility) maturing in October 2008 (of which \$21.5 million was available as of December 31, 2004). The LOC facility is secured by certain of our Medicaid and Veterans Administration accounts receivable and contains standard

70

Table of Contents

BEVERLY ENTERPRISES, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) Years ended December 31, 2004, 2003, and 2002

9. Long-term Debt (Continued)

terms and conditions, including a 2.375% fee on outstanding letters of credit. As of January 31, 2005, we had transferred all of our outstanding letters of credit commitments under our revolving credit facility to the LOC facility, thereby making available the \$90.0 million revolving credit facility for potential future borrowing.

During June 2004, we commenced a cash tender offer to purchase any and all of our \$200.0 million 95/8% senior notes due 2009 at an offer price of \$1,190 per \$1,000 principal amount tendered, plus accrued and unpaid interest, and a solicitation of consents to amend the indenture under which the 95/8% senior notes were issued. In conjunction therewith, we issued \$215.0 million of 77/8% Senior Subordinated Notes due June 15, 2014. The Senior Subordinated Notes were issued at a discount (98.318% of par) to yield 8.125%. The Senior Subordinated Notes are general unsecured obligations subordinated in right of payment to our existing and future senior unsubordinated indebtedness and are guaranteed by certain of our subsidiaries. The Senior Subordinated Notes were issued through a private placement. The proceeds from the Senior Subordinated Notes, together with cash on hand, were used to purchase for cash \$190.6 million of our 95/8% senior notes tendered by the holders, as well as to pay related fees and expenses. We recorded a pre-tax charge of \$40.4 million related to this transaction, including \$36.1 million for the prepayment premium and \$3.7 million for the write-off of deferred financing costs on the 95/8% senior notes, as well as \$681,000 for fees and expenses related to the cash tender offer. We filed a registration statement with the SEC in September 2004, in order to affect an exchange of the Senior Subordinated Notes for publicly tradable notes, and all of the notes were exchanged in February 2005.

During 2003, we issued through a public offering \$115.0 million of 2.75% convertible subordinated notes due 2033 (the Convertible Notes). The Convertible Notes are subordinated in right of payment to all of our existing and future senior debt. The Convertible Notes are convertible into shares of our common stock at an initial conversion price of \$7.45 per share, at the option of the holder, if any of the following conditions are met:

during any fiscal quarter, if the market price of our common stock is at least \$8.94 for at least 20 consecutive trading-days during the 30 consecutive trading-day period ending on the last day of the preceding fiscal quarter;

during the five business day period following any 10 consecutive trading-day period in which (a) the trading price of a note for each day of such period is less than 105% of the conversion value and (b) the conversion value for each day of such period is less than 95% of the principal amount of a Convertible Note;

if we call the Convertible Notes for redemption; or

upon the occurrence of certain corporate transactions specified in the agreement.

As of December 31, 2004, none of the conversion conditions had been met, however the common shares into which the Convertible Notes may be converted were included in the calculation of our diluted earnings per share, since their issuance in October 2003, in accordance with EITF 04-8. Our diluted net income per share from continuing operations for the year ended December 31, 2004, was reduced by \$0.02 per share to \$0.37 per share diluted as a result of the assumed conversion of the Convertible Notes. There was no impact on diluted earnings per share for the year ended December 31, 2003.

71

BEVERLY ENTERPRISES, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) Years ended December 31, 2004, 2003, and 2002

9. Long-term Debt (Continued)

Maturities and sinking fund requirements of long-term debt, including capital leases, for the years ended December 31 are estimated as follows (in thousands):

	2	005	2	2006	2007		2008		2009		Thereafter		Total	
Future minimum lease payments Less interest	\$	530 (326)	\$	474 (310)	\$	432 (296)	\$	411 (285)	\$	409 (274)	\$	5,543 (2,534)	\$	7,799 (4,025)
Net present value of future minimum lease payments Notes, mortgages and bonds ⁽¹⁾	1	204		164 10,101		136 48,099		126 105,312		135 16,238		3,009 366,117		3,774 557,903
	\$ 1	12,240	\$	10,265	\$ 4	48,235	\$	105,438	\$	16,373	\$	369,126	\$:	561,677

Most of our capital leases, as well as our operating leases, have original terms from ten to fifteen years and contain at least one renewal option (which could extend the terms of the leases by five to fifteen years), purchase options, escalation clauses and provisions for payments by us of real estate taxes, insurance and maintenance costs.

Our Senior Subordinated Notes are jointly and severally, fully and unconditionally guaranteed by most of our subsidiaries (the Guarantor Subsidiaries). As of December 31, 2004, the non-guarantor subsidiaries included Beverly Indemnity, Ltd., our captive insurance subsidiary, and Beverly Funding Corporation, our receivables-backed financing subsidiary (the Non-Guarantor Subsidiaries). Since the carrying value of the assets of the Non-Guarantor Subsidiaries exceeds three percent of the consolidated assets of Beverly Enterprises, Inc., we are required to disclose the following consolidating financial statements in our periodic filings with the SEC.

72

⁽¹⁾ Excludes \$3.5 million of unamortized discounts related to our 77/8% Senior Subordinated Notes.

BEVERLY ENTERPRISES, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) Years ended December 31, 2004, 2003, and 2002

9. Long-term Debt (Continued)

The consolidating balance sheets as of December 31, 2004, for Beverly Enterprises, Inc. (parent only), the combined Guarantor Subsidiaries and the combined Non-Guarantor Subsidiaries are as follows (in thousands):

	Non-									
			G	Guarantor	Gı	uarantor				
	Pa	rent	Sı	ıbsidiaries	Subs	sidiaries(a)	Eli	minations		Total
				ASSETS	5					
Current assets:										
Cash and cash equivalents Accounts receivable, less	\$ 1	42,515	\$	5,237	\$	67,913	\$		\$	215,665
allowance for doubtful accounts		8,160		183,920		43,397				235,477
Notes receivable, less allowance for doubtful		5,200				,				,
notes		18		2,768						2,786
Operating supplies		101		9,080						9,181
Assets held for sale				14,898						14,898
Prepaid expenses and other		10,952		10,285		16,029				37,266
Total current assets	1	61,746		226,188		127,339				515,273
Property and equipment, net		6,392		647,264						653,656
Other assets:				·						
Goodwill, net				124,066						124,066
Other, less allowance for				,						,
doubtful accounts and notes	2	255,350		32,385		709		(220,054)		68,390
Due from affiliates		53,483		-,,-		132,141		(585,624)		00,070
Total other assets	7	08,833		156,451		132,850		(805,678)		192,456
	\$ 8	376,971	\$	1,029,903	\$	260,189	\$	(805,678)	\$	1,361,385
	LIA	BILITII	ES A	ND STOCK	HOLD	DERS EQU	JITY			
Current liabilities:										
Accounts payable	\$	2,696	\$	65,082	\$		\$		\$	67,778
Accrued wages and related		,		,			•		·	- · , · · ·
liabilities		28,240		75,797						104,037
Accrued interest		2,618		875		109				3,602
General and professional		_,010		-0.0		107				- ,
liabilities		23,323				45,934		(15,041)		54,216
Federal government										
settlement obligations				14,359						14,359
Liabilities held for sale				676						676

Edgar Filing: SURMODICS INC - Form 8-K

Other accrued liabilities	18,694	64,403			83,097
Current portion of	,-,	2 1, 100			55,57
long-term debt	1,350	10,890			12,240
Total current liabilities	76,921	232,082	46,043	(15,041)	340,005
Long-term debt	467,858	78,085			545,943
Other liabilities and deferred					
items	59,779	56,269	86,976		203,024
Due to affiliates		585,624		(585,624)	
Commitments and					
contingencies					
Stockholders equity:					
Preferred stock					
Common stock	11,662	5,908	121	(6,029)	11,662
Additional paid-in capital	902,053	414,340	44,434	(458,774)	902,053
Retained earnings					
(accumulated deficit)	(532,804)	(342,405)	82,615	259,790	(532,804)
Treasury stock, at cost	(108,498)				(108,498)
Total stockholders equity	272,413	77,843	127,170	(205,013)	272,413
	\$ 876,971	\$ 1,029,903	\$ 260,189	\$ (805,678)	\$ 1,361,385

⁽a) See above for a discussion of our new LOC facility, which changed Beverly Funding Corporation s financial position, results of operations and cash flows in 2004.

BEVERLY ENTERPRISES, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) Years ended December 31, 2004, 2003, and 2002

9. Long-term Debt (Continued)

The consolidating balance sheets as of December 31, 2003, for Beverly Enterprises, Inc. (parent only), the combined Guarantor Subsidiaries and the combined Non-Guarantor Subsidiaries are as follows (in thousands):

	Parent	Guarantor Subsidiaries	Non- Guarantor Subsidiaries	Eliminations	Total
		ASSETS			
Current assets:					
Cash and cash equivalents	\$ 223,575	\$ 5,351	\$ 29,889	\$	\$ 258,815
Accounts receivable, less allowance for doubtful					
accounts	2,481	153,553	8,601		164,635
Notes receivable, less					
allowance for doubtful notes	18	13,706			13,724
Operating supplies	47	10,378			10,425
Assets held for sale		3,498			3,498
Investment in Beverly					
Funding Corporation	31,342				31,342
Prepaid expenses and other	10,964	10,604	11,809		33,377
Total current assets	268,427	197,090	50,299		515,816
Property and equipment, net	7,134	687,086			694,220
Other assets:					
Goodwill, net		57,102			57,102
Other, less allowance for					
doubtful accounts and notes	170,762	45,446		(136,925)	79,283
Due from affiliates	372,097		145,240	(517,337)	
Total other assets	542,859	102,548	145,240	(654,262)	136,385
	\$ 818,420	\$ 986,724	\$ 195,539	\$ (654,262)	\$ 1,346,421
				· ·	

	LIAB	ILITIES	AND	STOCKH	OLDE	RS EQU	JITY			
Current liabilities:										
Accounts payable	\$	8,123	\$	59,449	\$		\$		\$	67,572
Accrued wages and related										
liabilities		25,104		91,613						116,717
Accrued interest		5,733		1,163						6,896
General and professional										
liabilities		41,370				70,425		(18,059)		93,736
Federal government										
settlement obligations				13,125						13,125
Accrued wages and related liabilities Accrued interest General and professional liabilities Federal government	\$	25,104 5,733	\$	91,613 1,163	\$	70,425		(18,059)	2	116,7 6,8 93,7

Edgar Filing: SURMODICS INC - Form 8-K

Liabilities held for sale		672			672
Other accrued liabilities	16,502	85,787			102,289
Current portion of long-term					
debt	1,350	12,004			13,354
Total current liabilities	98,182	263,813	70,425	(18,059)	414,361
Long-term debt	448,313	104,560			552,873
Other liabilities and deferred					
items	33,739	69,342	37,920		141,001
Due to affiliates		517,337		(517,337)	
Commitments and					
contingencies					
Stockholders equity:					
Preferred stock					
Common stock	11,559	5,908	120	(6,028)	11,559
Additional paid-in capital	895,950	414,340	7,556	(421,896)	895,950
Retained earnings					
(accumulated deficit)	(560,825)	(388,576)	79,518	309,058	(560,825)
Treasury stock, at cost	(108,498)				(108,498)
Total stockholders equity	238,186	31,672	87,194	(118,866)	238,186
	\$ 818,420	\$ 986,724	\$ 195,539	\$ (654,262)	\$ 1,346,421

74

BEVERLY ENTERPRISES, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) Years ended December 31, 2004, 2003, and 2002

9. Long-term Debt (Continued)

Condensed consolidating statements of operations for the year ended December 31, 2004, for Beverly Enterprises, Inc. (parent only), the combined Guarantor Subsidiaries and the combined Non-Guarantor Subsidiaries are as follows (in thousands):

	Parent	Guarantor Subsidiaries	Non- Guarantor Subsidiaries(a)	Eliminations	Total
Revenues	\$ 2,696	\$ 1,986,083	\$ 86,938	\$ (86,865)	\$ 1,988,852
Costs and expenses:					
Wages and related	50,291	1,097,452			1,147,743
Provision for insurance and related items	9,288	118,365	90,323	(90,323)	127,653
Other operating and administrative	30,017	492,648	105	(167)	522,603
Overhead allocation	(109,448)	109,448			
Depreciation and amortization	6,526	55,640			62,166
Asset impairments, workforce reductions and other unusual items	(1,933)	2,381			448
Total costs and					
expenses	(15,259)	1,875,934	90,428	(90,490)	1,860,613
Income (loss) before other income (expenses) Other income (expenses):	17,955	110,149	(3,490)	3,625	128,239
Interest expense		(51,311)	(178)	5,852	(45,637)
Costs related to early extinguishments of			(1,0)	2,002	
debt	(40,430)	(505)	6.765	(5.050)	(40,935)
Interest income	2,493	2,079	6,765	(5,852)	5,485
Net gains on dispositions		396			396
Equity in income of affiliates	52,893			(52,893)	
Total other income (expenses), net	14,956	(49,341)	6,587	(52,893)	(80,691)
Income before provision for income taxes and discontinued operations	32,911	60,808	3,097	(49,268)	47,548

Edgar Filing: SURMODICS INC - Form 8-K

Provision for income taxes	4,890				4,890
To a come to a form discounting of					
Income before discontinued					
operations	28,021	60,808	3,097	(49,268)	42,658
Discontinued operations,					
net of taxes of \$55		(14,637)			(14,637)
Net income	\$ 28,021	\$ 46,171	\$ 3,097	\$ (49,268)	\$ 28,021

⁽a) See above for a discussion of our new LOC facility, which changed Beverly Funding Corporation s financial position, results of operations and cash flows in 2004.

BEVERLY ENTERPRISES, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) Years ended December 31, 2004, 2003, and 2002

9. Long-term Debt (Continued)

Condensed consolidating statements of operations for the year ended December 31, 2003, for Beverly Enterprises, Inc. (parent only), the combined Guarantor Subsidiaries and the combined Non-Guarantor Subsidiaries are as follows (in thousands):

	Parent	Guarantor Subsidiaries	Non- Guarantor Subsidiaries	Eliminations	Total
Revenues	\$ (63)	\$ 1,802,089	\$ 43,607	\$ (43,607)	\$ 1,802,026
Costs and expenses:					
Wages and related	53,350	1,025,198			1,078,548
Provision for insurance					
and related items	10,560	98,817	12,725	(12,725)	109,377
Other operating and					
administrative	27,701	434,443			462,144
Overhead allocation	(104,409)	104,409			
Depreciation and					
amortization	6,952	51,855			58,807
Adjustment related to California investigation settlement		(925)			(925)
Asset impairments,					
workforce reductions					
and other unusual items		3,825			3,825
Total costs and expenses	(5,846)	1,717,622	12,725	(12,725)	1,711,776
Income (loss) before other					
income (expenses)	5,783	84,467	30,882	(30,882)	90,250
Other income (expenses):	2,7.32	3 1,131	23,332	(= =,===)	7 0,-2 0
Interest expense		(71,679)		8,365	(63,314)
Costs related to early				·	, , ,
extinguishments of debt	(6,634)				(6,634)
Interest income	1,658	3,105	8,965	(8,365)	5,363
Net gains on					
dispositions		422			422
Gain on sale of equity					
investment		6,686			6,686
Equity in income of affiliates	84,730			(84,730)	
Total other income					
(expenses), net	79,754	(61,466)	8,965	(84,730)	(57,477)

Income before provision for income taxes and					
discontinued operations	85,537	23,001	39,847	(115,612)	32,773
Provision for income taxes	5,069				5,069
Income before discontinued					
operations	80,468	23,001	39,847	(115,612)	27,704
Discontinued operations, net					
of taxes of \$3,378		52,764			52,764
Net income	\$ 80,468	\$ 75,765	\$ 39,847	\$ (115,612)	\$ 80,468
		76			

BEVERLY ENTERPRISES, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) Years ended December 31, 2004, 2003, and 2002

9. Long-term Debt (Continued)

Condensed consolidating statements of operations for the year ended December 31, 2002, for Beverly Enterprises, Inc. (parent only), the combined Guarantor Subsidiaries and the combined Non-Guarantor Subsidiaries are as follows (in thousands):

	Parent	Guarantor Subsidiaries	Non- Guarantor Subsidiaries	Eliminations	Total
Revenues	\$ (2,971)	\$ 1,769,697	\$ 113,132	\$ (113,132)	\$ 1,766,726
Costs and expenses:					
Wages and related	51,457	1,017,172			1,068,629
Provision for insurance					
and related items	4,989	79,172	121,233	(121,233)	84,161
Other operating and					
administrative	28,607	429,704			458,311
Overhead allocation	(97,239)	97,239			
_					
	6,992	55,914			62,906
•		22,179			22,179
•		6.000			6.000
		6,300			6,300
settlements of federal government investigations		(9,441)			(9,441)
Asset impairments, workforce reductions and other unusual items	5,646	40,641			46,287
Total costs and expenses	452	1,738,880	121,233	(121,233)	1,739,332
Income (loss) before other income (expenses)	(3,423)	30,817	(8,101)	8,101	27,394
•				·	(62,652)
Interest income Net gains on dispositions	2,209	2,010 2,142	12,613	(12,144)	4,688 2,142
Equity in income (loss) of affiliates	(138,791)			138,791	
	(136,582)	(70,644)	12,613	138,791	(55,822)
Depreciation and amortization Florida insurance reserve adjustment Special charge related to California investigation settlement Adjustment related to settlements of federal government investigations Asset impairments, workforce reductions and other unusual items Total costs and expenses Income (loss) before other income (expenses) Other income (expenses): Interest expense Interest income Net gains on dispositions Equity in income (loss) of	5,646 452 (3,423) 2,209 (138,791)	55,914 22,179 6,300 (9,441) 40,641 1,738,880 30,817 (74,796) 2,010 2,142	(8,101) 12,613	8,101 12,144 (12,144) 138,791	22 6 (9 46 1,739 27 (62 4 2

Edgar Filing: SURMODICS INC - Form 8-K

Total other income					
(expenses), net					
Income (loss) before					
provision for income taxes,					
discontinued operations and					
cumulative effect of change in					
9	(140,005)	(20.927)	4.510	146 902	(20, 420)
accounting for goodwill	(140,005)	(39,827)	4,512	146,892	(28,428)
Provision for income taxes	6,085				6,085
Income (loss) before					
discontinued operations and					
cumulative effect of change in					
accounting for goodwill	(146,090)	(39,827)	4,512	146,892	(34,513)
Discontinued operations, net	(1.0,000)	(65,627)	.,612	1.0,0>2	(6.,610)
of taxes of \$0		(34,406)			(34,406)
· ·		(34,400)			(34,400)
Cumulative effect of change					
in accounting for goodwill,					
net of income taxes of \$0		(77,171)			(77,171)
Net income (loss)	\$ (146,090)	\$ (151,404)	\$ 4,512	\$ 146,892	\$ (146,090)
		77			
		, ,			

BEVERLY ENTERPRISES, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) Years ended December 31, 2004, 2003, and 2002

9. Long-term Debt (Continued)

Condensed consolidating statements of cash flows for the year ended December 31, 2004, for Beverly Enterprises, Inc. (parent only), the combined Guarantor Subsidiaries and the combined Non-Guarantor Subsidiaries are as follows (in thousands):

	Parent	Guarantor Subsidiaries	Non- Guarantor Subsidiaries(a)	Eliminations	Total
Cash flows provided by					
(used for) operating activities:					
	\$ (45,182)	\$ 115,399	\$ 5,443	\$	\$ 75,660
Cash flows from investing activities:					
Capital expenditures	(7,422)	(55,296)			(62,718)
Proceeds from					
dispositions of facilities					
and other assets, net	1,324	14,233			15,557
Payments for acquisitions,					
net of cash acquired		(71,352)			(71,352)
Collections on notes					
receivable	18	38,071			38,089
Payments for designated	(25.6)	(550)			(1.000)
funds, net	(256)	(753)			(1,009)
Proceeds from Beverly					
Funding Corporation	22 272			(2.217)	20.056
investment	32,273			(3,317)	28,956
Capital contribution to	(26.506)			26 506	
subsidiary Other, net	(36,596)	(12.942)		36,596	(17.502)
Other, net	(4,660)	(12,842)			(17,502)
Net cash used for					
investing activities	(15,319)	(87,939)		33,279	(69,979)
Cash flows from financing	(13,317)	(01,555)		33,217	(05,575)
activities:					
Proceeds from issuance of					
long-term debt	211,384				211,384
Repayments of long-term	,				·
debt	(191,960)	(27,468)			(219,428)
Capital contribution to					,
subsidiary			36,596	(36,596)	
Return of capital					
investment to parent			(3,317)	3,317	
	3,592				3,592

Edgar Filing: SURMODICS INC - Form 8-K

Proceeds from exercise of stock options

Stock options					
Deferred financing and					
other costs	(43,575)	(106)	(698)		(44,379)
Net cash provided by (used for) financing activities	(20,559)	(27,574)	32,581	(33,279)	(48,831)
Net increase (decrease) in					
cash and cash equivalents	(81,060)	(114)	38,024		(43,150)
Cash and cash equivalents at beginning of year	223,575	5,351	29,889		258,815
Cash and cash equivalents at end of year	\$ 142,515	\$ 5,237	\$ 67,913	\$	\$ 215,665

78

⁽a) See above for a discussion of our new LOC facility, which changed Beverly Funding Corporation s financial position, results of operations and cash flows in 2004.

BEVERLY ENTERPRISES, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) Years ended December 31, 2004, 2003, and 2002

9. Long-term Debt (Continued)

Condensed consolidating statements of cash flows for the year ended December 31, 2003, for Beverly Enterprises, Inc. (parent only), the combined Guarantor Subsidiaries and the combined Non-Guarantor Subsidiaries are as follows (in thousands):

	Parent		Guarantor Subsidiaries		Non- Guarantor Subsidiaries		Total	
Cash flows provided by (used for) operating activities:								
operating activities.	\$	121,391	\$	(60,946)	\$	9,416	\$	69,861
Cash flows from investing activities:		,		(= =)=	'	., .		,
Capital expenditures		(6,115)		(37,869)				(43,984)
Proceeds from dispositions of								
facilities and other assets, net				275,039				275,039
Payments for acquisitions, net of								
cash acquired				(459)				(459)
Collections on notes receivable		24		8,665				8,689
(Payments for) proceeds from								
designated funds, net		(5,723)		540				(5,183)
Other, net		940		(15,854)				(14,914)
Net cash provided by (used for) investing activities Cash flows from financing activities:		(10,874)		230,062				219,188
Proceeds from issuance of long-term								
debt		250,000						250,000
Repayments of long-term debt		(210,474)		(102,878)				(313,352)
Repayments of off-balance sheet financing				(69,456)				(69,456)
Proceeds from exercise of stock								
options		1,108						1,108
Deferred financing and other costs		(14,032)		53				(13,979)
Net cash provided by (used for) financing activities		26,602		(172,281)				(145,679)
Net increase (decrease) in cash and cash equivalents		137,119		(3,165)		9,416		143,370
Cash and cash equivalents at beginning		137,117		(3,103)		2,110		143,370
of year		86,456		8,516		20,473		115,445
or j car		00,130		0,510		20,173		110,110
Cash and cash equivalents at end of year	\$	223,575	\$	5,351	\$	29,889	\$	258,815

BEVERLY ENTERPRISES, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) Years ended December 31, 2004, 2003, and 2002

9. Long-term Debt (Continued)

Condensed consolidating statements of cash flows for the year ended December 31, 2002, for Beverly Enterprises, Inc. (parent only), the combined Guarantor Subsidiaries and the combined Non-Guarantor Subsidiaries are as follows (in thousands):

]	Parent	uarantor bsidiaries	Gu	Non- arantor sidiaries	Total
Cash flows provided by operating						
activities:	\$	35,788	\$ 70,132	\$	10,713	\$ 116,633
Cash flows from investing activities:		(0.075)	(0.5.0.50)			4400 400
Capital expenditures		(8,053)	(92,050)			(100,103)
Proceeds from dispositions of						
facilities and other assets, net			169,471			169,471
Collections on notes receivable		60	1,556			1,616
Payments for designated funds, net			(260)			(260)
Other, net		2,760	(11,149)			(8,389)
Net cash provided by (used for) investing activities Cash flows from financing activities:		(5,233)	67,568			62,335
Proceeds from issuance of long-term						
debt			5,000			5,000
Repayments of long-term debt		(15,136)	(101,360)			(116,496)
Repayments of off-balance sheet financing			(42,901)			(42,901)
Proceeds from exercise of stock						
options		1,699				1,699
Deferred financing and other costs		(2)	(166)			(168)
Net cash used for financing activities		(13,439)	(139,427)			(152,866)
Net increase (decrease) in cash and cash equivalents		17,116	(1,727)		10,713	26,102
Cash and cash equivalents at beginning of year		69,340	10,243		9,760	89,343
Cash and cash equivalents at end of year	\$	86,456	\$ 8,516	\$	20,473	\$ 115,445

10. Commitments and Contingencies

Our future minimum rental commitments required by all noncancelable operating leases with initial or remaining terms in excess of one year as of December 31, 2004, are estimated as follows (in thousands):

Year Ending December 31,

2005	\$ 37,362
2006	19,721
2007	10,594
2008	7,871
2009	7,042
Thereafter	12,898
	\$ 95,488

80

BEVERLY ENTERPRISES, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) Years ended December 31, 2004, 2003, and 2002

10. Commitments and Contingencies (Continued)

Our total future minimum rental commitments are net of approximately \$23.6 million of minimum sublease rental income due in the future under noncancelable subleases. The following table summarizes certain information relative to our operating leases, including operating leases for discontinued operations, for the years ended December 31 (in thousands):

	2004	2003	2002
Rent expense, net of sublease rent income	\$ 58,698	\$ 70,132	\$ 87,852
Sublease rent income	3,007	1,143	2,036
Estimated contingent rent expense, based primarily on revenues	1,100	2,000	2,000

We have unconditional purchase obligations totaling \$8.3 million, primarily due to our outsourcing of certain information technology functions, as well as contracts relative to our frame relay network and certain office equipment. These contracts involve future minimum commitments that are noncancelable or impose a penalty if these agreements are cancelled prior to expiration. We have excluded agreements that are cancelable without penalty. Our future minimum commitments under these agreements as of December 31, 2004, are estimated as follows: 2005 \$4.3 million; 2006 \$3.1 million and 2007 \$870,000. We incurred approximately \$8.5 million, \$9.5 million and \$6.7 million under these agreements during the years ended December 31, 2004, 2003 and 2002, respectively.

We are contingently liable for approximately \$11.8 million of long-term debt maturing on various dates through 2019, as well as annual interest. These contingent liabilities principally arose from our sale of nursing facilities. We operate two facilities related to approximately \$2.5 million of the principal amount for which we are contingently liable, pursuant to long-term agreements accounted for as operating leases. In addition we guarantee certain third-party operating leases. These guarantees arose from our dispositions of leased facilities and the underlying leases have approximately \$54.8 million of minimum rental commitments remaining through the initial lease terms, with the latest termination date being February 2019. In accordance with the FASB s Interpretation No. 45, *Guarantor s Accounting and Disclosure Requirements for Guarantees, Including Indirect Guarantees of Indebtedness of Others* (FIN 45), we have recorded approximately \$627,000, included in Other accrued liabilities on the consolidated balance sheet at December 31, 2004, as the estimated fair value of guarantees initiated in 2004 and 2003.

On January 26, 2005, a putative class action complaint brought on behalf of all shareholders of the Company was filed against the Company and each of its directors in the Delaware Chancery Court in New Castle County. The complaint, captioned *Chaya Perlstein v. William R. Floyd, et. al.*, Civil Action No. CA1050-N, asserts a claim for breach of fiduciary duty in connection with our response to an unsolicited expression of interest by a group of investors that collectively had purchased 8.1% of our common stock on the open market prior to January 24, 2005. A second, substantially identical, putative class action complaint was filed in the same court on February 1, 2005, bearing the caption *Robert Strougo v. Beverly Enterprises, Inc., et. al.*, Civil Action No. CA1067-N. On February 23, 2005, the Delaware Chancery Court consolidated these cases under the caption *In re Beverly Shareholders Litigation*, Civil Action No. CA1050-N, and designated the *Floyd* complaint as operative. In addition, the Chancery Court extended the defendants time to respond to the operative complaint to May 9, 2005. The plaintiffs seek preliminary and permanent injunctive relief, an unspecified amount of compensatory damages, an accounting, as well as an award of attorneys fees, expert fees, and costs. Due to the preliminary state of these actions, we are unable to assess the probable outcome and can give no assurance of the ultimate impact on our financial position, results of operations and cash flows.

In 2002, we notified federal and California healthcare regulatory authorities (CMS, Office of Inspector General (the OIG), the California Attorney General s office and the California Department of Health) of our intent to conduct

an internal investigation of past billing practices relating to MK Medical, our former

81

BEVERLY ENTERPRISES, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) Years ended December 31, 2004, 2003, and 2002

10. Commitments and Contingencies (Continued)

medical equipment business unit based in Fresno, California. An independent accounting firm has reviewed MK Medical s government payor billings since October 1, 1998, the date Beverly acquired the business unit. Deficiencies identified by the accounting firm primarily relate to inadequate documentation supporting Medicare and Medi-Cal claims for reimbursement for drugs, wheelchairs, and other durable medical equipment distributed by MK Medical. Specifically, the review identified instances of missing or incomplete certificates of medical necessity, treatment authorization requests, prescriptions and other documentation MK Medical is required to maintain in order to be entitled to reimbursement from government payors. Based on the results of the accounting firm s review, we established a reserve in 2002, included in Other accrued liabilities on the consolidated balance sheets in the amount of \$18.0 million to cover potential overpayments from government payors for the period from October 1, 1998 to 2002. We have advised regulatory authorities of the results of the accounting firm s review. On September 15, 2003, we received a subpoena from the United States Attorney s Office in Oakland, California, requesting the production of additional documents relating to MK Medical s operations and our review of MK Medical s claims. We have produced documents in response to this subpoena and continue to cooperate with the government s request for information. The reserved amount continues to be the best estimate of our exposure on this matter; however, our liability with respect to this matter could exceed the reserved amount. We are actively cooperating with the government in this matter and expect to fund or resolve this liability within 12 months. We can give no assurance of the final outcome of this matter or its impact on our financial position, results of operations and cash flows.

On February 3, 2000, we entered into a series of separate agreements with the U.S. Department of Justice and the OIG. These agreements settled the federal government s investigations of the Company relating to our allocation to the Medicare program of certain nursing labor costs in our skilled nursing facilities from 1990 to 1998 (the Allocation Investigations).

Under the Civil Settlement Agreement, we paid the federal government \$25.0 million during 2000 and are reimbursing the federal government an additional \$145.0 million through withholdings from our biweekly Medicare periodic interim payments in equal installments through the first quarter of 2008. The present value of the remaining obligation included as liabilities on our consolidated balance sheets was \$48.8 million and \$61.9 million at December 31, 2004 and 2003, respectively. In addition, we agreed to resubmit certain Medicare filings to reflect reduced labor costs allocated to the Medicare program. The adjustments for these resubmitted filings were part of the settlement agreement with CMS (see Note 4).

Under the Corporate Integrity Agreement, we are required to monitor, on an ongoing basis, our compliance with the requirements of the federal healthcare programs. This agreement addresses our obligations to ensure that we comply with the requirements for participation in the federal healthcare programs. It also includes functional and training obligations, audit and review requirements, recordkeeping and reporting requirements, as well as penalties for breach or noncompliance of the agreement. We believe that we are generally in compliance with the requirements of the Corporate Integrity Agreement.

On October 31, 2002, a shareholder derivative action entitled *Paul Dunne and Helene Dunne, derivatively on behalf of nominal defendant Beverly Enterprises, Inc. v. Beryl F. Anthony, Jr., et. al.* was filed in the Circuit Court of Sebastian County, Arkansas, Fort Smith Division (No. CIV-2002-1241). This case was purportedly brought derivatively on behalf of the Company against various current and former officers and directors. The complaint alleges causes of action for breach of fiduciary duty against the defendants based on: (1) allegations that defendants failed to establish and maintain adequate accounting controls such that the Company failed to record adequate reserves for general and professional liability costs; and (2) allegations that certain defendants sold Company stock while purportedly in possession of material non-public information. On May 16, 2003, two additional derivative complaints (*Holcombe v. Floyd, et. al. and Flowers v. Floyd, et. al.*) were filed and subsequently transferred to the Circuit Court of Sebastian County, Arkansas, Fort Smith Division and

82

Table of Contents

BEVERLY ENTERPRISES, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) Years ended December 31, 2004, 2003, and 2002

10. Commitments and Contingencies (Continued)

consolidated with the Dunne action as *Holcomb v. Beverly Enterprises, Inc.* The Dunnes were subsequently dismissed as plaintiffs.

On November 19, 2004, Beverly moved to dismiss these actions on the grounds that the plaintiffs failed to make a pre-suit demand upon Beverly s Board of Directors and did not show that the failure to make such demand was excused as futile. The other defendants also moved to dismiss the actions for failure to state a claim upon which relief can be granted. Plaintiffs have opposed both motions. The court has not yet considered the motions or heard oral argument. Due to the preliminary state of this action, we are unable to assess the probable outcome of the case and can give no assurance of the ultimate impact on our financial position, results of operations and cash flows.

In addition, since July 29, 1999, several derivative lawsuits have been filed in the state courts of Arkansas, California and Delaware, as well as the federal district court in Arkansas, assertedly on behalf of the Company (collectively, the Derivative Actions). The parties have agreed on a settlement in principle for these actions, which provides that we will incorporate various corporate governance practices that are consistent with our policies. In addition, the directors and officers liability insurance carriers, on behalf of the individual defendants, will pay no more than \$375,000 for plaintiffs attorney s fees. The court approved the settlement on September 28, 2004, and the actions have been dismissed with prejudice.

We are party to various legal matters relating to patient care, including claims that our services have resulted in injury or death to residents of our facilities. We have experienced an increasing trend in the number and severity of the claims asserted against us (see Note 2). We believe that there has been, and will continue to be, an increase in governmental investigations of long-term healthcare providers. Adverse determinations in legal proceedings or governmental investigations, whether currently asserted or arising in the future, could have a material adverse effect on us.

There are various other lawsuits and regulatory actions pending against the Company arising in the normal course of business, some of which seek punitive damages that are generally not covered by insurance. We do not believe that the ultimate resolution of such other matters will have a material adverse effect on our consolidated financial position, results of operations or cash flows.

11. Stockholders Equity

We have 300,000,000 shares of authorized \$.10 par value common stock. We are subject to certain restrictions under our long-term debt agreements related to the payment of cash dividends on, and the repurchase of, our common stock. During 2004 and 2003, we did not pay any cash dividends on, or repurchase any of, our common stock. We have 25,000,000 shares of authorized \$1 par value preferred stock, all of which remains unissued. See Note 15 for a discussion of our new Series A Junior Participating Preferred Stock.

During 2004, we issued approximately 955,000 shares of restricted stock to certain officers and other employees, which cliff vest three years following the grant date. If these additional shares had been issued prior to January 1, 2004, there would have been no material impact on our diluted net income per share for the year. In April 2003, we issued 2,500,000 shares of restricted stock to certain officers and other employees, which vest one-third per year. The restricted stock grants in 2004 and 2003 were issued, along with certain cash incentives, as part of a program designed to retain key associates. We recognize compensation expense for our restricted stock grants at the fair market value of our common stock on the date of grant, amortized over the respective vesting periods on a straight-line basis.

In January 2001, we filed a registration statement under Form S-8 with the Securities and Exchange Commission registering 1,174,500 shares of our common stock. These shares were previously repurchased by

Table of Contents

BEVERLY ENTERPRISES, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) Years ended December 31, 2004, 2003, and 2002

11. Stockholders Equity (Continued)

the Company and held in treasury. They were issued under the Stock Grant Plan to holders of restricted stock who, by virtue of the terms of their employment contracts, severance agreements or other similar arrangements, were entitled to the immediate vesting of their restricted stock. From 2001 to 2003, we issued 777,984 shares of our common stock out of the Stock Grant Plan to various officers in exchange for shares of restricted stock held by them, which were cancelled. Effective May 20, 2004, the Stock Grant Plan was terminated, and as a result of the termination, the 396,516 unissued shares will remain in treasury.

During 1997, the New Beverly 1997 Long-Term Incentive Plan was approved (the 1997 Long-Term Incentive Plan). The plan became effective December 3, 1997 and remains in effect until December 31, 2006, subject to early termination by our Board of Directors. The Compensation Committee of our Board of Directors (the Committee) is responsible for administering the 1997 Long-Term Incentive Plan and has complete discretion in determining the number of shares or units to be granted, in setting performance goals and in applying other restrictions to awards, as needed, under the plan. The 1997 Long-Term Incentive Plan was originally authorized to issue 10,000,000 shares of our common stock, subject to certain adjustments, in the form of nonqualified stock options, incentive stock options, stock appreciation rights, restricted stock, restricted stock units, performance awards, bonus stock and other stock unit awards. In May 2001 and 2004, our stockholders approved amendments to this plan, which authorized the issuance of an additional 5,000,000 and 5,250,000 shares, respectively.

Under our 1997 Long-Term Incentive Plan, nonqualified and incentive stock options must be granted at a purchase price equal to the fair market value of our common stock on the date of grant. Options are exercisable at such times and are subject to such restrictions and conditions as the Committee determines and expire no later than 10 years from the grant date. Options issued at fair market value do not currently require the recording of compensation expense upon issuance (see discussion of SFAS No. 123R below). Restricted stock awards are outright stock grants, which have a minimum vesting period of one year for performance-based awards and three years for other awards. Performance awards, bonus stock and other stock unit awards may be granted based on the achievement of certain performance or other goals and carry certain restrictions, as defined. The issuance of restricted stock and other stock awards usually requires the recognition of compensation expense measured by the fair value of the stock on the date of grant.

During 1997, the New Beverly Non-Employee Directors Stock Option Plan was approved (the Non-Employee Directors Stock Option Plan). The plan became effective December 3, 1997 and remains in effect until December 31, 2007, subject to early termination by our Board of Directors. During 2004, we filed a registration statement under Form S-8 registering an additional 450,000 shares of our common stock under this plan, which increased the number of shares authorized for issuance to 900,000, subject to certain adjustments, under the Non-Employee Directors Stock Option Plan. Until May 2004, the Non-Employee Directors Stock Option Plan, as amended, provided that each non-employee director be granted an option to purchase 11,000 shares of our common stock on June 1 of each year until the plan is terminated, subject to the availability of shares. These options were granted at a purchase price equal to the fair market value of our common stock on the date of grant, became exercisable one year after the date of grant and expire 10 years after the date of grant. On May 20, 2004, our Board of Directors eliminated the annual grant of stock options in lieu of Restricted Share Unit (RSU) grants. Each director will receive a grant of RSUs annually equal to \$120,000, as determined based on the closing share price on the date of the board meeting held in conjunction with our annual stockholders meeting. The RSUs will vest one year from the date of grant unless a director elects to defer his RSUs. If a director elects to defer his RSUs, the deferred RSUs will not be paid until the director retires or otherwise resigns his position from our board.

84

BEVERLY ENTERPRISES, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) Years ended December 31, 2004, 2003, and 2002

11. Stockholders Equity (Continued)

The following table summarizes stock option and restricted stock data relative to our long-term incentive plans for the years ended December 31:

	2004		2003	3	2002						
	Number of Shares	Weighted- Average Exercise Price	Number of Shares	Weighted- Average Exercise Price	Number of Shares	Weighted- Average Exercise Price					
Options outstanding at											
beginning of year	7,780,203	\$ 6.70	8,882,635	\$ 6.62	5,808,260	\$ 6.46					
Changes during the year:											
Granted	2,750	6.34	103,000	3.96	4,749,460	6.43					
Exercised	(684,045)	5.96	(234,850)	5.37	(512,612)	3.72					
Cancelled	(666,381)	8.84	(970,582)	5.98	(1,162,473)	6.30					
Options outstanding at end of year	6,432,527	6.56	7,780,203	6.70	8,882,635	6.62					
Options exercisable at											
end of year	4,257,001	6.41	3,580,102	6.86	2,274,231	7.09					
Restricted stock outstanding at beginning of year	3,141,006		1,122,402		1,290,572						
Changes during the year:											
Granted	1,048,311		2,503,125		175,000						
Vested	(1,347,349)		(131,550)		(112,684)						
Forfeited	(289,278)		(352,971)		(230,486)						
Restricted stock outstanding at end of year	2,552,690		3,141,006		1,122,402						
y our	2,332,070		5,141,000		1,122,102						
Options/restricted stock available for grant at end of year	7,572,030		1,967,432		2,933,703						

Exercise prices for options outstanding as of December 31, 2004, ranged from \$2.33 to \$14.38. The weighted-average remaining contractual life of these options is approximately six and a half years. The following table provides certain information with respect to stock options outstanding and exercisable at December 31, 2004:

Options Exercisable

4,257,001

6.41

Options Outstanding

Weighted-Average Weighted-Weighted-**Options** Average Average Remaining **Options Exercise** Contractual **Exercise** Outstanding Exercisable **Range of Exercise Prices Price** Life **Price** 3,095,306 \$ \$ \$2.33-\$6.85 5.15 6.60 2,062,164 4.80 \$7.00-\$14.38 3,337,221 7.87 6.31 2,194,837 7.93

6.56

85

6.47

SFAS No. 148, issued on December 31, 2002, provides companies alternative methods of transitioning to SFAS No. 123 s fair value method of accounting for stock-based employee compensation, and amends certain disclosure requirements. SFAS No. 148 does not mandate fair value accounting for stock-based employee compensation, but does require all companies to meet the disclosure provisions. We currently do not recognize compensation expense for our stock option grants, which are issued at fair market value on the date of grant,

6,432,527

\$2.33-\$14.38

BEVERLY ENTERPRISES, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) Years ended December 31, 2004, 2003, and 2002

11. Stockholders Equity (Continued)

and are accounted for under the intrinsic value method. We are in compliance with the current accounting rules surrounding stock-based compensation (see discussion of SFAS No. 123R below).

Pro forma information regarding net income (loss) and diluted net income (loss) per share has been determined as if we accounted for our stock option grants under the fair market value method described in SFAS No. 123. The fair market value of our stock options was estimated at the date of grant using a Black-Scholes option pricing model with the following weighted average assumptions for the years ended December 31, 2004, 2003 and 2002, respectively: risk-free interest rates of 4.6%, 3.0% and 4.8%;

volatility factors of the expected market price of our common stock of .82, .81 and .74; and

expected option lives of five years.

We do not currently pay cash dividends on our common stock and no future cash dividends are currently planned. The weighted average assumptions resulted in a weighted average estimated fair market value of options granted during 2004, 2003 and 2002 of \$4.32 per share, \$2.61 per share and \$3.55 per share, respectively.

For purposes of pro forma disclosures, the estimated fair market value of all outstanding stock options is amortized to expense over their respective vesting periods. The pro forma effects are not necessarily indicative of the effects on future years. The following table summarizes our pro forma net income (loss) and diluted net income (loss) per share, assuming we accounted for our stock option grants using the fair value method in accordance with SFAS No. 123, for the years ended December 31 (in thousands, except per share amounts):

	2004	2003	2002
Reported net income (loss)(a)	\$ 28,021	\$ 80,468	\$ (146,090)
Stock option compensation expense	3,967	6,865	6,218
Pro forma net income (loss)	\$ 24,054	\$ 73,603	\$ (152,308)
Reported basic net income (loss) per share	\$ 0.26	\$ 0.75	\$ (1.39)
Pro forma basic net income (loss) per share	\$ 0.22	\$ 0.69	\$ (1.45)
Reported diluted net income (loss) per share	\$ 0.25	\$ 0.74	\$ (1.39)
Pro forma diluted net income (loss) per share	\$ 0.22	\$ 0.68	\$ (1.45)

(a) Includes total charges to our consolidated statements of operations related to restricted stock grants of \$3.9 million, \$1.8 million and \$1.3 million for the years ended December 31, 2004, 2003 and 2002, respectively. In December 2004, the FASB issued SFAS No. 123R which eliminates the intrinsic value method as an alternative method of accounting for stock-based awards. SFAS No. 123R also revises the fair value-based method of accounting for share-based payment liabilities, forfeitures and modifications of stock-based awards and clarifies SFAS No. 123 s guidance in several areas, including measuring fair value, classifying an award as equity or as a liability and attributing compensation cost to reporting periods. In addition, SFAS No. 123R amends SFAS No. 95 to require that

excess tax benefits be reported as a financing cash inflow rather than as a reduction of taxes paid, which is included within operating cash flows. The Company is required to adopt SFAS No. 123R for the interim period beginning July 1, 2005 and we will use the modified version of prospective application. Based on the estimated value of unvested stock options, we expect wages and related expenses to increase \$1.5 million in the last six months of 2005.

86

BEVERLY ENTERPRISES, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) Years ended December 31, 2004, 2003, and 2002

12. Income Taxes

The provision for (benefit from) income taxes, including taxes allocated to discontinued operations of \$55,000 and \$3.4 million in 2004 and 2003, respectively, consists of the following for the years ended December 31 (in thousands):

	2004	2003	2002
Federal:			
Current	\$ (2,320)	\$ (11,122)	\$ (8,345)
Deferred	3,085	12,702	10,447
State:			
Current	2,688	6,867	3,835
Deferred	1,492		148
	\$ 4,945	\$ 8,447	\$ 6,085

A reconciliation of our income tax provision (benefit), including taxes allocated to discontinued operations, computed at the statutory federal income tax rate to our actual provision for (benefit from) income taxes is summarized as follows for the years ended December 31 (in thousands):

	2004	2003	2002
Tax (benefit) at statutory rate	\$ 11,538	\$ 31,121	\$ (49,002)
General business tax credits	(105)	(968)	(2,090)
State tax provision, net	1,884	8,423	2,593
Impairment charges			12,685
Increase (decrease) in valuation allowance	(10,792)	(30,141)	45,520
Other	2,420	12	(3,621)
	\$ 4,945	\$ 8,447	\$ 6,085

87

BEVERLY ENTERPRISES, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) Years ended December 31, 2004, 2003, and 2002

12. Income Taxes (Continued)

Deferred income taxes reflect the impact of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The tax effects of temporary differences giving rise to our deferred tax assets and liabilities at December 31, 2004 and 2003, are as follows (in thousands):

	December	31, 20	004	December 31, 2003						
	Asset	L	iability		Asset	L	iability			
Insurance reserves	\$ 71,430	\$		\$	70,838	\$				
General business tax credit carryforwards	38,999				37,708					
Alternative minimum tax credit										
carryforwards	23,042				21,279					
Provision for dispositions	6,838		1,908		3,539		16,016			
Provision for Medicare repayment	19,602				26,574					
Depreciation and amortization	1,877		52,456		21,572		55,687			
Operating supplies			5,287				9,538			
Federal net operating loss carryforwards	22,853				34,183					
Other	27,199		21,779		29,767		18,440			
	211,840		81,430		245,460		99,681			
Valuation allowances:										
Federal	(143,618)				(155,692)					
State	(14,666)				(13,384)					
Net deferred tax balances	\$ 53,556	\$	81,430	\$	76,384	\$	99,681			

The valuation allowance decreased \$10.8 million and \$30.1 million during 2004 and 2003, respectively, primarily due to the reversal of temporary differences and the utilization of federal net operating loss carryforwards, partially offset by increases in general business tax credits and state tax credits. During 2004, the decrease in the valuation allowance was further offset by the generation of alternative minimum tax credits.

At December 31, 2004, for federal income tax purposes, we had federal net operating loss carryforwards of \$60.8 million that expire in years 2018 through 2020; general business tax credit carryforwards of \$39.0 million that expire in years 2006 through 2024; and alternative minimum tax credit carryforwards of \$23.0 million that do not expire. Under the guidance of SFAS No. 109 and based upon our operating results, our reported cumulative losses, and the inherent uncertainty associated with the realization of future income in the near term, we have provided a valuation allowance on our net deferred tax assets as of December 31, 2004 and 2003.

13. Fair Values of Financial Instruments

Financial Accounting Standards Statement No. 107, *Disclosures about Fair Value of Financial Instruments*, (SFAS No. 107) requires disclosure of fair value information about financial instruments, whether or not recognized in the balance sheet, for which it is practicable to estimate that value. In cases where quoted market prices are not available, fair values are based on estimates using present value or other valuation techniques. Those techniques are significantly affected by the assumptions used, including the discount rate and estimates of future cash flows. In that

regard, the derived fair value estimates cannot be substantiated by comparison to independent markets and, in many cases, could not be realized in immediate settlement of the instrument. SFAS No. 107 excludes certain financial instruments and all nonfinancial instruments from its disclosure requirements. Accordingly, the aggregate fair value amounts presented do not represent our underlying value.

88

BEVERLY ENTERPRISES, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) Years ended December 31, 2004, 2003, and 2002

2004

2002

13. Fair Values of Financial Instruments (Continued)

The carrying amounts and estimated fair values of our financial instruments at December 31 are as follows (in thousands):

	20	004	200	13
	Carrying Amount	Fair Value	Carrying Amount	Fair Value
Cash and cash equivalents	\$ 215,665	\$ 215,665	\$ 258,815	\$ 258,815
Cash investments greater than three				
months	5,018	5,018		
Notes receivable, net (including current				
portion)	2,312	2,312	27,873	27,873
Beverly Indemnity funds	16,006	16,006	11,809	11,809
Long-term debt (including current				
portion)	558,183	638,312	566,227	640,723
Federal government settlement obligations (including current portion)	48,761	48,761	61,888	61,888

At December 31, 2004 and 2003, we had outstanding defeased long-term debt with aggregate carrying values of \$2.2 million and \$6.3 million, respectively. The fair value of such defeased debt was approximately \$2.3 million and \$6.4 million at December 31, 2004 and 2003, respectively. The fair value was estimated using discounted cash flow analyses, based on our incremental borrowing rates for similar types of borrowing arrangements.

In order to consummate certain dispositions and other transactions, we have agreed to guarantee the debt assumed or acquired by the purchaser or the performance under a lease, by the lessee. In accordance with FIN 45, we had approximately \$627,000 and \$531,000, included in Other accrued liabilities on the 2004 and 2003 consolidated balance sheets, respectively, as the estimated fair value of lease guarantees issued since the adoption of FIN 45.

We used the following methods and assumptions in estimating our fair value disclosures for financial instruments:

Cash and Cash Equivalents

The carrying amount reported in the consolidated balance sheets for cash and cash equivalents approximates its fair value.

Cash Investments with Original Maturity Dates Greater than Three Months

The carrying amount reported in the 2004 consolidated balance sheet for these investments, which have original maturities from three to six months, approximates fair value and is included in the consolidated balance sheet caption Prepaid expenses and other.

Notes Receivable, Net (Including Current Portion)

For variable-rate notes that reprice frequently and with no significant change in credit risk, fair values are based on carrying values. For fixed-rate notes, the fair values are estimated using discounted cash flow analyses, using interest rates currently being offered for loans with similar terms to borrowers of similar credit quality.

Beverly Indemnity Funds

The restricted cash reported in the consolidated balance sheets for the Beverly Indemnity funds approximates its fair value and is included in the consolidated balance sheet caption Prepaid expenses and other.

Table of Contents 118

89

BEVERLY ENTERPRISES, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) Years ended December 31, 2004, 2003, and 2002

13. Fair Values of Financial Instruments (Continued)

Long-term Debt (Including Current Portion)

The carrying amounts of our variable-rate borrowings approximate their fair values. The fair values of the remaining long-term debt are estimated using discounted cash flow analyses, based on our incremental borrowing rates for similar types of borrowing arrangements.

Federal Government Settlement Obligations (Including Current Portion)

The present value of our obligations to the federal government resulting from the settlements of the Allocation Investigations is included in the consolidated balance sheet captions. Federal government settlement obligations and Other liabilities and deferred items. These obligations are non-interest bearing, and as such, were imputed at their approximate fair market rate of 9% for accounting purposes. The carry amounts of these obligations approximate their fair values.

14. Segment Information

Statement of Financial Accounting Standards No. 131, *Disclosures about Segments of an Enterprise and Related Information*, provides disclosure guidelines for segments of a company based on a management approach to defining operating segments.

During the fourth quarter of 2004, we changed the name of our former Home Care operating segment to AseraCare.

Description of the Types of Services from which each Operating Segment Derives its Revenues

Our operations are currently organized into three primary segments:

Nursing Facilities, which provide long-term healthcare through the operation of skilled nursing homes and assisted living centers;

Aegis, which provides rehabilitation therapy services under contract to our nursing facilities and third-party nursing facilities; and

AseraCare, which primarily provides hospice services.

Measurement of Segment Income or Loss and Segment Assets

The accounting policies of the operating segments are the same as those described in the summary of significant accounting policies (see Note 1). We evaluate financial performance and allocate resources primarily based on earnings from continuing operations before interest expense (including costs related to early extinguishments of debt), interest income, income taxes, depreciation and amortization, as well as income or loss from operations before income taxes, excluding unusual items.

Factors Management Used to Identify Our Operating Segments

Our operating segments are strategic business units that offer different services within the healthcare continuum. Business in each operating segment is conducted by one or more direct or indirect wholly owned subsidiaries of the Company. Each of these subsidiaries has separate governing bodies.

90

BEVERLY ENTERPRISES, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) Years ended December 31, 2004, 2003, and 2002

14. Segment Information (Continued)

The following table summarizes certain information for each of our operating segments (in thousands):

Year ended December 31, 2004 Revenues from external customers \$ 1,794,471 \$ 121,846 \$ 65,604 \$ 6,931 \$ 1,988,852 \$ 177,914 Intercompany revenues 150,039 2,230 152,269 Interest income 2,079 21 3,385 5,485 36 Interest expense 7,731 1 37,905 45,637 179 Depreciation and
Revenues from external customers \$ 1,794,471 \$ 121,846 \$ 65,604 \$ 6,931 \$ 1,988,852 \$ 177,914 Intercompany revenues 150,039 2,230 152,269 Interest income 2,079 21 3,385 5,485 36 Interest expense 7,731 1 37,905 45,637 179 Depreciation and
external customers \$ 1,794,471 \$ 121,846 \$ 65,604 \$ 6,931 \$ 1,988,852 \$ 177,914 Intercompany revenues 150,039 2,230 152,269 Interest income 2,079 21 3,385 5,485 36 Interest expense 7,731 1 37,905 45,637 179 Depreciation and
Intercompany revenues 150,039 2,230 152,269 Interest income 2,079 21 3,385 5,485 36 Interest expense 7,731 1 37,905 45,637 179 Depreciation and 1
Interest income 2,079 21 3,385 5,485 36 Interest expense 7,731 1 37,905 45,637 179 Depreciation and 179
Interest expense 7,731 1 37,905 45,637 179 Depreciation and
Depreciation and
amortization 52,711 887 697 7,871 62,166 2,135
Pre-tax income (loss) 96,722 45,849 8,782 (103,805) 47,548 (14,582)
Goodwill 44,756 79,310 124,066 332
Total assets 846,253 33,664 101,441 349,250 1,330,608 30,777
Capital expenditures 53,477 1,033 652 6,291 61,453 1,265
Year ended
December 31, 2003
Revenues from
external customers \$ 1,680,420 \$ 77,007 \$ 39,164 \$ 5,435 \$ 1,802,026 \$ 553,953
Intercompany revenues 153,140 1,322 154,462
Interest income 2,939 25 1 2,398 5,363 161
Interest expense 11,641 8 51,665 63,314 2,984
Depreciation and
amortization 49,722 831 547 7,707 58,807 10,856
Pre-tax income (loss) 66,305 45,265 5,030 (83,827) 32,773 56,142
Goodwill 44,745 11,723 269 56,737 697
Total assets 898,274 21,015 22,577 346,295 1,288,161 58,260
Capital expenditures 26,917 1,434 387 9,785 38,523 5,461
Year ended
December 31, 2002
Revenues from
external customers \$ 1,677,892 \$ 52,871 \$ 34,315 \$ 1,648 \$ 1,766,726 \$ 751,814
Intercompany revenues 154,306 626 154,932
Interest income 1,565 42 13 3,068 4,688 60
Interest expense 12,813 23 49,816 62,652 4,177
Depreciation and
amortization 54,263 710 724 7,209 62,906 26,039
Pre-tax income (loss) 108,142 35,569 (1,633) (170,506) (28,428) (34,406)
Goodwill 44,015 11,724 269 56,008 11,082
Total assets 892,283 15,966 20,873 138,413 1,067,535 282,360

Capital expenditures 73,573 1,676 258 7,778 83,285 16,818

- (1) Pre-tax income includes profit on intercompany revenues which is eliminated in All Other.
- (2) Consists of the operations of our corporate headquarters and related overhead, as well as certain non-operating revenues and expenses, including \$40.9 million and \$6.6 million of pre-tax charges in 2004 and 2003, respectively, related to the early extinguishments of debt. These amounts also include special pre-tax charges and adjustments totaling approximately \$448,000, \$2.9 million and \$65.3 million for 2004, 2003 and 2002, respectively, that primarily related to asset impairments, workforce reductions and other unusual items, a special charge and adjustment related to government investigation settlements and increasing reserves for general and professional liability costs in 2002.
- (3) The results of operations of 2004 and 2003 disposed facilities, clinics and other assets have been reported as discontinued operations for all periods presented, as well as the results of operations of held-for-sale assets at December 31, 2004. Pre-tax income (loss) includes net losses on sales, exit costs, asset impairments and other unusual items of \$5.5 million in 2004; net gains on sales, exit costs, asset impairments and other unusual items of \$60.7 million in 2003; and net losses on sales, exit costs, asset impairments and other unusual items of \$39.6 million in 2002 (see Note 6).

91

BEVERLY ENTERPRISES, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) Years ended December 31, 2004, 2003, and 2002

15. Subsequent Events

In January 2005, a group including Arnold Whitman, the Chief Executive Officer of Formation Capital, LLC and Appaloosa Management, LP, a New Jersey based hedge fund, among others, publicly announced an unsolicited indication of interest in an acquisition of all of our outstanding common stock. This group has also nominated a slate of individuals for election to our Board of Directors in an effort to obtain control of the Company. These actions may materially impact our ability to attract and retain customers, management and employees and may result in the incurrence of significant advisory fees, litigation costs and other expenses.

On January 25, 2005, our Board of Directors unanimously adopted a Share Purchase Rights Plan (the Rights Plan). The Rights Plan assigns one right (collectively, the Rights) to purchase one one-thousandth of a share of a newly created Series A Junior Participating Preferred Stock, \$1.00 par value (the Preferred Stock) for each share of our common stock outstanding on February 7, 2005. Initially, the Rights will not be exercisable and will not trade separately from the common stock. Under certain circumstances, stockholders will be able to exercise their Rights if a person or group initiates an unsolicited takeover or change of control of the Company by acquiring at least 10% of our common stock. However, the rights would not be exercisable if the takeover or change of control is approved by the Board as being in the best interest of all stockholders. If the Rights are triggered by a non-Board approved acquisition of 10% or more of our common stock, all of our stockholders, other than the acquirer, would be able to purchase our common stock at a 50% discount.

The dividend, liquidation and voting rights, and the non-redemption feature of the Preferred Stock are designed so that the value of a one one-thousandth interest in a share of Preferred Stock will approximate the value of one share of our common stock. The Rights Plan will expire at the close of business on January 26, 2015.

On February 23, 2005, we sold 10 outpatient clinics for \$4.6 million, including cash and \$3.9 million of notes receivable. The purchase price is subject to adjustment based on a working capital settlement, a reconciliation of the 2004 earnings before interest expense, interest income, income taxes, depreciation and amortization and the renewal of an operating lease, all of which are expected to be finalized by the third quarter of 2005. These assets and related liabilities of our former Matrix segment were held for sale as of December 31, 2004, and as such the operating results were included in discontinued operations.

92

107,331

107,464

108,039

BEVERLY ENTERPRISES, INC. SUPPLEMENTARY DATA (Unaudited) QUARTERLY FINANCIAL DATA

The following is a summary of our quarterly results of operations for the years ended December 31, 2004 and 2003:

						2004										2003				
		1st		2nd		3rd		4th		Total		1st		2nd		3rd		4th		Total
	(In thousands, except per share data) \$480,618 \$488,229 \$503,432 \$516,573 \$1,988,852 \$433,231 \$441,760 \$456,788 \$470,247 \$1,802,02																			
Revenues	\$4	180,618	\$ 4	188,229	\$5	03,432	\$:				_	-			\$ 4	156,788	\$ 4	470,247	\$ 1	,802,026
Income (loss) before provision for income taxes and discontinued																				
operations	\$	22,575	\$	(13,833)	\$	22,079	\$	16,727	\$	47,548	\$	3,787	\$	6,562	\$	10,198	\$	12,226	\$	32,773
Provision for income taxes		1,442		1,060		536		1,852		4,890		1,236		1,201		1,853		779		5,069
Income (loss) before discontinued operations Discontinued operations, net		21,133	,	(14,893)		21,543		14,875		42,658		2,551		5,361		8,345		11,447		27,704
of taxes Net income (loss)	\$	2,306 23,439		(11,030) (25,923)	\$	2,857 24,400	\$	(8,770) 6,105		(14,637) 28,021	\$	9,637 12,188	\$	12,130 17,491	\$	1,638 9,983	\$	29,359	\$	52,764 80,468
Income (loss) per share of common stock: Basic:																				
Before discontinued operations Discontinued operations,	\$	0.20	\$	(0.14)	\$	0.20	\$	0.14		0.40	\$	0.02	\$	0.05	\$	0.08	\$	0.11	\$	0.26
net of taxes Net income		0.02		(0.10)		0.03		(0.08)		(0.14)		0.10		0.11		0.01		0.27		0.49
(loss)	\$	0.22	\$	(0.24)	\$	0.23	\$	0.06	\$	0.26	\$	0.12	\$	0.16	\$	0.09	\$	0.38	\$	0.75
		07.001		105 161	4	00.020		100 150		107.710		101561		105 15 1		107 160		107.001		106.503

Table of Contents 123

107,749

104,761

107,174

107,160

107,201

106,582

108,153

Shares used
to compute
basic net
income (loss)
per share
amounts

Diluted:(1)																				
Before discontinued operations	\$	0.18	\$	(0.11)	\$	0.18	\$	0.13	\$	0.37	\$	0.02	\$	0.05	\$	0.08	\$	0.10	\$	0.26
Discontinued operations, net of taxes		0.02		(0.09)		0.02		(0.07)		(0.12)		0.10		0.11		0.01		0.25		0.48
Net income	\$	0.20	¢		¢	0.20	¢		¢	0.25			¢		¢		¢	0.35	ď	0.74
(loss)	Ф	0.20	Ф	(0.20)	Ф	0.20	Ф	0.06	Ф	0.23	Ф	0.12	Ф	0.16	Ф	0.09	Ф	0.55	Ф	0.74
Shares used to compute diluted net income (loss) per share																				
amounts	12	3,888	12	23,930	124	4,493		125,031		124,334	10	04,761	1	07,180		107,618	119	9,999		109,922
Common stock price range:																				
High	\$	8.96	\$	8.92	\$	8.70	\$	9.41			\$	3.00	\$	4.30	\$	6.99	\$	8.60		
Low	\$	5.84	\$	5.83	\$	6.78	\$	7.49			\$	1.63	\$	1.80	\$	3.71	\$	5.06		

(1) In accordance with EITF 04-8, we have assumed the conversion of our 2.75% Convertible Notes issued in October 2003, therefore, the number of shares used to compute diluted earnings per share differ from amounts previously reported in our Form 10-Qs. Using the if-converted method, we have also adjusted interest expense, net of income taxes of \$0, by \$825,000 for each quarter of 2004 and \$633,000 for the fourth quarter of 2003 used in the calculations of diluted net income (loss) per share amounts.

We recorded provisions for income taxes, including taxes allocated to discontinued operations, at 15% and 9.5% for the years ended December 31, 2004 and 2003, respectively, primarily due to state income taxes.

The operations of Matrix (including 10 outpatient clinics), MK Medical, Care Focus, 125 nursing facilities and eight assisted living centers have been reported as discontinued operations for all periods presented, including 27 nursing facilities classified as held for sale during the year ended December 31, 2004, as they met the criteria under SFAS No. 144 and therefore, the results above differ from amounts previously reported in our Form 10-Qs.

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.

None.

ITEM 9A. CONTROLS AND PROCEDURES.

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures, which are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC s rules and forms. Such information is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

As required by SEC Rule 13a-15(b), we have carried out an evaluation as of December 31, 2004, the end of the period covered by this report, under the supervision and with the participation of management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures. Based upon their evaluation and subject to the foregoing, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level.

Management s Report on Internal Control Over Financial Reporting

We are responsible for establishing and maintaining internal control over financial reporting, as such term is defined in Exchange Act Rules 13a-15(f). We maintain a system of internal controls that is designed to provide reasonable assurance as to the fair and reliable preparation and presentation of the consolidated financial statements. Management recognizes that all internal control systems, no matter how well designed and operated, have inherent limitations. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation.

Pursuant to Section 404 of the Sarbanes-Oxley Act of 2002, management, including our Chief Executive Officer and Chief Financial Officer, conducted an evaluation of the effectiveness of the design and operation of its internal control over financial reporting based on the framework set forth in the *Internal Control-Integrated Framework* issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on the evaluation, management has concluded that its internal control over financial reporting was effective as of December 31, 2004, the end of the period covered by this report.

Our external auditors, Ernst & Young LLP, an independent registered public accounting firm, have completed an audit of management s assessment, as stated in their report, which is included in Item 8.

Changes in Internal Control Over Financial Reporting

There has been no change in our internal control over financial reporting during our fourth fiscal quarter ended December 31, 2004, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

ITEM 9B. OTHER INFORMATION.

None.

94

PART III

ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE COMPANY.

Information appearing in the definitive proxy statement for the 2005 Annual Meeting of Stockholders to be held on April 21, 2005, under the headings BEI Nominees for the Board of Directors, Board of Directors Committees During 2004, Executive Officers and Section 16(a) Beneficial Ownership Reporting Compliance, as well as information in Question No. 27 under the heading Answers to Frequently asked Questions, is hereby incorporated by reference.

We made the annual certification required by Section 303A.12(a) of the NYSE Company Manual on June 18, 2004. In addition, we have filed with the SEC as exhibits to this Form 10-K the certifications of William R. Floyd, our Chairman of the Board, President and Chief Executive Officer, and Jeffrey P. Freimark, our Executive Vice President and Chief Financial Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

ITEM 11. EXECUTIVE COMPENSATION.

Information appearing in the definitive proxy statement for the 2005 Annual Meeting of Stockholders to be held on April 21, 2005, under the headings Executive Compensation, Board of Directors Compensation, Compensation Committee Interlocks and Insider Participation, Nominating and Compensation committee Report on 2004 Executive Compensation, Stock Performance Graph and Employment Contracts, Termination of Employment and Change in Control Agreements is hereby incorporated by reference.

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.

Information appearing in the definitive proxy statement for the 2005 Annual Meeting of Stockholders to be held on April 21, 2005, under the headings Security Ownership of Certain Beneficial Owners and Management and Equity Compensation Plan Information is hereby incorporated by reference.

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS.

Information appearing in the definitive proxy statement for the 2005 Annual Meeting of Stockholders to be held on April 21, 2005, under the heading Certain Transactions with Management and Others is hereby incorporated by reference.

ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES.

Information appearing in the definitive proxy statement for the 2005 Annual Meeting of Stockholders under the headings Ratification of the Appointment of Ernst & Young LLP as our Independent Registered Public Accounting Firm for 2005 and Audit and Compliance Committee Report is hereby incorporated by reference.

95

PART IV

ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES AND REPORTS ON FORM 8-K.

(a) 1 and 2. The Consolidated Financial Statements and Consolidated Financial Statement Schedule

The consolidated financial statements and consolidated financial statement schedule listed in the
accompanying index to consolidated financial statements and financial statement schedules are filed as part of this
annual report.

3. Exhibits

The exhibits listed in the accompanying index to exhibits are incorporated by reference herein or are filed as part of this annual report.

(c) Exhibits

See the accompanying index to exhibits referenced in Item 15(a)(3) above for a list of exhibits incorporated herein by reference or filed as part of this annual report.

(d) Financial Statement Schedule

See the accompanying index to consolidated financial statements and financial statement schedules referenced in Item 15(a)1 and 2, above.

96

Table of Contents

BEVERLY ENTERPRISES, INC. INDEX TO CONSOLIDATED FINANCIAL STATEMENTS AND FINANCIAL STATEMENT SCHEDULES (Item 15(a))

r	rage
1. Consolidated financial statements:	
Reports of Ernst & Young LLP, Independent Registered Public Accounting Firm	47
Reports of Ernst & Young LLP, Independent Registered Public Accounting Firm	48
Consolidated Balance Sheets at December 31, 2004 and 2003	49
Consolidated Statements of Operations for each of the three years in the period ended December 31,	
2004	50
Consolidated Statements of Stockholders Equity for each of the three years in the period ended	
December 31, 2004	51
Consolidated Statements of Cash Flows for each of the three years in the period ended December 31,	
2004	52
Notes to Consolidated Financial Statements	53
Supplementary Data (Unaudited) Quarterly Financial Data	93
2. Consolidated financial statement schedule for each of the three years in the period ended December 31,	
2004:	
Schedule II Valuation and Qualifying Accounts	98
All other schedules are omitted because they are either not applicable or the items do not meet the various disclosure requirements.	

97

BEVERLY ENTERPRISES, INC. SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS Years ended December 31, 2004, 2003 and 2002

	В	alance at		Charged Credited)				Oue to				
	В	eginning		to			Acq	uisitions and			Ba	alance at
Description	•	of Year	OI	Operations		rite-offs	Dis	positions	(Other		End of Year
						(In thou	ısand	s)				
Year ended December 31, 2004: Allowance for doubtful												
accounts:	Ф	01.745	ф	0.000	ф	(17,006)	ф	2.722	ф	(1.50)	Ф	26 220vk
Accounts receivable Notes receivable	\$	31,745 5,326	\$	8,898 (83)	\$	(17,896) (1,746)	\$	3,732 (58)	\$	(159) (216)	\$	26,320* 3,223*
	\$	37,071	\$	8,815	\$	(19,642)	\$	3,674	\$	(375)	\$	29,543
Valuation allowance on net deferred tax assets	\$	169,076	\$	(10,792)	\$		\$		\$		\$	158,284(A)
Year ended December 31, 2003: Allowance for doubtful												
accounts: Accounts receivable	\$	44,666	\$	22,743	\$	(30,307)	\$	(3,482)	\$	(1,875)	\$	31,745*
Notes receivable	Ψ	7,761	Ψ	(1,138)	Ψ	(4,085)	Ψ	682	Ψ	2,106	Ψ	5,326*
	\$	52,427	\$	21,605	\$	(34,392)	\$	(2,800)	\$	231	\$	37,071
Valuation allowance on net deferred tax assets	\$	199,217	\$	(30,141)	\$		\$		\$		\$	169,076(A)
Year ended December 31, 2002:												
Allowance for doubtful accounts:												
Accounts receivable Notes receivable	\$	52,474 4,941	\$	54,558 1,012	\$	(60,000)	\$	(4,221) 181	\$	1,855 1,666	\$	44,666* 7,761*
	\$	57,415	\$	55,570	\$	(60,039)	\$	(4,040)	\$	3,521	\$	52,427
Valuation allowance on net deferred tax	\$	153,697	\$	45,520	\$		\$		\$		\$	199,217(A)

assets

- (A) Represents a full valuation allowance on our net deferred tax assets.
- * Includes amounts classified in long-term other assets as well as current assets.

98

10.2*

BEVERLY ENTERPRISES, INC. INDEX TO EXHIBITS (ITEM 15(a)(3))

Exhibit Number	Description
3.1	Form of Restated Certificate of Incorporation of New Beverly Holdings, Inc. (incorporated by reference to Exhibit 3.1 to Beverly Enterprises, Inc. s Annual Report on Form 10-K for the year ended December 31, 1997)
3.2	Form of Certificate of Amendment of Certificate of Incorporation of New Beverly Holdings Inc., changing its name to Beverly Enterprises, Inc. (incorporated by reference to Exhibit 3.2 to Beverly Enterprises, Inc. s Annual Report on Form 10-K for the year ended December 31, 1997)
3.3	By-Laws of Beverly Enterprises, Inc. (incorporated by reference to Exhibit 3.4 to Beverly Enterprises, Inc. s Registration Statement on Form S-1 filed on June 4, 1997 (File No. 333-28521))
4.1	Indenture, dated as of April 25, 2001, between Beverly Enterprises, Inc., and The Bank of New York, as Trustee, with respect to Beverly Enterprises, Inc. s 95/8% Senior Notes due 2009 (the \$\frac{9}{2}8\%\$ Senior Notes Indenture) (incorporated by reference to Exhibit 4.3 to Beverly Enterprises, Inc. s Annual Report on Form 10-K for the year ended December 31, 2001)
4.2	First Supplemental Indenture, dated as of June 17, 2004, to the 9 ⁵ /8% Senior Notes Indenture (incorporated by reference to Exhibit 4.2 to Beverly Enterprises, Inc. s Quarterly Report on Form 10-Q for the quarter ended June 30, 2004)
4.3	Subordinated Indenture, dated as of October 22, 2003, between Beverly Enterprises, Inc, as Issuer, and The Bank of New York, as Trustee, with respect to Beverly Enterprises, Inc. s 2.75% Convertible Subordinated Notes due 2033 (the 2.75% Note Indenture) (incorporated by reference to Exhibit 4.2 to Beverly Enterprises, Inc. s Current Report on Form 8-K dated October 17, 2003)
4.4	First Supplement, dated October 22, 2003, to the 2.75% Note Indenture (incorporated by reference to Exhibit 4.3 to Beverly Enterprises, Inc. s Current Report on Form 8-K dated October 17, 2003)
4.5	Indenture, dated as of June 25, 2004, by and among Beverly Enterprises, Inc., the subsidiary guarantors named therein, and BNY Midwest Trust Company, as Trustee, with respect to Beverly Enterprises, Inc. s 78% Senior Subordinated Notes due 2014 (incorporated by reference to Exhibit 4.1 to Beverly Enterprises, Inc. s Quarterly Report on Form 10-Q for the quarter ended June 30, 2004)
4.6	Rights agreement, dated as of January 26, 2005, between Beverly Enterprises, Inc. and The Bank of New York, as Rights Agent, which includes the form of Certificate of Designations of the Series A Junior Participating Preferred Stock of Beverly Enterprises, Inc. as Exhibit A, the form of Right Certificate as Exhibit B and the Summary of Rights to Purchase Preferred Shares as Exhibit C (incorporated by reference to Exhibit 4.1 to Beverly Enterprises, Inc. s Current Report on Form 8-K dated January 26, 2005)
10.1*	Beverly Enterprises, Inc. Annual Incentive Plan (incorporated by reference to Exhibit 10.1 to Beverly Enterprises, Inc. s Annual Report on Form 10-K for the year ended December 31, 2001)

	1997 Long-Term Incentive Plan, as amended and restated as of June 1, 2001 (the 1997 LTIP) (incorporated by reference to Exhibit 10.2 to Beverly Enterprises, Inc. s Annual Report on Form 10-K for the year ended December 31, 2001)
10.3 *	First Amendment, effective as of June 1, 2004, to the 1997 LTIP
10.4 *	Beverly Enterprises, Inc. Non-Employee Directors Stock Option Plan (as amended and restated effective as of June 1, 2004)
10.5*	Beverly Enterprises, Inc. Stock Grant Plan (incorporated by reference to Exhibit 10.6 to Beverly Enterprises, Inc. s Annual Report on Form 10-K for the year ended December 31, 2000)
10.6*	Executive Medical Reimbursement Plan (incorporated by reference to Exhibit 10.5 to Beverly Enterprises, Inc. s Annual Report on Form 10-K for the year ended December 31, 1987)

Exhibit Number	Description
10.7*	Form of the Beverly Enterprises, Inc. Executive Life Insurance Plan Split Dollar Agreement (incorporated by reference to Exhibit 10.8 to Beverly Enterprises, Inc. s Annual Report on Form 10-K for the year ended December 31, 2000)
10.8*	Amended and Restated Deferred Compensation Plan effective July 18, 1991 (incorporated by reference to Exhibit 10.6 to Beverly Enterprises, Inc. s Annual Report on Form 10-K for the year ended December 31, 1991)
10.9*	Amendment No. 1, effective September 29, 1994, to the Amended and Restated Deferred Compensation Plan (incorporated by reference to Exhibit 10.13 to Beverly Enterprises, Inc. s Registration Statement on Form S-4 filed on February 13, 1995 (File No. 33-57663))
10.10*	Executive Retirement Plan (incorporated by reference to Exhibit 10.9 to Beverly Enterprises, Inc. s Annual Report on Form 10-K for the year ended December 31, 1987)
10.11*	Amendment No. 1, effective as of July 1, 1991, to the Executive Retirement Plan (incorporated by reference to Exhibit 10.8 to Beverly Enterprises, Inc. s Annual Report on Form 10-K for the year ended December 31, 1991)
10.12*	Amendment No. 2, effective as of December 12, 1991, to the Executive Retirement Plan (incorporated by reference to Exhibit 10.9 to Beverly Enterprises, Inc. s Annual Report on Form 10-K for the year ended December 31, 1991)
10.13*	Amendment No. 3, effective as of July 31, 1992, to the Executive Retirement Plan (incorporated by reference to Exhibit 10.10 to Beverly Enterprises, Inc. s Annual Report on Form 10-K for the year ended December 31, 1992)
10.14*	Amendment No. 4, effective as of January 1, 1993, to the Executive Retirement Plan (incorporated by reference to Exhibit 10.18 to Beverly Enterprises, Inc. s Annual Report on Form 10-K for the year ended December 31, 1994)
10.15*	Amendment No. 5, effective as of September 29, 1994, to the Executive Retirement Plan (incorporated by reference to Exhibit 10.19 to Beverly Enterprises, Inc. s Annual Report on Form 10-K for the year ended December 31, 1994)
10.16*	Amendment No. 6, effective as of January 1, 1996, to the Executive Retirement Plan (incorporated by reference to Exhibit 10.18 to Beverly Enterprises, Inc. s Annual Report on Form 10-K for the year ended December 31, 1997)
10.17*	Amendment No. 7, effective as of September 1, 1997, to the Executive Retirement Plan (incorporated by reference to Exhibit 10.19 to Beverly Enterprises, Inc. s Annual Report on Form 10-K for the year ended December 31, 1997)
10.18*	Amendment No. 8, dated as of December 11, 1997, to the Executive Retirement Plan, changing its name to the Executive SavingsPlus Plan (incorporated by reference to Exhibit 10.20 to Beverly Enterprises, Inc. s Annual Report on Form 10-K for the year ended December 31, 1997)
10.19*	Beverly Enterprises, Inc. Amended and Restated Supplemental Executive Retirement Plan effective as of April 1, 2000 (the Supplemental Executive Retirement Plan) (incorporated by reference to Exhibit 10.21 to Beverly Enterprises, Inc. s Annual Report on Form 10-K for the year ended December 31, 2000)
10.20*	Amendment No. 1, effective as of October 16, 2001, to the Beverly Enterprises, Inc. Supplemental Executive Retirement Plan (incorporated by reference to Exhibit 10.5 to Beverly Enterprises, Inc. s Quarterly Report on Form 10-Q for the quarter ended

		June 30, 2002)
10.21*	10.21*	Beverly Enterprises, Inc. Amended and Restated Executive Deferred Compensation
		Plan effective July 1, 2000 (incorporated by reference to Exhibit 10.22 to Beverly
		Enterprises, Inc. s Annual Report on Form 10-K for the year ended December 31,
		2000)
	10.22*	Beverly Enterprises, Inc. Executive Deferred Compensation Plan effective
		December 31, 2002 (incorporated by reference to Exhibit 10.22 to Beverly
		Enterprises, Inc. s Annual Report on Form 10-K for the year ended December 31,
		2002)
10.23*	10.23*	First Amendment, effective March 11, 2004, to Executive Deferred Compensation
		Plan (incorporated by reference to Exhibit 10.2 to Beverly Enterprises, Inc. s Quarterly
		Report on Form 10-Q for the quarter ended March 30, 2004)

Exhibit Number	Description
10.24*	Beverly Enterprises, Inc. Non-Employee Director Deferred Compensation Plan (the Directors Plan) (incorporated by reference to Exhibit 10.1 to Beverly Enterprises, Inc. s Quarterly Report on Form 10-Q for the quarter ended June 30, 1997)
10.25*	Amendment No. 1, effective as of December 3, 1997, to the Directors Plan (incorporated by reference to Exhibit 10.26 to Beverly Enterprises, Inc. s Annual Report on Form 10-K for the year ended December 31, 1997)
10.26*	Beverly Enterprises, Inc. s Supplemental Long-Term Disability Plan (incorporated by reference to Exhibit 10.24 to Beverly Enterprises, Inc. s Annual Report on Form 10-K for the year ended December 31, 1996)
10.27*	Form of Indemnification Agreement between Beverly Enterprises, Inc. and its officers, directors and certain of its employees (incorporated by reference to Exhibit 19.14 to Beverly Enterprises, Inc. s Quarterly Report on Form 10-Q for the quarter ended June 30, 1987)
10.28*	Form of request by Beverly Enterprises, Inc. to certain of its officers or directors relating to indemnification rights (incorporated by reference to Exhibit 19.5 to Beverly Enterprises, Inc. s Quarterly Report on Form 10-Q for the quarter ended September 30, 1987)
10.29*	Form of request by Beverly Enterprises, Inc. to certain of its officers or employees relating to indemnification rights (incorporated by reference to Exhibit 19.6 to Beverly Enterprises, Inc. s Quarterly Report on Form 10-Q for the quarter ended September 30, 1987)
10.30*	Severance Agreement and Release of Claims between Beverly Enterprises, Inc. and David R. Banks (incorporated by reference to Exhibit 10.28 to Beverly Enterprises, Inc. s Annual Report on Form 10-K for the year ended December 31, 2001)
10.31*	Employment Contract, made as of December 6, 2001, between Beverly Enterprises, Inc. and William R. Floyd (incorporated by reference to Exhibit 10.32 to Beverly Enterprises, Inc. s Annual Report on Form 10-K for the year ended December 31, 2002)
10.32 *	Amendment, dated December 1, 2004, to Employment Agreement with William R. Floyd
10.33*	Employment and Severance Agreement, made as of June 1, 2001, between Beverly Enterprises, Inc. and David R. Devereaux (incorporated by reference to Exhibit 10.33 to Beverly Enterprises, Inc. s Annual Report on Form 10-K for the year ended December 31, 2002)
10.34*	Severance Agreement and Release of Claims made as of October 5, 2002, between Beverly Enterprises, Inc. and Bobby W. Stephens (incorporated by reference to Exhibit 10.34 to Beverly Enterprises, Inc. s Annual Report on Form 10-K for the year ended December 31, 2002)
10.35*	Employment Contract, made as of April 1, 2000, between Beverly Enterprises, Inc. and Douglas J. Babb (incorporated by reference to Exhibit 10.35 to Beverly Enterprises, Inc. s Annual Report on Form 10-K for the year ended December 31, 2002)
10.36 *	Amendment, dated December 1, 2004, to Employment Agreement between Beverly Enterprises, Inc. and Douglas J. Babb
10.37*	

	Severance Agreement and Release of Claims made as of October 11, 2002, between Beverly Enterprises, Inc. and Michael J. Matheny (incorporated by reference to Exhibit 10.36 to Beverly Enterprises, Inc. s Annual Report on Form 10-K for the year ended December 31, 2002)
10.38*	Severance Agreement and Release of Claims made as of December 31, 2001, between Beverly Enterprises, Inc. and T. Jerald Moore (incorporated by reference to Exhibit 10.37 to Beverly Enterprises, Inc. s Annual Report on Form 10-K for the year ended December 31, 2002)
10.39*	Employment Agreement, dated February 15, 2001, between Beverly Enterprises, Inc. and William A. Mathies (incorporated by reference to Exhibit 10.1 to Beverly Enterprises, Inc. s Quarterly Report on Form 10-Q for the quarter ended June 30, 2001)
10.40*	Form of Employment Contract, made as of August 22, 1997, between New Beverly Holdings, Inc. and certain of its officers (incorporated by reference to Exhibit 10.20 to Amendment No. 2 to Beverly Enterprises, Inc. s Registration Statement on Form S-1 filed on September 22, 1997 (File No. 333-28521))
10.41*	Retention Stock Option Agreement, effective as of June 1, 2001, between Beverly Enterprises, Inc. and David R. Devereaux (incorporated by reference to Exhibit 10.1 to Beverly Enterprises, Inc. s Quarterly Report on Form 10-Q for the quarter ended September 30, 2002)

Exhibit Number	Description
10.42*	Description of Non-Employee Directors Group Term Life Insurance Plan (incorporated by reference to Exhibit 10.4 to Beverly Enterprises, Inc. s Quarterly Report on Form 10-Q for the quarter ended June 30, 2002)
10.43*	Performance based Stock Option Award, dated June 6, 2002, to Jeffrey P. Freimark pursuant to Process Improvement Team Awards Program (incorporated by reference to Exhibit 10.6 to Beverly Enterprises, Inc. s Quarterly Report on Form 10-Q for the
10.44*	quarter ended June 30, 2002) Performance based Stock Option Award, dated June 6, 2002, to L. Darlene Burch pursuant to Process Improvement Team Awards Program (incorporated by reference to Exhibit 10.7 to Beverly Enterprises, Inc. s Quarterly Report on Form 10-Q for the quarter ended June 30, 2002)
10.45*	Description of Long Term Disability Policy for William R. Floyd (incorporated by reference to Exhibit 10.8 to Beverly Enterprises, Inc. s Quarterly Report on Form 10-Q for the quarter ended June 30, 2002)
10.46*	Employment Agreement, made as of December 31, 2001, between Beverly Enterprises, Inc. and Jeffrey P. Freimark (incorporated by reference to Exhibit 10.9 to Beverly Enterprises, Inc. s Quarterly Report on Form 10-Q for the quarter ended June 30, 2002)
10.47 *	Amendment, dated December 1, 2004, to Employment Agreement between Beverly Enterprises, Inc. and Jeffrey P. Freimark
10.48*	Demand Promissory Note, made as of April 1, 2002, by Richard D. Skelly, Jr. for the benefit of Beverly Enterprises, Inc. (incorporated by reference to Exhibit 10.10 to Beverly Enterprises, Inc. s Quarterly Report on Form 10-Q for the quarter ended June 30, 2002)
10.49*	Enhanced Supplemental Executive Retirement Plan, effective as of January 1, 2004 (incorporated by reference to Exhibit 10.1 to Beverly Enterprises, Inc. s Quarterly Report on Form 10-Q for quarter ended March 30, 2004)
10.50*	Form of Long-Term Incentive Plan Notice (incorporated by reference to Exhibit 10.2 to Beverly Enterprises, Inc. s Quarterly Report on Form 10-Q for the quarter ended September 30, 2004)
10.51*	Form of Restricted Stock Agreement for Non-Employee Directors Stock Option Plan (incorporated by reference to Exhibit 10.3 to Beverly Enterprises, Inc. s Quarterly Report on Form 10-Q for the quarter ended September 30, 2004)
10.52*	Form of Restricted Stock Agreement for the 1997 LTIP (incorporated by reference to Exhibit 10.4 to Beverly Enterprises, Inc. s Form 10-Q for the quarter ended September 30, 2004)
10.53*	Form of Option Agreement for the Non-Employee Directors Stock Option Plan (incorporated by reference to Exhibit 10.5 to Beverly Enterprises, Inc. s Quarterly Report on Form 10-Q for the quarter ended September 30, 2004)
10.54*	Form of Option Agreement for the 1997 LTIP (incorporated by reference to Exhibit 10.6 to Beverly Enterprises, Inc. s Quarterly Report on Form 10-Q for the quarter ended September 30, 2004)
10.55	Master Lease Document General Terms and Conditions, dated December 30, 1985, for Leases between Beverly California Corporation and various subsidiaries thereof as lessees and Beverly Investment Properties, Inc. as lessor (incorporated by reference to

	Exhibit 10.12 to Beverly California Corporation s Annual Report on Form 10-K for the year ended December 31, 1985)
10.56	Agreement to Sale of Nursing Home Properties, dated as of July 13, 2001, among
	Beverly Enterprises Florida, Inc., Beverly Health and Rehabilitation Services, Inc.,
	Beverly Savana Cay Manor, Inc., Vantage Healthcare Corporation, Peterson Health
	Care, Inc. and NMC of Florida, LLC (the Florida Sale Agreement) (incorporated by
	reference to Exhibit 10.36 to Beverly Enterprises, Inc. s Annual Report on Form 10-K
	for the year ended December 31, 2001)
10.57	First Amendment to Florida Sale Agreement, dated as of August 30, 2001
	(incorporated by reference to Exhibit 10.37 to Beverly Enterprises, Inc. s Annual
	Report on Form 10-K for the year ended December 31, 2001)
10.58	Second Amendment to Florida Sale Agreement, dated as of October 29, 2001
	(incorporated by reference to Exhibit 10.38 to Beverly Enterprises, Inc. s Annual
	Report on Form 10-K for the year ended December 31, 2001)
	· · · · · · · · · · · · · · · · · · ·

Exhibit Number	Description
10.59	Amendment No. 5 to Amended and Restated Participation Agreement, dated as of December 20, 2002 (incorporated by reference to Exhibit 10.59 to Beverly Enterprises, Inc. s Annual Report on Form 10-K for the year ended December 31, 2002)
10.60	Amendment No. 6 to Amended and Restated Participation Agreement, dated as of February 28, 2003 (incorporated by reference to Exhibit 10.60 to Beverly Enterprises, Inc. s Annual Report on Form 10-K for the year ended December 31, 2002) [Note: Confidential treatment has been requested for portions of this document.]
10.61	Amended and Restated Credit Agreement, dated as of April 25, 2001, among Beverly Enterprises, Inc., the Banks listed therein and Morgan Guaranty Trust Company of New York, as Issuing Bank and Agent (the Morgan Credit Agreement) (incorporated by reference to Exhibit 10.46 to Beverly Enterprises, Inc. s Annual Report on Form 10-K for the year ended December 31, 2001)
10.62	Amendment No. 1 to the Morgan Credit Agreement, dated as of December 31, 2001 (incorporated by reference to Exhibit 10.47 to Beverly Enterprises, Inc. s Annual Report for the year ended December 31, 2001)
10.63	Amendment No. 3 to the Morgan Credit Agreement, dated as of December 20, 2002 (incorporated by reference to Exhibit 10.65 to Beverly Enterprises, Inc. s Annual Report on Form 10-K for the year ended December 31, 2002)
10.64	Amendment No. 4 to the Morgan Credit Agreement, dated as of February 28, 2003 (incorporated by reference to Exhibit 10.66 to Beverly Enterprises, Inc. s Annual Report on Form 10-K for the year ended December 31, 2002) [Note: Confidential treatment has been requested for portions of this document.]
10.65	Corporate Integrity Agreement between the Office of Inspector General of the Department of Health and Human Services and Beverly Enterprises, Inc. (the Corporate Integrity Agreement) (incorporated by reference to Exhibit 10.43 to Beverly Enterprises, Inc. s Annual Report on Form 10-K for the year ended December 31, 1999)
10.66	First Amendment to the Corporate Integrity Agreement (incorporated by reference to Exhibit 10.3 to Beverly Enterprises, Inc. s Quarterly Report on Form 10-Q for the quarter ended March 30, 2004)
10.67	Second Amendment to the Corporate Integrity Agreement (incorporated by reference to Exhibit 10.4 to Beverly Enterprises, Inc. s Quarterly Report on Form 10-Q for the quarter ended March 30, 2004)
10.68	Plea Agreement (incorporated by reference to Exhibit 10.44 to Beverly Enterprises, Inc. s Annual Report on Form 10-K for the year ended December 31, 1999)
10.69	Addendum to Plea Agreement (incorporated by reference to Exhibit 10.45 to Beverly Enterprises, Inc. s Annual Report on Form 10-K for the year ended December 31, 1999)
10.70	Settlement Agreement between the United States of America, Beverly Enterprises, Inc. and Domenic Todarello (incorporated by reference to Exhibit 10.46 to Beverly Enterprises, Inc. s Annual Report on Form 10-K for the year ended December 31, 1999)
10.71	Agreement Regarding the Operations of Beverly Enterprises California, Inc. (incorporated by reference to Exhibit 10.47 to Beverly Enterprises, Inc. s Annual

	Report on Form 10-K for the year ended December 31, 1999)
10.72	Settlement Agreement, effective October 15, 2002, between the Centers for Medicare
	and Medicaid Services, United States Department of Health and Human Services and
	Beverly Enterprises, Inc. (incorporated by reference to Exhibit 10.2 to Beverly
	Enterprises, Inc. s Quarterly Report on Form 10-Q for the quarter ended September 30,
	2002)
10.73	Permanent Injunction and Final Judgment, entered on August 1, 2002, in People of the
	State of California v. Beverly Enterprises, Inc.; Beverly Health and Rehabilitation
	Services, Inc.; Beverly Enterprises California, Inc.; and Beverly Healthcare
	California, Inc., Superior Court of the State of California For the County of
	Santa Barbara (incorporated by reference to Exhibit 10.1 to Beverly Enterprises, Inc. s
	Quarterly Report on Form 10-Q for the quarter ended June 30, 2002)

Exhibit Number	Description
10.74	Waiver of Constitutional Rights and Plea Form and Court Finding and Order, dated August 1, 2002, in The People of California v. Beverly Enterprises California, Inc., Superior Court of the State of California For the County of Santa Barbara (S.C. No. 1094923) (incorporated by reference to Exhibit 10.2 to Beverly Enterprises, Inc. s Quarterly Report on Form 10-Q for the quarter ended June 30, 2002)
10.75	Investigation Conclusion letter dated August 1, 2002, from the State of California Department of Justice (incorporated by reference to Exhibit 10.3 to Beverly Enterprises, Inc. s Quarterly Report on Form 10-Q for the quarter ended June 30, 2002)
10.76	Loan Agreement, dated as of December 24, 2002, between Beverly Enterprises Washington, Inc. and Bank of America, N.A. (incorporated by reference to Exhibit 10.76 to Beverly Enterprises, Inc. s Annual Report on Form 10-K for the year ended December 31, 2002)
10.77	Guaranty, dated December 24, 2002, between Beverly Enterprises, Inc. and Bank of America, N.A. (incorporated by reference to Exhibit 10.77 to Beverly Enterprises, Inc. s Annual Report on Form 10-K for the year ended December 31, 2002)
10.78	Credit Agreement, dated as of October 22, 2003, (the Lehman Credit Agreement) among Beverly Enterprises, Inc., Lehman Brothers Inc., Lehman Commercial Paper Inc., Bank of Montreal and General Electric Capital Corporation [Note: Confidential treatment has been requested for portions of this document.] (incorporated by reference to Exhibit 10.1 to Beverly Enterprises, Inc. s Quarterly Report on Form 10-Q for the quarter ended September 30, 2003)
10.79	Guaranty and Collateral Agreement, dated as of October 22, 2003 (incorporated by reference to Exhibit 10.1 to Beverly Enterprises, Inc. s Quarterly Report on Form 10-Q for the quarter ended September 30, 2003)
10.80	First Amendment, dated as of May 13, 2004, to the Lehman Credit Agreement (incorporated by reference to Exhibit 10.4 to Beverly Enterprises, Inc. s Quarter Report on Form 10-Q for the quarter ended June 30, 2004)
10.81	Second Amendment, dated as of June 17, 2004, to the Lehman Credit Agreement (incorporated by reference to Exhibit 10.5 to Beverly Enterprises, Inc. s Quarter Report on Form 10-Q for the quarter ended June 30, 2004)
10.82	Asset Purchase Agreement (Hospice USA Asset Purchase Agreement), dated as of May 27, 2004, by and among Hospice USA, LLC, the Affiliated Sellers named therein, and Hospice Preferred Choice, Inc. (incorporated by reference to Exhibit 10.6 to Beverly Enterprises, Inc. s Quarterly Report on Form 10-Q for the quarter ended June 30, 2004)
10.83	First Amendment, dated as of July 30, 2004, to Hospice USA Asset Purchase Agreement (incorporated by reference to Exhibit 10.7 to Beverly Enterprises, Inc. s Quarterly Report on Form 10-Q for the quarter ended June 30, 2004)
10.84	Purchase Agreement, dated as of June 18, 2004, by and among Beverly Enterprises, Inc., the subsidiary guarantors named therein and Lehman Brothers Inc. and J.P. Morgan Securities Inc., as the Initial Purchasers, with respect to Beverly Enterprises, Inc. s 78% Senior Subordinated Notes (incorporated by reference to Exhibit 10.1 to Beverly Enterprises, Inc. s Quarterly Report on Form 10-Q for the quarter ended June 30, 2004)

10.85	Registration Rights Agreement, dated as of June 25, 2004, by and among Beverly Enterprises, Inc., the subsidiary guarantors named therein and Lehman Brothers Inc. and J.P. Morgan Securities Inc. as the Initial Purchasers (incorporated by reference to Exhibit 10.2 to Beverly Enterprises, Inc. s Quarterly Report on Form 10-Q for the
10.86	quarter ended June 30, 2004) Dealer Manager and Solicitation Agent Agreement, dated as of June 8, 2004, by and between Beverly Enterprises, Inc. and Lehman Brothers Inc. (incorporated by
	reference to Exhibit 10.3 to Beverly Enterprises, Inc. s Quarterly Report on Form 10-Q for the quarter ended June 30, 2004)
10.87	Credit Agreement, dated as of October 6, 2004, among Beverly Funding Corporation, Merrill Lynch Capital (as agent and lender) and Additional Lenders From Time to
	Time Party Thereto (incorporated by reference to Exhibit 10.1 to Beverly Enterprises, Inc. s Current Report on Form 8-K dated October 6, 2004)
10.88 *	Employment Contract, made as of December 4, 2003, between Beverly Enterprises, Inc. and Cindy Susienka

Table of Contents

Exhibit Number	Description
10.89 *	Beverly Enterprises, Inc. Employee Stock Purchase Plan, as amended and restated effective July 1, 2000 (the ESPP)
10.90 *	First Amendment to the ESPP, effective January 1, 2003
21.1	Subsidiaries of Registrant
23.1	Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm
31.1	Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer
31.2	Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer
32.1	Section 1350 Certification of Chief Executive Officer
32.2	Section 1350 Certification of Chief Financial Officer

^{*} Indicates management contracts, compensatory plans, contracts and arrangements in which any director or named executive officer participates.

Filed herewith.

Table of Contents

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Beverly Enterprises, Inc. Registrant

Dated: March 15, 2005

By: /s/ William R. Floyd

William R. Floyd
Chairman of the Board, President,
Chief Executive Officer and Director

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of Registrant and in the capacities and on the dates indicated:

/s/ William R. Floyd	Chairman of the Board, President, Chief Executive Officer and Director	March 15, 2005
William R. Floyd		
/s/ Jeffrey P. Freimark	Executive Vice President, Chief Financial and Information Officer	March 15, 2005
Jeffrey P. Freimark	Timulotal and Information Officer	
/s/ Pamela H. Daniels	Senior Vice President, Controller and Chief Accounting Officer	March 15, 2005
Pamela H. Daniels	<i>g</i>	
/s/ Melanie Creagan Dreher	Director	March 15, 2005
Melanie Creagan Dreher		
/s/ John D. Fowler, Jr.	Director	March 15, 2005
John D. Fowler, Jr.		
/s/ John P. Howe, III	Director	March 15, 2005
John P. Howe, III		
/s/ James W. McLane	Director	March 15, 2005
James W. McLane		
/s/ Ivan R. Sabel	Director	March 15, 2005
Ivan R. Sabel		
/s/ Donald L. Seeley	Director	March 15, 2005

Donald L. Seeley

/s/ Marilyn R. Seymann

Director

March 15, 2005

Marilyn R. Seymann